Aim	O
To	O
evaluate	O
the	O
risk	O
factors	O
and	O
incidence	B-EPI
of	O
Asherman	B-DIS
Syndrome	I-DIS
in	O
women	O
with	O
post	O
-	O
abortion	O
uterine	O
evacuation	O
and	O
curettage	O
.	O

Methods	O
A	O
total	O
of	O
2546	O
patients	O
who	O
had	O
surgical	O
abortion	O
uterine	O
evacuation	O
and	O
curettage	O
before	O
the	O
20th	O
gestational	O
week	O
with	O
indications	O
of	O
missed	O
abortion	B-DIS
anembryonic	O
pregnancy	O
incomplete	O
abortion	B-DIS
and	O
elective	O
curettage	O
in	O
a	O
tertiary	O
antenatal	O
care	O
center	O
were	O
recruited	O
.	O

The	O
patients	O
were	O
called	O
and	O
surveyed	O
for	O
their	O
symptoms	O
;	O
including	O
infertility	B-DIS
oligo	I-DIS
-	O
amenorrhea	O
and	O
recurrent	O
pregnancy	O
loss	O
preterm	O
birth	B-DIS
and	I-DIS
intrauterine	I-DIS
growth	O
retardation	O
and	O
abnormal	O
placentation	O
as	O
criteria	B-DIS
of	I-DIS
Asherman	O
Syndrome	O
.	O

Diagnostic	O
office	O
hysteroscopy	O
was	O
performed	O
for	O
177	O
who	O
had	O
one	O
of	O
those	O
complaints	O
.	O

Results	O
The	O
incidence	B-EPI
of	O
Asherman	B-DIS
Syndrome	I-DIS
was	O
1.6	B-STAT
%	I-STAT
n	O
=	O
43/2546	B-STAT
.	O

History	O
of	O
â‰¥3	O
abortions	O
was	O
the	O
main	O
factor	O
that	O
increased	O
the	O
risk	O
of	O
Asherman	B-DIS
Syndrome	I-DIS
for	O
by	O
4.6	O
times	O
.	O

Use	O
of	O
vacuum	O
aspiration	O
or	O
sharp	O
curettage	O
premedication	O
for	O
cervical	O
priming	O
and	O
having	O
a	O
pregnanc	O
10th	O
gestational	O
weeks	O
were	O
not	O
risk	O
factors	O
for	O
Asherman	B-DIS
Syndrome	I-DIS
.	O

Conclusion	O
When	O
the	O
diagnosis	O
was	O
based	O
on	O
presence	O
of	O
symptoms	O
who	O
underwent	O
uterine	O
instrumentation	O
the	O
incidence	B-EPI
of	O
Asherman	B-DIS
Syndrome	I-DIS
was	O
found	O
to	O
be	O
1.6	B-STAT
%	I-STAT
.	O

Repeated	O
abortions	B-DIS
were	O
the	O
main	O
risk	O
factor	O
for	O
Asherman	B-DIS
Syndrome	I-DIS
and	O
avoiding	O
from	O
repeated	O
uterine	O
instrumentations	O
may	O
have	O
a	O
role	O
in	O
prevention	O
.	O

The	O
relationship	O
between	O
autoinflammatory	B-DIS
and	I-DIS
autoimmune	I-DIS
conditions	I-DIS
has	O
been	O
demonstrated	O
in	O
recent	O
decades	O
.	O

Several	O
autoimmune	O
conditions	O
exhibit	O
an	O
autoinflammatory	O
component	O
which	O
can	O
manifest	O
in	O
various	O
ways	O
.	O

Neutrophilic	B-DIS
dermatosis	I-DIS
in	O
the	O
context	O
of	O
lupus	B-DIS
erythematosus	I-DIS
LE	O
is	O
one	O
example	O
.	O

Otherwise	O
neutrophils	O
are	O
rare	O
in	O
LE	O
except	O
for	O
the	O
bullous	O
variant	O
and	O
nonbullous	O
neutrophilic	O
LE	O
.	O

In	O
this	O
paper	O
we	O
describe	O
a	O
case	O
of	O
scarring	O
alopecia	B-DIS
due	O
to	O
LE	O
that	O
stopped	O
responding	O
to	O
a	O
treatment	O
that	O
had	O
been	O
effective	O
for	O
years	O
.	O

The	O
biopsy	O
specimen	O
demonstrated	O
the	O
presence	O
of	O
neutrophils	O
in	O
the	O
inflammatory	O
infiltrate	O
.	O

A	O
treatment	O
with	O
dapsone	O
was	O
prescribed	O
and	O
yielded	O
rapid	O
improvement	O
.	O

This	O
first	O
case	O
of	O
scarring	O
alopecia	B-DIS
in	O
the	O
context	O
of	O
nonbullous	B-DIS
neutrophilic	I-DIS
LE	O
emphasizes	O
the	O
importance	O
of	O
the	O
infiltrate	O
in	O
determining	O
the	O
optimal	O
therapeutic	O
choice	O
.	O

Since	O
its	O
first	O
clinical	O
description	O
on	O
his	O
son	O
by	O
William	O
James	O
West	O
1793	O
-	O
1848	O
in	O
1841	O
and	O
the	O
definition	O
of	O
the	O
classical	O
triad	O
of	O
1	B-DIS
infantile	I-DIS
spasms	I-DIS
;	O
2	O
hypsarrhythmia	B-DIS
and	O
3	O
developmental	O
arrest	O
or	O
regression	O
as	O
`	O
`	O
West	B-DIS
syndrome	I-DIS
''	O
new	O
and	O
relevant	O
advances	O
have	O
been	O
recorded	O
in	O
this	O
uncommon	O
disorder	O
.	O

New	O
approaches	O
include	O
terminology	O
of	O
clinical	O
spasms	O
e.g	O
.	O

infantile	O
IS	O
vs.	O
epileptic	B-DIS
spasms	I-DIS
ES	O
variety	O
of	O
clinical	O
and	O
electroencephalographic	O
EEG	O
features	O
e.g	O
.	O

typical	O
ictal	O
phenomena	O
without	O
EEG	O
abnormalities	O
burden	O
of	O
developmental	O
delay	O
spectrum	O
of	O
associated	O
genetic	O
abnormalities	O
pathogenesis	O
treatment	O
options	O
and	O
related	O
outcome	O
and	O
prognosis	O
.	O

Aside	O
the	O
classical	O
manifestations	O
IS	O
or	O
ES	O
may	O
present	O
with	O
atypical	O
electroclinical	O
phenotypes	O
e.g	O
.	O

subtle	O
spasms	B-DIS
;	O
modified	O
hypsarrhythmia	B-DIS
and	O
may	O
have	O
their	O
onset	O
outside	O
infancy	O
.	O

An	O
increasing	O
number	O
of	O
genes	O
proteins	O
and	O
signaling	O
pathways	O
play	O
crucial	O
roles	O
in	O
the	O
pathogenesis	O
.	O

This	O
condition	O
is	O
currently	O
regarded	O
as	O
a	O
spectrum	O
of	O
disorders	O
the	O
so	O
-	O
called	B-DIS
infantile	I-DIS
spasm	O
syndrome	O
ISs	O
in	O
association	O
with	O
other	O
causal	O
factors	B-DIS
including	I-DIS
structural	I-DIS
infectious	I-DIS
metabolic	O
syndromic	O
and	O
immunologic	O
events	O
all	O
acting	O
on	O
a	O
genetic	O
predisposing	O
background	O
.	O

Hormonal	O
therapy	O
and	O
ketogenic	O
diet	O
are	O
widely	O
used	O
also	O
in	O
combination	O
with	O
classical	O
and	O
recent	O
pharmacological	O
drugs	O
.	O

Biologically	O
targeted	O
and	O
gene	O
therapies	O
are	O
increasingly	O
studied	O
.	O

The	O
present	O
narrative	O
review	O
searched	O
in	O
seven	O
electronic	O
databases	O
primary	O
MeSH	O
terms	O
/	O
keywords	B-DIS
included	I-DIS
West	I-DIS
syndrome	I-DIS
infantile	O
spasms	B-DIS
and	I-DIS
infantile	I-DIS
spasms	O
syndrome	O
and	O
were	O
coupled	O
to	O
25	O
secondary	O
clinical	O
EEG	O
therapeutic	O
outcomes	O
and	O
associated	O
conditions	O
terms	O
including	O
MEDLINE	O
Embase	O
Cochrane	O
Central	O
Web	O
of	O
Sciences	O
Pubmed	O
Scopus	B-DIS
and	O
OMIM	O
to	O
highlight	O
the	O
past	O
knowledge	O
and	O
more	O
recent	O
advances	O
.	O

Background	O
Antiretroviral	O
chemoprophylaxis	O
before	O
exposure	O
is	O
a	O
promising	O
approach	O
for	O
the	O
prevention	O
of	O
human	B-DIS
immunodeficiency	I-DIS
virus	I-DIS
HIV	I-DIS
acquisition	O
.	O

Methods	O
We	O
randomly	O
assigned	O
2499	O
HIV	O
-	O
seronegative	O
men	O
or	O
transgender	O
women	O
who	O
have	O
sex	O
with	O
men	O
to	O
receive	O
a	O
combination	O
of	O
two	O
oral	O
antiretroviral	O
drugs	O
emtricitabine	O
and	O
tenofovir	O
disoproxil	O
fumarate	O
FTC	O
-	O
TDF	O
or	O
placebo	O
once	O
daily	O
.	O

All	O
subjects	O
received	O
HIV	O
testing	O
risk	O
-	O
reduction	O
counseling	O
condoms	O
and	O
management	O
of	O
sexually	B-DIS
transmitted	O
infections	O
.	O

Results	O
The	O
study	O
subjects	O
were	O
followed	O
for	O
3324	O
person	O
-	O
years	O
median	O
1.2	O
years	O
;	O
maximum	O
2.8	O
years	O
.	O

Of	O
these	O
subjects	O
10	O
were	O
found	O
to	O
have	O
been	O
infected	B-DIS
with	I-DIS
HIV	I-DIS
at	I-DIS
enrollment	I-DIS
and	I-DIS
100	O
became	O
infected	O
during	O
follow	O
-	O
up	O
36	O
in	O
the	O
FTC	O
-	O
TDF	O
group	O
and	O
64	O
in	O
the	O
placebo	O
group	O
indicating	O
a	O
44	B-STAT
%	B-EPI
reduction	O
in	O
the	O
incidence	O
of	O
HIV	O
95	B-STAT
%	I-STAT
confidence	O
interval	O
15	O
to	O
63	O
;	O
P=0.005	O
.	O

In	O
the	O
FTC	O
-	O
TDF	O
group	O
the	O
study	O
drug	O
was	O
detected	O
in	O
22	O
of	O
43	O
of	O
seronegative	O
subjects	O
51	B-STAT
%	I-STAT
and	O
in	O
3	O
of	O
34	O
HIV	O
-	O
infected	O
subjects	O
9	B-STAT
%	I-STAT
P	O
<	O
0.001	O
.	O

Nausea	B-DIS
was	O
reported	O
more	O
frequently	O
during	O
the	O
first	O
4	O
weeks	O
in	O
the	O
FTC	O
-	O
TDF	O
group	O
than	O
in	O
the	O
placebo	O
group	O
P	O
<	O
0.001	O
.	O

The	O
two	O
groups	O
had	O
similar	O
rates	O
of	O
serious	O
adverse	O
events	O
P=0.57	O
.	O

Conclusions	O
Oral	O
FTC	O
-	O
TDF	O
provided	O
protection	O
against	O
the	O
acquisition	B-DIS
of	I-DIS
HIV	O
infection	O
among	O
the	O
subjects	O
.	O

Detectable	O
blood	O
levels	O
strongly	O
correlated	O
with	O
the	O
prophylactic	O
effect	O
.	O

Funded	O
by	O
the	O
National	O
Institutes	O
of	O
Health	O
and	O
the	O
Bill	O
and	O
Melinda	O
Gates	O
Foundation	O
;	O
ClinicalTrials.gov	O
number	O
NCT00458393	B-LOC
.	O

.	O

Background	O
.	O

Human	O
T	B-DIS
-	I-DIS
cell	I-DIS
lymphotropic	I-DIS
virus	I-DIS
type	I-DIS
1	O
HTLV-1	O
is	O
responsible	O
for	B-DIS
tropical	I-DIS
spastic	O
paraparesis	B-DIS
and	I-DIS
HTLV-1	O
-	O
associated	O
leukemia	O
/	O
lymphoma	O
.	O

The	O
infection	B-DIS
is	O
endemic	O
in	O
some	O
areas	O
of	O
Peru	B-LOC
but	O
its	O
prevalence	B-EPI
in	O
the	O
Peruvian	O
Amazon	O
is	O
not	O
well	O
established	O
.	O

We	O
aimed	O
to	O
assess	O
the	O
seroprevalence	O
of	O
HTLV-1	B-DIS
infection	I-DIS
in	O
pregnant	O
women	O
in	O
the	O
Peruvian	O
Amazon	O
.	O

Moreover	O
we	O
performed	O
a	O
systematic	O
literature	O
review	O
and	O
meta	O
-	O
analysis	O
of	O
the	O
seroprevalence	B-DIS
of	I-DIS
HTLV	O
infection	O
in	O
Peru	B-LOC
.	O

2	O
Methods	O
.	O

This	O
is	O
a	O
prospective	O
cross	O
-	O
sectional	O
study	O
involving	O
pregnant	O
women	O
attending	O
health	O
centers	O
in	O
the	O
city	O
of	O
Iquitos	B-LOC
Peru	I-LOC
in	O
May	O
and	O
June	O
2019	O
.	O

The	O
presence	O
of	O
antibodies	O
against	O
HTLV-1	B-DIS
was	O
assessed	O
using	O
ELISA	O
HTLV	O
I	O
+	O
II	O
ELISA	O
recombinant	O
v.4.0	O
Wiener	O
lab	O
Rosario	O
Argentina	O
.	O

Positive	O
cases	O
were	O
confirmed	O
by	O
Western	O
Blot	O
and	O
HTLV-1	O
proviral	O
load	O
.	O

3	O
Results	O
.	O

The	O
study	O
included	O
300	O
pregnant	O
women	O
with	O
a	O
mean	O
age	O
of	O
26	O
years	O
standard	O
deviation	O
[	O
SD	O
]	O
6.4	O
.	O

Five	O
patients	O
were	O
diagnosed	O
with	O
HTLV-1	B-DIS
infection	I-DIS
prevalence	B-EPI
1.7	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
confidence	O
interval	O
CI	O
0.7	B-STAT
%	I-STAT
to	O
3.8	B-STAT
%	I-STAT
.	O

Pregnant	O
women	O
with	O
HTLV-1	B-DIS
infection	I-DIS
were	O
discretely	O
younger	O
mean	O
age	O
22.6	O
[	O
SD	O
22.6	O
]	O
vs	O
26.8	O
[	O
SD	O
6.3	O
]	O
;	O
p	O
=	O
0.128	O
.	O

None	O
of	O
the	O
five	O
women	O
had	O
been	O
transfused	O
and	O
all	O
were	O
asymptomatic	O
.	O

Two	B-STAT
40	I-STAT
%	I-STAT
also	O
had	O
a	O
positive	O
serology	O
for	O
Strongyloides	O
but	O
larvae	O
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
parasitological	O
stool	O
studies	O
.	O

The	O
systematic	O
review	O
component	O
identified	O
40	O
studies	O
which	O
showed	O
that	O
the	O
prevalence	B-EPI
of	O
HTLV	B-DIS
infection	I-DIS
in	O
the	O
general	O
population	O
was	O
2.9	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
1.2	B-STAT
%	I-STAT
to	I-STAT
5.3	B-STAT
%	I-STAT
and	O
in	O
women	O
of	O
childbearing	O
age	B-STAT
2.5	I-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
1.2	B-STAT
%	I-STAT
to	O
4.0	B-STAT
%	I-STAT
.	O

4	O
Conclusion	O
.	O

The	O
prevalence	B-EPI
of	O
HTLV-1	O
in	O
the	O
Peruvian	O
Amazon	O
basin	O
is	O
about	B-STAT
1.7	I-STAT
%	I-STAT
indicating	O
an	O
endemic	O
presence	O
.	O

Screening	O
for	O
HTLV-1	O
in	O
prenatal	O
care	O
is	O
warranted	O
.	O

Encephalocele	O
is	O
a	O
herniation	B-DIS
of	I-DIS
the	I-DIS
brain	I-DIS
cranium	I-DIS
bifidum	I-DIS
cephalocele	I-DIS
craniocele	O
formed	O
during	O
embryonic	O
development	O
because	O
of	O
the	O
incomplete	O
closure	O
of	O
Neural	O
Tube	O
.	O

It	O
is	O
a	O
rare	O
skull	O
defect	O
with	O
the	O
incidence	B-EPI
of	O
0.8	O
to	O
5	O
per	O
10000	O
live	O
births	O
.	O

The	O
article	O
presents	O
the	O
medical	O
history	O
of	O
a	O
four	O
month	O
old	O
patient	O
with	O
frontoethmoidal	B-DIS
encephalocele	I-DIS
and	O
multiple	B-DIS
skeletal	I-DIS
anomalies	I-DIS
such	O
as	O
amniotic	O
knots	O
on	O
limbs	O
foot	O
deformity	O
sindactilia	O
and	O
cleft	B-DIS
palate	I-DIS
.	O

Despite	O
the	O
known	O
association	O
of	O
cardiac	B-DIS
rupture	I-DIS
with	O
acute	B-DIS
myocardial	I-DIS
infarction	I-DIS
AMI	I-DIS
it	O
is	O
still	O
unclear	O
whether	O
the	O
clinical	O
characteristics	O
are	O
associated	O
with	O
the	O
risk	O
of	O
in	O
-	O
hospital	O
mortality	O
in	O
patients	O
with	O
AMI	O
complicated	B-DIS
by	I-DIS
cardiac	O
rupture	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
association	O
between	O
the	O
time	O
of	O
cardiac	B-DIS
rupture	I-DIS
occurrence	O
and	O
the	O
risk	O
of	O
in	O
-	O
hospital	O
mortality	O
after	O
AMI	O
.	O

We	O
conducted	O
a	O
retrospective	O
analysis	O
of	O
multicenter	O
registry	O
data	O
from	O
eight	O
medical	O
universities	O
in	O
Eastern	B-LOC
Japan	I-LOC
.	O

From	O
10278	O
consecutive	O
patients	O
with	O
AMI	O
we	O
included	O
183	O
patients	O
who	O
had	O
cardiac	B-DIS
rupture	I-DIS
after	O
AMI	O
and	O
examined	O
the	O
incidence	B-EPI
of	O
in	O
-	B-DIS
hospital	O
deaths	O
during	O
a	O
median	O
follow	O
-	O
up	O
of	O
26	O
days	O
.	O

Patients	O
were	O
stratified	O
into	O
three	O
groups	O
according	O
to	O
the	O
AMI	B-DIS
-	I-DIS
to	O
-	O
cardiac	O
rupture	O
time	O
namely	O
th	O
24	O
-	O
h	O
group	O
n	O
=	O
11124	O
-	O
48	O
-	O
h	O
group	O
n	O
=	O
20	O
and	O
<	O
48	O
-	O
h	O
group	O
n	O
=	O
52	O
.	O

Cox	O
proportional	O
hazards	O
regression	O
analysis	O
was	O
used	O
to	O
estimate	O
the	O
hazard	O
ratio	O
HR	O
and	O
the	O
confidence	O
interval	O
CI	O
for	O
in	O
-	O
hospital	O
mortality	O
.	O

Around	O
8748	B-STAT
%	I-STAT
patients	O
experienced	O
in	O
-	B-DIS
hospital	O
death	O
and	O
12667	B-STAT
%	I-STAT
underwent	O
a	O
cardiac	O
surgery	O
.	O

Multivariable	O
Cox	O
regression	O
analysis	O
revealed	O
a	O
non	O
-	O
linear	O
association	O
across	O
the	O
three	O
groups	O
for	O
mortality	O
HR	O
[	O
CI	O
]	O
;	O
<	O
24	O
h	O
1.0	O
reference	O
;	O
24	O
-	O
48	O
h	O
0.73	O
[	O
0.27	O
-	O
1.86	O
]	O
48	O
h	O
2.25	O
[	O
1.22	O
-	O
4.15	O
]	O
after	O
adjustments	O
for	O
age	O
sex	O
Killip	O
classification	O
percutaneous	O
coronary	O
intervention	O
blood	O
pressure	O
creatinine	O
peak	O
creatine	O
kinase	O
myocardial	O
band	O
fraction	O
left	O
ventricular	O
ejection	O
fraction	O
and	O
type	O
of	O
rupture	O
.	O

Cardiac	O
surgery	O
was	O
independently	O
associated	O
with	O
a	O
reduction	O
in	O
the	O
HR	O
of	O
mortality	O
HR	O
[	O
CI	O
]	O
0.27	O
[	O
0.12	O
-	O
0.61	O
]	O
and	O
attenuated	O
the	O
association	O
between	O
the	O
three	O
AMI	B-DIS
-	I-DIS
to	O
-	O
cardiac	O
rupture	O
time	O
categories	O
and	O
mortality	O
statistically	O
non	O
-	O
significant	O
in	O
the	O
Cox	O
model	O
.	O

These	O
data	O
suggest	O
that	O
the	O
AMI	B-DIS
-	I-DIS
to	O
-	O
cardiac	O
rupture	O
time	O
contributes	O
significantly	O
to	O
the	O
risk	O
of	O
in	O
-	O
hospital	O
mortality	O
;	O
however	O
rapid	O
diagnosis	O
and	O
prompt	O
surgical	O
interventions	O
are	O
crucial	O
for	B-DIS
improving	I-DIS
outcomes	O
in	O
patients	O
with	O
cardiac	O
rupture	O
after	O
AMI	O
.	O

Malignancy	B-DIS
must	O
be	O
considered	O
in	O
the	O
management	O
of	O
adrenal	O
lesions	O
including	O
those	O
incidentally	O
identified	O
on	O
imaging	O
studies	O
.	O

Adrenocortical	B-DIS
carcinomas	I-DIS
ACCs	O
are	O
rare	O
tumors	B-DIS
with	O
an	O
estimated	O
annual	O
incidence	B-EPI
of	O
0.7	O
-	O
2	O
cases	O
per	O
year	O
and	O
a	O
worldwide	O
prevalence	B-EPI
of	O
4	O
-	O
12	O
cases	O
per	O
million	O
/	O
year	O
.	O

However	O
a	O
much	O
higher	O
incidence	B-EPI
of	O
these	O
tumors	B-DIS
15	O
times	O
has	O
been	O
demonstrated	O
in	O
south	O
and	O
southeastern	O
Brazil	B-LOC
.	O

Most	O
ACCs	O
cause	O
hypersecretion	O
of	O
steroids	O
including	O
glucocorticoids	O
and	O
androgens	O
.	O

ACC	O
patients	O
have	O
a	O
very	O
poor	O
prognosis	O
with	O
a	O
5	O
-	O
year	O
overall	O
survival	O
OS	O
below	B-STAT
30	I-STAT
%	I-STAT
in	O
most	O
series	O
.	O

Pheochromocytoma	B-DIS
or	I-DIS
paraganglioma	I-DIS
PPGL	O
is	O
a	O
metabolically	O
active	O
tumor	B-DIS
originating	O
from	O
the	O
chromaffin	O
cells	O
of	O
the	O
adrenal	O
medulla	O
.	O

The	O
incidence	B-EPI
of	O
PPGL	O
is	O
0.2	O
to	O
0.9	O
cases	O
per	O
100000	O
individuals	O
per	O
year	O
.	O

Pheochromocytomas	B-DIS
are	O
present	O
in	O
approximately	O
4	O
-	O
7	O
%	O
of	O
patients	O
with	O
adrenal	B-DIS
incidentalomas	I-DIS
.	O

Classically	O
PPGL	O
manifests	O
as	O
paroxysmal	O
attacks	O
of	O
the	O
following	O
4	O
symptoms	O
headaches	B-DIS
diaphoresis	I-DIS
palpitations	I-DIS
and	O
severe	O
hypertensive	B-DIS
episodes	O
.	O

The	O
diagnosis	O
of	O
malignant	O
PPGL	O
relies	O
on	O
the	O
presence	O
of	O
local	O
invasion	O
or	O
metastasis	B-DIS
.	O

In	O
this	O
review	O
we	O
present	O
the	O
clinical	O
and	O
biochemical	O
characteristics	O
and	O
pathogenesis	O
of	O
malignant	B-DIS
primary	I-DIS
lesions	I-DIS
that	O
affect	O
the	O
cortex	O
and	O
medulla	O
of	O
human	O
adrenal	O
glands	O
.	O

Rationale	O
A	O
growing	O
body	O
of	O
literature	O
has	O
identified	O
a	O
robust	O
relationship	O
between	O
the	O
experience	O
of	O
racial	O
discrimination	O
and	O
negative	O
self	O
-	O
reported	O
physical	O
and	O
mental	O
health	O
outcomes	O
.	O

Objective	O
The	O
current	O
study	O
seeks	O
to	O
identify	O
which	O
factors	O
-at	O
the	O
community	O
level-	O
predict	O
racial	O
disparities	O
in	O
actual	O
disease	O
manifestation	O
.	O

This	O
study	O
focuses	O
on	O
the	O
extent	O
to	O
which	O
regional	O
demographics	O
and	O
racial	O
attitudes	O
both	O
implicit	O
and	O
explicit	O
are	O
associated	O
with	O
prevalence	B-EPI
rates	O
of	O
several	O
diseases	O
for	O
Black	O
and	O
White	O
patients	O
in	O
the	B-LOC
United	I-LOC
States	I-LOC
.	O

Methods	O
Implicit	O
and	O
explicit	O
racial	O
attitudes	O
obtained	O
from	O
Project	O
Implicit	O
Xu	O
et	O
al	O
.	O

2017	O
were	O
aggregated	O
at	O
the	O
county	O
level	O
to	O
predict	O
variation	O
in	O
the	O
prevalence	B-EPI
rates	O
of	O
several	O
chronic	B-DIS
illnesses	I-DIS
among	O
Medicare	O
recipients	O
.	O

Results	O
When	O
controlling	O
for	O
economic	O
indicators	O
Black	O
and	O
White	O
patients	O
who	O
live	O
in	O
areas	O
with	O
high	O
implicit	O
and	O
explicit	O
racial	O
bias	O
tend	O
to	O
exhibit	O
a	O
higher	O
incidence	B-EPI
of	O
chronic	O
health	O
problems	O
including	O
cancer	B-DIS
stroke	I-DIS
asthma	O
diabetes	B-DIS
and	O
heart	B-DIS
failure	I-DIS
.	O

These	O
relationships	O
tended	O
to	O
be	O
stronger	O
for	O
Black	O
patients	O
.	O

Additionally	O
patients	O
in	O
racially	O
diverse	O
and	O
racially	O
segregated	O
regions	O
also	O
tended	O
to	O
exhibit	O
a	O
higher	O
incidence	B-EPI
of	O
chronic	O
health	O
problems	O
.	O

Conclusion	O
Findings	O
from	O
the	O
study	O
highlight	O
the	O
reliable	O
relationship	O
between	O
both	O
racial	O
biases	O
and	O
regional	O
demographics	O
and	O
the	O
incidence	B-EPI
rates	O
of	O
several	O
chronic	B-DIS
diseases	I-DIS
particularly	O
in	O
Black	O
patients	O
.	O

Methylmalonic	O
acidemia	O
/	O
aciduria	O
MMA	O
is	O
a	O
genetically	O
heterogeneous	O
group	O
of	B-DIS
inherited	I-DIS
metabolic	O
disorders	O
biochemically	O
characterized	O
by	O
the	O
accumulation	O
of	O
methylmalonic	O
acid	O
.	O

Isolated	O
MMA	O
is	O
primarily	O
caused	O
by	O
the	O
deficiency	O
of	O
methylmalonyl	O
-	O
CoA	O
mutase	O
MMA	O
mut	O
;	O
EC	O
5.4.99.2	O
.	O

A	O
systematic	O
literature	O
review	O
and	O
a	O
meta	O
-	O
analysis	O
were	O
undertaken	O
to	O
assess	O
and	O
compile	O
published	O
epidemiological	O
data	O
on	O
MMA	O
with	O
a	O
focus	O
on	O
the	O
MMA	O
mut	B-DIS
subtype	O
OMIM	O
#	O
251000	O
.	O

Of	O
the	O
1114	O
identified	O
records	O
227	O
papers	O
were	O
assessed	O
for	O
eligibility	O
in	O
full	O
text	O
48	O
articles	O
reported	O
on	O
disease	O
epidemiology	O
and	O
39	O
articles	O
were	O
included	O
into	O
the	O
quantitative	O
synthesis	O
.	O

Implementation	O
of	O
newborn	O
screening	O
in	O
various	O
countries	O
has	O
allowed	O
for	O
the	O
estimation	O
of	O
birth	O
prevalence	B-EPI
of	O
MMA	O
and	O
its	O
isolated	O
form	O
.	O

Meta	O
-	O
analysis	O
pooled	O
point	O
estimates	O
of	O
MMA	O
all	O
types	O
detection	O
rates	O
were	O
0.79	O
1.12	O
1.22	O
and	O
6.04	O
per	O
100000	O
newborns	O
in	O
Asia	B-LOC
-	I-LOC
Pacific	I-LOC
Europe	I-LOC
North	I-LOC
America	I-LOC
and	O
the	B-LOC
Middle	I-LOC
East	I-LOC
and	O
North	B-LOC
Africa	I-LOC
MENA	I-LOC
regions	O
respectively	O
.	O

The	O
detection	O
rate	O
of	O
isolated	O
MMA	O
was	O
<	O
1	B-STAT
per	I-STAT
100000	I-STAT
newborns	O
in	O
all	O
regions	O
with	O
the	O
exception	O
of	O
MENA	O
where	O
it	O
approached	O
6	O
per	O
100000	O
newborns	O
.	O

Few	O
studies	O
published	O
data	O
on	O
the	O
epidemiology	O
of	O
MMA	O
mut	O
therefore	O
no	O
meta	O
-	O
analysis	O
could	O
have	O
been	O
performed	O
on	O
this	O
subtype	O
.	O

Most	O
of	O
the	O
identified	O
papers	O
reported	O
birth	O
prevalence	B-EPI
estimates	O
below	O
1	B-STAT
per	I-STAT
100000	I-STAT
newborns	O
for	O
MMA	O
mut	O
.	O

The	O
systematic	O
literature	O
review	O
clearly	O
demonstrates	O
that	O
MMA	O
and	O
its	O
subtypes	O
are	O
ultra	O
-	O
rare	O
disorders	O
.	O

Since	O
the	O
discovery	O
of	O
human	O
leukocyte	O
antigens	O
HLAs	O
the	O
function	O
of	O
major	O
histocompatibility	O
complex	O
MHC	O
gene	O
families	O
in	O
a	O
wide	O
range	O
of	O
diseases	O
have	O
been	O
the	O
subject	O
of	O
research	O
for	O
decades	O
.	O

In	O
particular	O
the	O
associations	O
of	O
autoimmune	B-DIS
disorders	I-DIS
to	O
allelic	O
variants	O
and	O
candidate	O
genes	O
encoding	O
the	O
MHC	O
are	O
well	O
documented	O
.	O

However	O
despite	O
decades	O
of	O
research	O
the	O
knowledge	O
of	O
MHC	O
associations	O
with	O
human	B-DIS
disease	I-DIS
susceptibility	O
have	O
been	O
predominantly	O
studied	O
in	O
European	O
origin	O
with	O
limited	O
understanding	O
in	O
different	O
populations	O
and	O
ethnic	O
groups	O
.	O

This	O
is	O
particularly	O
evident	O
in	O
countries	O
and	O
ethnic	O
populations	O
of	O
the	B-LOC
Arabian	I-LOC
Peninsula	I-LOC
.	O

Human	O
MHC	O
haplotypes	O
and	O
its	O
association	O
with	O
diseases	B-DIS
of	I-DIS
the	I-DIS
variable	I-DIS
ethnic	O
groups	O
of	O
this	O
region	O
are	O
poorly	O
studied	O
.	O

This	O
review	O
compiled	O
published	O
manuscripts	O
that	O
have	O
reported	O
a	O
list	O
of	O
autoimmune	B-DIS
diseases	I-DIS
insulin	I-DIS
-	I-DIS
dependent	I-DIS
diabetes	I-DIS
mellitus	I-DIS
systemic	I-DIS
lupus	I-DIS
erythematosus	I-DIS
myasthenia	I-DIS
gravis	I-DIS
rheumatoid	I-DIS
arthritis	I-DIS
psoriasis	O
vulgaris	B-DIS
and	I-DIS
multiple	O
sclerosis	O
associated	O
with	O
MHC	O
class	O
I	O
and	O
class	O
II	O
in	O
the	O
populations	O
of	O
the	B-LOC
Arabian	I-LOC
Peninsula	I-LOC
specifically	O
Bahrain	B-LOC
Kuwait	I-LOC
Oman	B-LOC
Qatar	B-LOC
Saudi	B-LOC
Arabia	I-LOC
the	B-LOC
United	I-LOC
Arab	I-LOC
Emirates	I-LOC
and	O
Yemen	B-LOC
.	O

Data	O
available	O
was	O
compared	O
with	O
other	O
three	O
ethnic	O
groups	O
namely	O
Caucasians	O
Asians	O
and	O
Africans	O
.	O

The	O
limited	O
data	O
available	O
in	O
the	O
public	O
domain	O
on	O
the	O
association	O
between	O
MHC	O
gene	O
and	O
autoimmune	B-DIS
diseases	I-DIS
highlight	O
the	O
challenges	O
in	O
the	O
Middle	B-LOC
Eastern	I-LOC
region	O
.	O

BACKGROUNDBalanced	O
reciprocal	O
chromosomal	O
translocations	O
RCTs	O
are	O
the	O
ones	O
of	O
the	O
most	O
common	O
structural	O
aberrations	O
in	O
the	O
population	O
with	O
an	O
incidence	B-EPI
of	O
1625	O
.	O

RCT	O
carriers	O
usually	O
do	O
not	O
demonstrate	O
changes	O
in	O
phenotype	O
except	O
when	O
the	O
translocation	O
results	O
in	O
gene	O
interruption	O
.	O

However	O
these	O
people	O
are	O
at	O
risk	O
of	O
production	O
of	O
unbalanced	O
gametes	O
during	O
meiosis	O
as	O
a	O
result	O
of	O
various	O
forms	O
of	O
chromosome	O
segregation	O
.	O

This	O
may	O
cause	O
infertility	B-DIS
non	O
-	O
implantation	O
of	O
the	O
embryo	O
shorter	O
embryo	O
or	O
foetus	O
survival	O
as	O
well	B-DIS
as	I-DIS
congenital	O
defects	O
and	O
developmental	O
disorders	O
in	O
children	O
after	O
birth	O
.	O

The	O
increasing	O
popularity	O
of	O
cytogenetic	O
molecular	O
techniques	O
such	O
as	O
microarray	O
-	O
based	O
CGH	O
aCGH	O
contributed	O
to	O
the	O
improved	O
detection	B-DIS
of	I-DIS
chromosomal	O
abnormalities	O
in	O
patients	B-DIS
with	I-DIS
intellectual	O
disability	O
however	O
these	O
modern	O
techniques	O
do	O
not	O
allow	O
the	O
identification	O
of	O
the	O
balanced	O
in	O
potential	O
carriers	O
.	O

Therefore	O
classical	O
chromosome	O
analysis	O
with	O
GTG	O
technique	O
still	O
plays	O
an	O
important	O
role	O
in	O
the	O
identification	O
of	O
balanced	O
rearrangements	O
in	O
every	O
case	O
of	O
procreation	O
failure	O
.	O

CASE	O
PRESENTATIONIn	O
this	O
article	O
a	O
family	O
with	O
multiple	O
occurrences	O
of	O
17p13.3	O
duplication	O
syndrome	O
in	O
the	O
offspring	O
and	O
multiple	O
miscarriages	O
resulting	O
from	O
carrying	O
of	O
the	O
balanced	O
reciprocal	O
translocation	O
t	O
7	O
;	O
17	O
p22	O
;	O
p13.2	O
by	O
proband	O
father	O
is	O
presented	O
.	O

The	O
aCGH	O
diagnostics	O
allowed	O
the	O
identification	O
of	O
an	O
unbalanced	O
fragment	O
responsible	O
for	O
the	O
occurrence	O
of	O
clinical	O
signs	O
in	O
the	O
female	O
patient	O
while	O
karyotyping	O
and	O
FISH	O
using	O
specific	O
probes	O
allowed	O
the	O
localization	O
of	O
the	O
additional	O
material	O
in	O
the	O
patient	O
chromosomes	O
and	O
identified	O
the	O
type	O
of	O
this	O
translocation	O
in	O
the	O
carriers	O
.	O

CONCLUSIONSIdentification	O
of	O
a	O
balanced	O
structural	O
aberration	O
in	O
one	O
of	O
the	O
partners	O
allows	O
direct	O
diagnostics	O
for	O
the	O
exclusion	O
or	O
confirmation	O
of	O
genetic	O
imbalance	O
in	O
the	O
foetus	O
via	O
traditional	O
invasive	O
prenatal	O
diagnostics	O
.	O

It	O
is	O
also	O
possible	O
to	O
use	O
an	O
alternative	O
method	O
Preimplantation	O
Genetic	O
Diagnosis	O
PGD	O
after	O
in	O
vitro	O
fertilization	O
which	O
prevents	O
initiating	O
pregnancy	O
if	O
genetic	O
imbalance	O
is	O
detected	O
in	O
the	O
embryo	O
.	O

Frontal	B-DIS
fibrosing	I-DIS
alopecia	I-DIS
FFA	O
is	O
a	O
variant	O
of	O
lichen	B-DIS
planopilaris	I-DIS
LPP	O
with	O
characteristic	O
band	B-DIS
-	I-DIS
like	I-DIS
frontotemporal	O
hairline	O
involvement	B-DIS
and	I-DIS
eyebrow	O
loss	O
.	O

It	O
most	O
commonly	O
occurs	O
in	O
post	O
-	O
menopausal	O
White	O
women	O
.	O

1	O
<	O
/s	O
In	O
skin	O
of	O
color	O
SOC	O
individuals	O
FFA	O
is	O
often	O
misdiagnosed	O
as	O
traction	O
alopecia	B-DIS
TA	O
2	O
<	O
/s	O
and	O
little	O
data	O
exists	O
regarding	O
the	O
presentation	O
of	O
FFA	O
in	O
the	O
SOC	O
patient	O
population	O
.	O

3	O
<	O
/s	O
As	O
FFA	O
incidence	B-EPI
continues	O
to	O
increase	O
4	O
<	O
/s	O
we	O
aim	O
to	O
understand	O
differences	O
in	O
the	O
presentation	O
of	O
FFA	O
between	O
White	O
and	O
Black	O
women	O
in	O
order	O
to	O
aid	O
in	O
the	O
accurate	O
and	O
timely	O
diagnosis	O
as	O
well	O
as	O
help	O
inform	O
prognosis	O
and	O
management	O
.	O

Introduction	O
Globally	O
eye	O
diseases	O
are	O
considered	O
as	O
one	O
of	O
the	O
major	O
contributors	O
of	O
nonfatal	O
disabling	O
conditions	O
.	O

In	O
Bangladesh	B-LOC
1.5	B-STAT
%	I-STAT
of	O
adults	O
are	O
blind	O
and	O
21.6	B-STAT
%	I-STAT
have	O
low	B-DIS
vision	I-DIS
.	O

Therefore	O
this	O
paper	O
aimed	O
to	O
identify	O
the	O
community	O
-	B-EPI
based	O
prevalence	O
and	O
associated	O
risk	O
factors	O
of	O
eye	O
diseases	O
among	O
slum	O
dwellers	O
of	O
Dhaka	B-LOC
city	O
.	O

Methods	O
The	O
study	O
was	O
carried	O
out	O
in	O
two	O
phases	O
.	O

In	O
the	O
first	O
phase	O
a	O
survey	O
was	O
conducted	O
using	O
multistage	O
cluster	O
sampling	O
among	O
1320	O
households	O
of	O
three	O
purposively	O
selected	O
slums	O
in	O
Dhaka	B-LOC
city	O
.	O

From	O
each	O
household	O
one	O
family	O
member	O
â‰¥	O
18	O
years	O
old	O
was	O
randomly	O
interviewed	O
by	O
trained	O
data	O
collectors	O
using	O
a	O
structured	O
questionnaire	O
.	O

After	O
that	O
each	O
of	O
the	O
participants	O
was	O
requested	O
to	O
take	O
part	O
in	O
the	O
second	O
phase	O
of	O
the	O
study	O
.	O

Following	O
the	O
request	O
432	O
participants	O
out	O
of	O
1320	O
participants	O
came	O
into	O
the	O
tertiary	O
care	O
hospitals	O
where	O
they	O
were	O
clinically	O
assessed	O
by	O
ophthalmologist	O
for	O
presence	O
of	O
eye	O
diseases	O
.	O

A	O
number	O
of	O
descriptive	O
and	O
inferential	O
statistics	O
were	O
performed	O
using	O
Stata	O
13	O
.	O

Result	O
The	O
majority	O
of	O
total	O
432	O
study	O
participants	O
were	O
female	O
68.6	B-STAT
%	I-STAT
married	O
82.6	B-STAT
%	I-STAT
and	O
Muslim	O
98.8	B-STAT
%	I-STAT
.	O

Among	O
them	O
almost	O
all	O
92.8	B-STAT
%	I-STAT
were	O
clinically	O
diagnosed	O
with	O
eye	B-DIS
disease	I-DIS
.	O

The	O
most	O
prevalent	O
eye	O
diseases	O
were	O
refractive	O
error	O
63.2	B-STAT
%	I-STAT
conjunctivitis	B-DIS
17.1	B-STAT
%	I-STAT
visual	B-DIS
impairment	I-DIS
16.4	B-STAT
%	I-STAT
and	O
cataract	B-DIS
7.2	B-STAT
%	I-STAT
.	O

Refractive	O
error	O
was	O
found	O
significantly	O
associated	O
with	O
older	O
age	O
female	O
gender	O
and	O
income	O
generating	O
work	O
.	O

Cataract	B-DIS
was	O
found	O
negatively	O
associated	O
with	O
the	O
level	O
of	O
education	O
however	O
opposite	O
relationship	O
was	O
found	O
between	O
cataract	B-DIS
and	O
visual	B-DIS
impairment	I-DIS
.	O

Conclusion	O
Our	O
study	O
provides	O
epidemiologic	O
data	O
on	O
the	O
prevalence	B-EPI
of	O
eye	B-DIS
diseases	I-DIS
among	O
adult	O
population	O
in	O
low	O
-	O
income	O
urban	O
community	O
of	O
Dhaka	B-LOC
city	O
.	O

The	O
high	O
prevalence	B-EPI
of	O
refractive	O
error	O
allergic	B-DIS
conjunctivitis	I-DIS
visual	I-DIS
impairment	I-DIS
and	O
cataract	B-DIS
among	O
this	O
group	O
of	O
people	O
suggests	O
the	O
importance	O
of	O
increasing	O
access	O
to	O
eye	O
care	O
services	O
.	O

Objective	O
This	O
study	O
aimed	O
to	O
evaluate	O
the	O
epidemiological	O
and	O
clinicopathological	O
spectrum	O
of	O
ocular	B-DIS
malignancies	I-DIS
among	O
patients	O
presenting	O
to	O
a	O
teaching	O
hospital	O
in	O
Northern	B-LOC
India	I-LOC
.	O

Methods	O
A	O
total	O
of	O
246	O
histopathologically	O
diagnosed	O
patients	O
with	O
ocular	B-DIS
malignancies	I-DIS
were	O
included	O
in	O
the	O
study	O
.	O

Tumor	B-DIS
type	O
and	O
size	O
primary	O
origin	O
and	O
location	O
of	O
tumor	B-DIS
clinical	O
staging	O
radiological	O
findings	O
histopathological	O
type	O
and	O
treatment	O
outcomes	O
were	O
assessed	O
.	O

Results	O
Overall	O
males	O
over	O
55	O
years	O
of	O
age	O
were	O
most	O
commonly	O
affected	O
and	O
the	O
majority	O
of	O
cases	O
were	O
primary	B-DIS
ocular	I-DIS
or	I-DIS
adnexal	I-DIS
malignancies	I-DIS
n	O
=	O
226	O
;	O
91.87	B-STAT
%	I-STAT
.	O

The	O
eyelids	O
and	O
periocular	O
structures	O
n	O
=	O
92	O
;	O
37.40	B-STAT
%	I-STAT
were	O
the	O
most	O
commonly	O
involved	O
site	O
followed	O
by	O
the	O
orbit	O
n	O
=	O
72	O
;	O
29.27	B-STAT
%	I-STAT
ocular	O
surface	O
n	O
=	O
46	O
;	O
18.70	B-STAT
%	I-STAT
and	O
intraocular	O
region	O
n	O
=	O
36	O
;	O
14.63	B-STAT
%	I-STAT
.	O

The	O
majority	O
of	O
the	O
patients	O
n	O
=	O
68	O
;	O
27.64	B-STAT
%	I-STAT
were	O
managed	O
by	O
primary	O
surgical	O
excision	O
and	O
reconstruction	O
.	O

However	O
46	O
patients	O
18.70	B-STAT
%	I-STAT
with	O
advanced	O
lesions	O
underwent	O
neoadjuvant	O
chemotherapy	O
followed	O
by	O
surgical	O
excision	O
and	O
more	O
extensive	O
orbital	O
lesions	O
were	O
treated	O
by	O
exenteration	O
followed	O
by	O
adjuvant	O
chemotherapy	O
n=48	O
;	O
19.51	B-STAT
%	I-STAT
while	O
patients	O
with	O
metastatic	O
tumor	B-DIS
were	O
given	O
palliative	O
chemotherapy	O
/	O
external	O
beam	O
radiation	O
therapy	O
n=	O
46	O
;	O
18.70	B-STAT
%	I-STAT
.	O

Overall	O
45.12	B-STAT
%	I-STAT
of	O
patients	O
were	O
cured	O
completely	O
15.45	B-STAT
%	I-STAT
showed	O
a	O
partial	O
response	O
to	O
the	O
treatment	O
13.04	B-STAT
%	I-STAT
had	O
progressive	O
disease	O
and	O
16.67	B-STAT
%	I-STAT
demonstrated	O
disease	O
recurrence	O
.	O

Conclusion	O
A	O
clinicopathological	O
analysis	O
of	O
ocular	B-DIS
malignancies	I-DIS
at	O
a	O
teaching	O
hospital	O
in	O
Northern	B-LOC
India	I-LOC
indicated	O
the	O
preponderance	O
of	O
primary	B-DIS
ocular	I-DIS
malignancies	I-DIS
with	O
eyelid	B-DIS
sebaceous	I-DIS
gland	I-DIS
carcinomas	I-DIS
being	O
the	O
most	O
common	O
pathological	O
diagnosis	O
.	O

Most	O
of	O
our	O
patients	O
had	O
advanced	O
and	O
extensive	B-DIS
disease	I-DIS
among	O
them	O
majority	O
belonged	O
to	O
the	O
rural	O
background	O
and	O
poor	O
socio	O
-	O
economic	O
status	O
.	O

Grafting	O
watermelon	O
scions	O
to	O
interspecific	O
squash	O
hybrids	O
has	O
been	O
found	O
to	O
increase	O
fruit	O
firmness	O
.	O

Triploid	B-DIS
seedless	I-DIS
watermelon	I-DIS
are	O
prone	O
to	O
hollow	O
heart	O
HH	O
an	O
internal	O
fruit	O
disorder	O
characterized	O
by	O
a	O
crack	O
in	O
the	O
placental	O
tissue	O
expanding	O
to	O
a	O
cavity	O
.	O

Although	O
watermelon	O
with	O
lower	O
tissue	O
firmness	O
tend	O
to	O
have	O
a	O
higher	O
HH	B-DIS
incidence	B-EPI
associated	O
differences	O
in	O
cell	O
wall	O
polysaccharide	O
composition	O
are	O
unknown	O
.	O

Grafting	O
`	O
`	O
Liberty	O
''	O
watermelon	O
to	O
`	O
`	O
Carnivor	O
''	O
interspecific	O
hybrid	O
rootstock	O
C.	O
moschata	O
Ã—	O
C.	O
maxima	O
reduced	O
HH	B-DIS
39	B-STAT
%	I-STAT
and	O
increased	O
tissue	O
firmness	O
by	O
3	O
N.	O
Fruit	O
with	O
and	O
without	O
severe	O
HH	B-DIS
from	O
both	O
grafted	O
and	O
non	O
-	O
grafted	O
plants	O
were	O
analyzed	O
to	O
determine	O
differences	O
in	O
cell	O
wall	O
polysaccharides	O
associated	O
with	O
grafting	B-DIS
and	O
HH	O
.	O

Alcohol	O
insoluble	O
residues	O
AIR	O
were	O
sequentially	O
extracted	O
from	O
placental	O
tissue	O
to	O
yield	O
water	O
soluble	O
WSF	O
carbonate	O
soluble	O
CSF	O
alkali	O
soluble	O
ASF	O
or	O
unextractable	O
UNX	O
pectic	O
fractions	O
.	O

The	O
CSF	O
was	O
lower	O
in	O
fruit	O
with	O
HH	B-DIS
24.5	B-STAT
%	I-STAT
compared	O
to	O
those	O
without	O
HH	B-DIS
27.1	B-STAT
%	I-STAT
.	O

AIRs	O
were	O
also	O
reduced	O
hydrolyzed	O
and	O
acetylated	O
for	O
GC	O
-	O
MS	O
analysis	O
of	O
monosaccharide	O
composition	O
and	O
a	O
portion	O
of	O
each	O
AIR	O
was	O
methylated	O
prior	O
to	O
hydrolysis	O
and	O
acetylation	O
to	O
produce	O
partially	O
methylated	O
alditol	O
acetates	O
for	O
polysaccharide	O
linkage	O
assembly	O
.	O

No	O
differences	O
in	O
degree	O
of	O
methylation	O
or	O
galacturonic	O
and	O
glucuronic	O
acid	O
concentrations	O
were	O
found	O
.	O

Glucose	O
and	O
galactose	O
were	O
in	O
highest	O
abundance	O
at	O
75.9	O
and	O
82.4	O
Î¼gâ‹…mg	O
-1	O
<	O
/s	O
AIR	O
respectively	O
followed	O
by	O
xylose	O
and	O
arabinose	O
29.3	O
and	O
22.0	O
Î¼gâ‹…mg	O
-1	O
<	O
/s	O
.	O

Mannose	O
was	O
higher	O
in	O
fruit	O
with	O
HH	O
p	O
<	O
0.05	O
and	O
xylose	O
was	O
highest	O
in	O
fruit	O
from	O
grafted	O
plants	O
p	O
<	O
0.05	O
.	O

Mannose	O
is	O
primarily	O
found	O
in	O
heteromannan	O
and	O
rhamnogalacturonan	O
I	O
side	O
chains	O
while	O
xylose	O
is	O
found	O
in	O
xylogalacturonan	O
or	O
heteroxylan	O
.	O

In	O
watermelon	O
34	O
carbohydrate	O
linkages	O
were	O
identified	O
with	O
galactose	O
glucose	O
and	O
arabinose	O
linkages	O
in	O
highest	O
abundance	O
.	O

This	O
represents	O
the	O
most	O
comprehensive	O
polysaccharide	O
linkage	O
analysis	O
to	O
date	O
for	O
watermelon	O
including	O
the	O
identification	O
of	O
several	O
new	O
linkages	O
.	O

However	O
total	O
pectin	O
and	O
cell	O
wall	O
composition	O
data	O
could	O
not	O
explain	O
the	O
increased	O
tissue	O
firmness	O
observed	O
in	O
fruit	O
from	O
grafted	O
plants	O
.	O

Nonetheless	O
grafting	O
onto	O
the	O
interspecific	O
hybrid	O
rootstock	O
decreased	O
the	O
incidence	B-EPI
of	O
HH	B-DIS
and	O
can	O
be	O
a	O
useful	O
method	O
for	O
growers	O
using	O
HH	B-DIS
susceptible	O
cultivars	O
.	O

Aims	O
To	O
review	O
and	O
present	O
the	O
current	O
knowledge	O
of	O
incidence	B-EPI
signs	O
and	O
symptoms	O
diagnosis	O
and	O
treatment	O
of	O
the	O
occipital	B-DIS
encephalocele	I-DIS
.	O

Background	O
Encephalocele	O
E	O
is	O
a	O
defect	O
of	O
the	O
neural	O
tube	O
that	O
refers	O
to	O
congenital	B-DIS
malformations	I-DIS
featured	O
by	O
skull	O
defect	O
and	O
dura	O
with	O
extracranial	O
spread	O
of	O
intracranial	O
structures	O
.	O

Occipital	B-DIS
encephalocele	I-DIS
OE	O
are	O
the	O
most	O
common	O
form	O
of	O
this	O
congenital	B-DIS
disorder	I-DIS
and	O
are	O
manifested	O
as	O
a	O
swelling	B-DIS
of	O
different	O
sizes	O
over	O
the	O
occipital	O
bone	O
in	O
the	O
midline	O
.	O

Proper	O
diagnosis	O
and	O
treatment	O
is	O
highly	O
important	O
in	O
the	O
management	O
of	O
this	O
congenital	B-DIS
malformation	I-DIS
of	O
brain	O
.	O

Objective	O
To	O
review	O
and	O
present	O
the	O
current	O
knowledge	O
of	O
incidence	B-EPI
signs	O
and	O
symptoms	O
diagnosis	O
and	O
treatment	O
of	O
the	O
occipital	B-DIS
encephalocele	I-DIS
.	O

Methods	O
We	O
conducted	O
a	O
search	O
of	O
case	O
reports	O
or	O
case	O
-	O
series	O
of	O
patients	O
by	O
the	O
use	O
of	O
electronic	O
databases	O
Pub	O
Med	O
Medline	O
Index	O
Medicus	O
Scorpus	O
.	O

The	O
key	O
words	O
were	O
encephalocele	B-DIS
occipital	I-DIS
encephalocele	I-DIS
neural	I-DIS
tube	I-DIS
defect	I-DIS
congenital	B-DIS
malformation	I-DIS
.	O

The	O
search	O
was	O
updated	O
to	O
December	O
312018	O
.	O

Papers	O
published	O
in	O
English	O
were	O
the	O
only	O
source	O
of	O
information	O
.	O

Results	O
Occipital	O
encephalocelle	O
are	O
more	O
frequent	O
in	O
females	O
than	O
in	O
males	O
.	O

The	O
incidence	B-EPI
is	O
between	O
1	B-STAT
in	I-STAT
3000	I-STAT
to	O
1	B-STAT
in	I-STAT
10000	I-STAT
live	O
births	O
;	O
approximately	B-STAT
90	I-STAT
%	I-STAT
of	O
them	O
involve	O
the	O
midline	O
.	O

Magnetic	O
resonance	O
imaging	O
is	O
the	O
method	O
of	O
choice	O
in	O
diagnosis	O
and	O
surgery	O
is	O
the	O
best	O
option	O
for	O
the	O
treatment	O
of	O
OE	O
.	O

Overall	O
morbidity	O
and	O
mortality	O
is	O
still	O
high	O
in	O
spite	O
of	O
advenced	O
surgical	O
management	O
but	O
have	O
been	O
significantly	O
improved	O
in	O
recent	O
years	O
thanks	O
to	O
sophisticated	O
highresolution	O
imaging	O
adequate	O
and	O
proper	O
surgical	O
treatment	O
and	O
decent	O
post	O
-	O
operative	O
care	O
.	O

Conclusion	O
Occipital	O
encephalocele	O
is	O
the	O
most	O
common	O
form	O
of	O
encephalocele	B-DIS
.	O

The	O
diagnosis	O
is	O
mostly	O
based	O
by	O
the	O
use	O
of	O
neuroimaging	O
techniques	O
.	O

Operation	O
is	O
the	O
best	O
option	O
for	O
treatment	O
.	O

Overall	O
morbidity	O
and	O
mortality	O
is	O
still	O
high	O
but	O
have	O
been	O
significantly	O
improved	O
in	O
recent	O
years	O
thanks	O
to	O
sophisticated	O
high	O
-	O
resolution	O
imaging	O
adequate	O
and	O
proper	O
surgical	O
treatment	O
and	O
decent	O
post	O
-	O
operative	O
care	O
.	O

Background	O
Twenty	O
-	O
one	B-DIS
-	I-DIS
hydroxylase	I-DIS
-	O
deficient	O
non	O
-	O
classic	O
adrenal	B-DIS
hyperplasia	I-DIS
NC	B-LOC
-	B-EPI
CAH	O
is	O
a	O
very	O
common	O
autosomal	O
recessive	O
syndrome	O
with	O
prevalence	O
between	O
11000	O
and	O
12000	O
individuals	O
and	O
the	O
frequency	O
varies	O
according	O
to	O
ethnicity	O
.	O

On	O
the	O
other	O
hand	B-DIS
polycystic	I-DIS
ovary	I-DIS
syndrome	I-DIS
has	O
a	O
familial	O
basis	O
and	O
it	O
is	O
inherited	O
under	O
a	O
complex	O
hereditary	O
trait	O
.	O

This	O
syndrome	O
affects	O
6	B-STAT
to	I-STAT
10	I-STAT
%	I-STAT
of	O
women	O
in	O
reproductive	O
age	O
and	O
it	O
is	O
the	O
most	O
common	O
endocrine	B-DIS
disorder	I-DIS
in	O
young	O
women	O
.	O

Our	O
aim	O
was	O
to	O
investigate	O
through	O
a	O
systematic	O
review	O
the	O
distinct	O
characteristics	O
and	O
common	O
findings	O
of	O
these	O
syndromes	O
.	O

Methods	O
The	O
search	O
period	O
covered	O
January	O
1970	O
to	O
November	O
2018	O
using	O
the	O
scientific	O
databases	O
PubMed	O
.	O

Inclusion	O
criteria	O
were	O
adult	O
women	O
patients	O
with	O
PCOS	B-DIS
or	O
NC	B-DIS
-	O
CAH	O
.	O

Search	O
terms	O
were	O
`	O
`	O
polycystic	B-DIS
ovary	I-DIS
syndrome	I-DIS
`	O
`	O
`	O
`	O
PCOS	B-DIS
`	O
`	O
`	O
`	O
non	O
-	B-DIS
classical	I-DIS
adrenal	I-DIS
hyperplasia	I-DIS
`	I-DIS
`	I-DIS
`	I-DIS
`	O
NC	O
-	O
CAH	O
`	B-DIS
`	I-DIS
`	O
`	O
21	O
-	O
hydroxylase	O
deficiency	O
.	O
''	O

From	O
an	O
initial	O
16255	O
titles	O
the	O
evaluations	O
led	O
to	O
the	O
final	O
inclusion	O
of	O
97	O
papers	O
.	O

Results	O
The	O
clinical	O
features	O
of	O
NC	B-DIS
-	O
CAH	B-DIS
are	O
hirsutism	O
and	O
ovulatory	B-DIS
and	I-DIS
menstrual	O
dysfunction	O
therefore	O
;	O
differentiation	O
between	O
these	O
two	O
syndromes	O
is	O
difficult	O
based	O
on	O
clinical	O
grounds	O
only	O
.	O

Additionally	O
NC	B-DIS
-	O
CAH	B-DIS
and	O
PCOS	O
are	O
both	O
associated	B-DIS
with	O
obesity	O
insulin	O
resistance	B-DIS
and	O
dyslipidaemia	O
.	O

Reproductive	O
abnormalities	O
are	O
also	O
common	O
between	O
these	O
hyperandrogenemic	B-DIS
disorders	I-DIS
since	O
in	O
patients	O
with	O
NC	B-DIS
-	I-DIS
CAH	I-DIS
polycystic	O
ovarian	O
morphology	B-DIS
and	O
subfertility	O
are	O
present	O
as	O
they	O
are	O
in	O
women	B-DIS
with	O
PCOS	O
.	O

The	O
diagnosis	O
of	O
PCOS	B-DIS
is	O
confirmed	O
once	O
other	O
disorders	O
that	O
mimic	O
PCOS	B-DIS
have	O
been	O
excluded	O
e.g	O
.	O

conditions	O
that	O
are	O
related	O
to	O
oligoovulation	B-DIS
or	O
anovulation	B-DIS
and/or	O
hyperandrogenism	B-DIS
such	O
as	O
hyperprolactinaemia	B-DIS
thyroid	I-DIS
disorders	I-DIS
non	I-DIS
-	I-DIS
classic	I-DIS
congenital	I-DIS
adrenal	I-DIS
hyperplasia	I-DIS
and	I-DIS
androgen	O
-	O
producing	O
neoplasms	O
.	O

Conclusions	O
The	O
screening	O
tool	O
to	O
distinguish	O
non	B-DIS
-	B-DIS
classic	I-DIS
adrenal	O
hyperplasia	B-DIS
from	O
PCOS	O
is	O
the	O
measurement	O
of	O
17	O
-	O
hydroxyprogesterone	O
levels	O
.	O

The	O
basal	O
levels	O
of	O
17	O
-	O
hydroxyprogesterone	O
may	O
overlap	O
but	O
ACTH	O
stimulation	O
testing	O
can	O
distinguish	O
the	O
two	O
entities	O
.	O

In	O
this	O
review	O
these	O
two	O
common	O
endocrine	B-DIS
disorders	I-DIS
are	O
discussed	O
in	O
an	O
effort	O
to	O
unveil	O
their	O
commonalities	O
and	O
to	O
illuminate	O
their	O
shadowed	O
distinctive	O
characteristics	O
.	O

Pulmonary	B-DIS
agenesis	I-DIS
is	O
a	O
rarely	O
encountered	O
congenital	B-DIS
anomaly	I-DIS
and	O
its	O
average	O
prevalence	B-EPI
is	O
about	O
1	B-STAT
in	I-STAT
100000	I-STAT
births	O
.	O

Anomalies	B-DIS
of	I-DIS
the	I-DIS
cardiovascular	I-DIS
musculoskeletal	I-DIS
gastrointestinal	I-DIS
or	I-DIS
genitourinary	I-DIS
systems	I-DIS
may	O
accompany	O
in	O
nearly	O
half	O
of	O
the	O
cases	O
.	O

The	O
diagnosis	O
of	O
pulmonary	B-DIS
agenesis	I-DIS
is	O
usually	O
made	O
during	O
childhood	O
but	O
the	O
diagnosis	O
may	O
be	O
delayed	O
until	O
adulthood	O
in	O
case	O
of	O
an	O
absence	O
of	O
comorbid	B-DIS
anomalies	I-DIS
.	O

Herein	O
we	O
present	O
a	O
case	O
of	O
pulmonary	B-DIS
agenesis	I-DIS
that	O
was	O
diagnosed	O
during	O
adulthood	O
.	O

Past	O
studies	O
strongly	O
connected	O
stool	O
consistency	O
-	O
as	O
measured	O
by	O
Bristol	O
Stool	O
Scale	O
BSS	O
-with	O
microbial	O
gene	O
richness	B-DIS
and	I-DIS
intestinal	O
inflammation	O
colonic	O
transit	O
time	O
and	O
metabolome	O
characteristics	O
that	O
are	O
of	O
clinical	O
relevance	O
in	O
numerous	O
gastro	O
intestinal	O
conditions	O
.	O

While	O
retention	O
time	O
defecation	O
rate	O
BSS	O
but	O
not	O
water	O
activity	O
have	O
been	O
shown	O
to	O
account	O
for	O
BSS	O
-	O
associated	O
inflammatory	O
effects	O
the	O
potential	O
correlation	O
with	O
the	O
strength	O
of	O
a	O
gel	O
in	O
the	O
context	O
of	O
intestinal	O
forces	O
abrasion	O
mucus	O
imprinting	O
fecal	O
pore	O
clogging	O
remains	O
unexplored	O
as	O
a	O
shaping	O
factor	B-DIS
for	I-DIS
intestinal	O
inflammation	O
and	O
has	O
yet	O
to	O
be	O
determined	O
.	O

Our	O
study	O
introduced	O
a	O
minimal	O
pressure	O
approach	O
MP	B-DIS
by	O
probe	O
indentation	O
as	O
measure	O
of	O
stool	O
material	O
crosslinking	O
in	O
fecal	O
samples	O
.	O

Results	O
reported	O
here	O
were	O
obtained	O
from	O
170	O
samples	O
collected	O
in	O
two	O
independent	O
projects	O
including	O
males	O
and	O
females	O
covering	O
a	O
wide	O
span	O
of	O
moisture	O
contents	O
and	O
BSS	O
.	O

MP	B-DIS
values	O
increased	O
exponentially	O
with	O
increasing	O
consistency	O
i.e	O
.	O

lower	O
BSS	O
and	O
enabled	O
stratification	O
of	O
samples	O
exhibiting	O
mixed	O
BSS	O
classes	O
.	O

A	O
trade	O
-	O
off	O
between	B-DIS
lowest	O
MP	O
and	O
highest	O
dry	O
matter	O
content	O
delineated	O
the	O
span	O
of	O
intermediate	O
healthy	O
density	O
of	O
gel	O
crosslinks	O
.	O

The	O
crossectional	O
transects	O
identified	O
fecal	O
surface	O
layers	O
with	O
exceptionally	O
high	O
MP	B-DIS
and	O
of	O
<	O
5	O
mm	O
thickness	O
followed	O
by	O
internal	O
structures	O
with	O
an	O
order	O
of	O
magnitude	O
lower	O
MP	B-DIS
characteristic	O
of	O
healthy	O
stool	O
consistency	O
.	O

The	O
MP	B-DIS
and	O
BSS	O
values	O
reported	O
in	O
this	O
study	O
were	O
coupled	O
to	O
reanalysis	O
of	O
the	O
PlanHab	O
data	O
and	O
fecal	O
1H	O
-	O
NMR	O
metabolomes	O
reported	O
before	O
.	O

The	O
exponential	O
association	O
between	O
stool	O
consistency	O
and	O
MP	B-DIS
determined	O
in	O
this	O
study	O
was	O
mirrored	O
in	O
the	O
elevated	O
intestinal	O
and	O
also	O
systemic	O
inflammation	B-DIS
and	O
other	O
detrimental	O
physiological	O
deconditioning	O
effects	O
observed	O
in	O
the	O
PlanHab	O
participants	O
reported	O
before	O
.	O

The	O
MP	B-DIS
approach	O
described	O
in	O
this	O
study	O
can	O
be	O
used	O
to	O
better	O
understand	O
fecal	B-DIS
hardness	I-DIS
and	O
its	O
relationships	O
to	O
human	O
health	O
as	O
it	O
provides	O
a	O
simple	O
fine	O
scale	O
and	O
objective	O
stool	O
classification	O
approach	O
for	O
the	O
characterization	O
of	O
the	O
exact	O
sampling	O
locations	O
in	O
future	O
microbiome	O
and	O
metabolome	O
studies	O
.	O

Many	O
adrenocortical	B-DIS
diseases	I-DIS
are	O
more	O
prevalent	O
in	O
women	O
than	O
in	O
men	O
but	O
the	O
reasons	O
underlying	O
this	O
sex	O
bias	O
are	O
still	O
unknown	O
.	O

Recent	O
studies	O
involving	O
gonadectomy	O
and	O
sex	O
hormone	O
replacement	O
experiments	O
in	O
mice	O
have	O
shed	O
some	O
light	O
onto	O
the	O
molecular	O
basis	O
of	O
sexual	B-DIS
dimorphism	I-DIS
in	O
the	O
adrenal	O
cortex	O
.	O

Indeed	O
it	O
has	O
been	O
shown	O
that	O
gonadal	O
hormones	O
influence	O
many	O
aspects	O
of	O
adrenal	O
physiology	O
ranging	O
from	O
stem	O
cell	O
-	O
dependent	O
tissue	O
turnover	O
to	O
steroidogenesis	O
and	O
X	O
-	O
zone	O
dynamics	O
.	O

This	O
article	O
reviews	O
current	O
knowledge	O
on	O
adrenal	O
cortex	O
sexual	O
dimorphism	O
and	O
the	O
potential	O
mechanisms	O
underlying	O
sex	O
hormone	O
influence	O
of	O
adrenal	O
homeostasis	O
.	O

Both	O
topics	O
are	O
expected	O
to	O
contribute	O
to	O
personalized	O
and	O
novel	O
therapeutic	O
approaches	O
in	O
the	O
future	O
.	O

Coronavirus	B-DIS
2019	I-DIS
disease	I-DIS
COVID-19	O
is	O
associated	O
with	O
coagulation	B-DIS
dysfunction	I-DIS
that	O
predisposes	O
patients	O
to	O
an	O
increased	O
risk	O
for	O
both	O
arterial	O
ATE	O
and	O
venous	B-DIS
thromboembolism	I-DIS
VTE	I-DIS
and	O
consequent	O
poor	O
prognosis	O
;	O
in	O
particular	O
the	O
incidence	B-EPI
of	O
ATE	O
and	O
VTE	B-DIS
in	O
critically	B-DIS
ill	I-DIS
COVID-19	I-DIS
patients	O
can	O
reach	O
5	B-STAT
%	I-STAT
and	O
31	B-STAT
%	I-STAT
respectively	O
.	O

The	O
mechanism	O
of	O
thrombosis	B-DIS
in	O
COVID-19	O
patients	O
is	O
complex	O
and	O
still	O
not	O
completely	O
clear	O
.	O

Recent	O
literature	O
suggests	O
a	O
link	O
between	O
the	O
presence	O
of	O
antiphospholipid	B-DIS
antibodies	O
aPLs	B-DIS
and	O
thromboembolism	B-DIS
in	O
COVID-19	O
patients	O
.	O

However	O
it	O
remains	O
uncertain	O
whether	O
aPLs	O
are	O
an	O
epiphenomenon	O
or	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
the	O
disease	O
.	O

Objectives	O
This	O
study	O
aimed	O
to	O
report	O
the	O
prevalence	B-EPI
and	O
clinical	O
characteristics	O
of	O
adults	O
with	O
cerebral	B-DIS
palsy	I-DIS
CP	O
in	O
a	O
geographically	O
defined	O
region	O
of	O
the	O
UK	B-LOC
.	O

Design	O
and	O
setting	O
Cross	O
-	O
sectional	O
study	O
using	O
the	O
Northern	B-DIS
Ireland	I-DIS
Cerebral	O
Palsy	O
Register	O
NICPR	O
.	O

Participants	O
All	O
validated	O
cases	O
known	O
to	O
the	O
NICPR	O
born	O
1981	O
-	O
2001	O
and	O
alive	O
and	O
resident	O
in	O
Northern	B-LOC
Ireland	I-LOC
at	O
age	O
19	O
years	O
were	O
included	O
.	O

Results	O
The	O
study	O
included	O
1218	O
persons	O
with	O
CP	O
aged	O
19	O
-	O
39	O
years	O
46	O
of	O
whom	O
died	O
in	O
adulthood	O
.	O

The	O
prevalence	B-EPI
of	O
CP	O
was	O
2.38	O
per	O
1000	O
.	O

The	O
majority	O
of	O
cases	O
had	O
spastic	B-DIS
CP	O
n=1132/121893	O
%	O
and	O
could	O
walk	O
n=949/121878	O
%	O
.	O

Those	O
that	O
died	O
in	O
adulthood	O
typically	O
had	O
bilateral	O
spastic	B-DIS
CP	O
n=39/46	O
and	O
used	O
a	O
wheelchair	O
n=40/46	O
.	O

Conclusion	O
The	O
prevalence	B-EPI
of	O
CP	O
in	O
adults	O
is	O
similar	O
to	O
other	O
common	O
neurological	O
conditions	O
such	O
as	O
multiple	B-DIS
sclerosis	I-DIS
and	O
Parkinson	B-DIS
's	I-DIS
disease	I-DIS
.	O

The	O
needs	O
of	O
adults	O
with	O
CP	O
vary	O
widely	O
with	O
almost	O
half	O
having	O
two	O
or	O
more	O
associated	O
impairments	O
that	O
may	O
require	O
multiprofessional	O
and	O
multiagency	O
coordination	O
.	O

Results	O
from	O
this	O
study	O
can	O
be	O
used	O
to	O
inform	O
transformation	O
of	O
health	O
and	O
care	O
services	O
for	O
adults	O
with	O
CP	O
.	O

Background	O
Nonclassical	O
congenital	B-DIS
adrenal	I-DIS
hyperplasia	I-DIS
due	O
to	O
21	B-DIS
-	I-DIS
hydroxylase	O
deficiency	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
active	O
21	O
-	O
hydroxylase	O
gene	O
CYP21A2	O
.	O

The	O
clinical	O
symptoms	O
can	O
vary	O
greatly	O
.	O

To	O
date	O
no	O
systematic	O
studies	O
have	O
been	O
undertaken	O
in	O
Germany	B-LOC
.	O

Aims	O
Description	O
of	O
the	O
phenotype	O
evaluation	O
of	O
the	O
diagnostics	O
and	O
genotype	O
-	O
phenotype	O
correlation	O
PATIENTS	O
AND	O
METHODOLOGY	O
Retrospective	O
analysis	O
of	O
the	O
data	O
of	O
134	O
patients	O
age	O
range	O
0.1	O
-	O
18.6	O
years	O
in	O
a	O
multicentre	O
study	O
covering	O
10	O
paediatric	O
endocrinology	O
centres	O
in	O
Bavaria	B-LOC
and	O
Baden	B-LOC
-	I-LOC
WÃ¼rttemberg	I-LOC
.	O

The	O
data	O
was	O
gathered	O
on	O
site	O
from	O
the	O
medical	O
records	O
.	O

Two	O
hundred	O
and	O
thirty	O
-	O
three	O
alleles	O
with	O
a	O
mutation	O
of	O
the	O
CYP21A2	O
gene	O
were	O
identified	O
in	O
126	O
patients	O
.	O

A	O
genotype	O
-	O
phenotype	O
correlation	O
of	O
the	O
mutation	O
findings	O
was	O
undertaken	O
C1	O
severe	O
/	O
mild	O
;	O
C2	O
mild	O
/	O
mild	O
.	O

Individuals	O
with	O
a	O
heterozygous	O
mutation	O
of	O
the	O
CYP21A2	O
were	O
also	O
included	O
C3	O
.	O

The	O
data	O
was	O
collected	O
with	O
the	O
approval	O
of	O
the	O
ethics	O
committee	O
of	O
the	O
University	O
Hospital	O
of	O
Erlangen	O
during	O
the	O
period	O
of	O
2014	O
and	O
2015	O
.	O

RESULTS	O
MW	O
Â±	O
SD	O
One	O
hundred	O
and	O
seventeen	O
out	O
of	O
134	O
patients	O
115	O
f	O
29	O
m	O
were	O
symptomatic	O
.	O

The	O
chronological	O
age	O
CA	O
at	O
diagnosis	O
was	O
7.1	O
Â±	O
4.4	O
years	O
.	O

The	O
most	O
frequent	O
symptom	O
73.5	B-STAT
%	I-STAT
was	O
premature	B-DIS
pubarche	I-DIS
.	O

The	O
height	O
-	O
SDS	O
on	O
diagnosis	O
was	O
0.8	O
Â±	O
1.3	O
and	O
the	O
BMI	O
-	O
SDS	O
was	O
0.8	O
Â±	O
1.2	O
.	O

Bone	O
age	O
BA	O
was	O
ascertained	O
in	O
82.9	B-STAT
%	I-STAT
of	O
the	O
symptomatic	O
patients	O
.	O

The	O
difference	O
between	O
BA	O
and	O
CA	O
was	O
1.9	O
Â±	O
1.4	O
years	O
.	O

Basal	O
17OHP	O
concentrations	O
were	O
14.5	O
Â±	O
19.1	O
ng	O
/	O
ml	O
18	O
patients	O
<	O
2	O
ng	O
/	O
ml	O
.	O

In	O
total	O
58.1	B-STAT
%	I-STAT
mild	O
and	O
34.7	B-STAT
%	I-STAT
severe	O
mutations	O
were	O
found	O
.	O

The	O
most	O
common	O
mutation	O
was	O
p.	O
Val281Leu	O
39.1	B-STAT
%	I-STAT
;	O
65.8	B-STAT
%	I-STAT
of	O
the	O
patients	O
could	O
be	O
allocated	O
to	O
group	O
C1	O
.	O

No	O
phenotypical	O
differences	O
were	O
found	O
between	O
the	O
3	O
mutation	O
groups	O
.	O

The	O
17OHP	O
levels	O
basal	O
and	O
after	O
ACTH	O
in	O
the	O
standard	O
ACTH	O
stimulation	O
test	O
were	O
highest	O
in	O
group	O
C1	O
and	O
also	O
significantly	O
higher	O
in	O
group	O
C2	O
as	O
in	O
C3	O
the	O
ACTH	O
-	O
stimulated	O
cortisol	O
levels	O
ng	O
/	O
ml	O
were	O
significantly	O
lower	O
in	O
groups	O
C1	O
192.1	O
Â±	O
62.5	O
and	O
C2218	O
Â±	O
50	O
than	O
in	O
C3	O
297.3	O
Â±	O
98.7	O
.	O

Conclusion	O
Most	O
of	O
the	O
patients	O
have	O
symptoms	O
of	O
mild	O
androgenisation	B-DIS
.	O

Male	O
patients	O
are	O
underdiagnosed	O
.	O

Diagnostics	O
are	O
not	O
standardised	O
.	O

Differences	O
between	O
the	O
types	O
of	O
mutations	O
are	O
found	O
in	O
the	O
hormone	O
concentrations	O
but	O
not	O
in	O
phenotype	O
.	O

We	O
speculate	O
that	O
further	O
as	O
yet	O
not	O
clearly	O
defined	O
factors	O
are	O
responsible	O
for	O
the	O
development	O
of	O
the	O
respective	O
phenotypes	O
.	O

Purpose	O
of	O
review	O
The	O
aim	O
was	O
to	O
review	O
evidence	O
about	O
diabetes	B-DIS
secondary	O
to	O
hereditary	B-DIS
pancreatitis	I-DIS
seeking	O
novel	O
diagnostic	O
and	O
treatment	O
features	O
.	O

Recent	O
findings	O
Hereditary	B-DIS
pancreatitis	I-DIS
HP	O
is	O
an	O
autosomal	O
dominant	O
condition	O
characterized	O
by	O
recurrent	O
episodes	O
of	O
acute	O
pancreatitis	B-DIS
progression	O
to	O
fibrosis	B-DIS
and	O
chronic	B-DIS
pancreatitis	I-DIS
.	O

Clinical	O
presentation	O
includes	O
diabetes	B-DIS
of	I-DIS
the	I-DIS
exocrine	I-DIS
pancreas	I-DIS
DEP	I-DIS
.	O

HP	O
prevalence	B-EPI
ranges	O
from	O
0.3	B-STAT
to	I-STAT
0.57	O
per	O
100000	O
people	O
with	O
up	B-STAT
to	I-STAT
80	I-STAT
%	I-STAT
of	O
these	O
develop	O
DEP	O
.	O

This	O
condition	O
often	O
requires	O
specific	O
interventions	O
with	O
regard	O
to	O
metabolic	O
control	O
metformin	O
is	O
the	O
first	O
choice	O
for	O
those	O
with	O
mild	O
DEP	O
and	O
for	O
those	O
in	O
advanced	O
disease	O
insulin	O
is	O
considered	O
the	O
first	O
-	O
line	O
therapy	O
.	O

Insulin	O
analogues	O
and	O
insulin	O
pump	O
therapy	O
are	O
preferred	O
due	O
to	O
the	O
brittle	O
glycemic	O
pattern	O
and	O
risk	O
of	O
hypoglycemia	B-DIS
.	O

In	O
case	O
of	O
exocrine	B-DIS
insufficiency	I-DIS
pancreatic	O
enzyme	O
replacement	O
therapy	O
is	O
recommended	O
.	O

Pancreatic	O
polypeptide	O
administration	O
is	O
a	O
promising	O
novel	O
treatment	O
feature	O
.	O

DEP	O
due	O
to	O
HP	O
appears	O
to	O
be	O
a	O
misdiagnosed	O
condition	O
.	O

The	O
requirement	O
of	O
specific	O
management	O
demonstrates	O
the	O
importance	O
of	O
this	O
matter	O
;	O
therefore	O
appropriate	O
recognition	O
and	O
classification	O
are	O
important	O
.	O

Maternal	O
hypertensive	B-DIS
disorders	I-DIS
during	O
pregnancy	O
HDP	O
have	O
been	O
associated	O
with	O
neuropsychiatric	O
problems	O
in	O
offspring	O
.	O

We	O
aim	O
to	O
investigate	O
the	O
associations	O
between	O
specific	O
types	O
of	O
maternal	O
HDP	O
and	O
offspring	O
neurodevelopmental	B-DIS
disorders	I-DIS
and	O
further	O
examine	O
whether	O
the	O
timing	O
of	O
onset	O
and	O
severity	O
of	O
HDP	O
would	O
affect	O
these	O
associations	O
.	O

The	O
study	O
population	O
consisted	O
of	O
4489044	O
live	O
-	O
born	O
singletons	O
in	O
Denmark	B-LOC
during	O
1978	O
-	O
2012	O
and	O
Sweden	B-LOC
during	O
1987	O
-	O
2010	O
.	O

Maternal	O
HDP	O
was	O
categorized	O
into	O
chronic	O
hypertension	B-DIS
gestational	O
hypertension	B-DIS
and	O
pre	B-DIS
-	O
eclampsia	B-DIS
;	O
pre	O
-	O
eclampsia	O
was	O
further	O
stratified	O
according	O
to	O
timing	O
early	O
-	O
onset	O
late	O
-	O
onset	O
or	O
severity	O
moderate	O
severe	O
of	O
the	O
disease	O
.	O

Neurodevelopmental	B-DIS
disorders	I-DIS
including	O
attention	B-DIS
-	I-DIS
deficit	I-DIS
/	I-DIS
hyperactivity	I-DIS
disorder	I-DIS
ADHD	I-DIS
autism	O
spectrum	B-DIS
disorder	I-DIS
ASD	O
and	O
intellectual	O
disability	O
ID	O
were	O
defined	O
by	O
ICD	O
-	O
coded	O
register	O
diagnosis	O
.	O

Cox	O
regression	O
was	O
used	O
to	O
calculate	O
hazard	O
ratios	O
HR	O
while	O
adjusting	O
for	O
potential	O
confounders	O
and	O
sibling	O
analyses	O
assessed	O
the	O
influence	O
of	O
unmeasured	O
shared	O
familial	O
factors	O
.	O

Maternal	O
HDP	O
was	O
associated	O
with	O
increased	O
risks	O
of	O
ADHD	B-DIS
HR	O
1.24	O
;	O
95	B-STAT
%	I-STAT
confidence	O
interval	O
[	O
CI	O
]	O
1.20	O
-	O
1.28	O
ASD	O
1.29	O
[	O
1.24	O
-	O
1.34	O
]	O
and	O
ID	O
1.58	O
[	O
1.50	O
-	O
1.66	O
]	O
in	O
offspring	O
respectively	O
which	O
was	O
mostly	O
driven	O
by	O
pre	B-DIS
-	O
eclampsia	O
.	O

The	O
strongest	O
associations	O
were	O
observed	O
for	O
early	B-DIS
-	O
onset	O
and	B-DIS
severe	O
pre	O
-	O
eclampsia	O
and	O
the	B-DIS
corresponding	O
HRs	O
for	O
ADHD	O
ASD	O
and	O
ID	O
were	O
1.93	O
[	O
1.73	O
-	O
2.16	O
]	O
1.86	O
[	O
1.61	O
-	O
2.15	O
]	O
and	O
3.99	O
[	O
3.42	O
-	O
4.65	O
]	O
respectively	O
.	O

The	O
results	O
were	O
similar	O
in	O
the	O
sibling	O
analyses	O
.	O

The	O
associations	O
between	O
maternal	O
HDP	O
and	O
offspring	O
neurodevelopmental	B-DIS
disorders	I-DIS
were	O
consistent	O
across	O
the	O
subgroups	O
of	O
sex	O
preterm	O
status	O
parity	O
maternal	O
age	O
and	O
psychiatric	B-DIS
disorders	I-DIS
.	O

Maternal	O
HDP	O
especially	O
early	O
-	B-DIS
onset	O
pre	O
-	O
eclampsia	O
are	O
associated	O
with	B-DIS
increased	O
risks	O
of	O
ADHD	O
ASD	O
and	O
ID	O
in	O
particular	O
independent	O
of	O
shared	O
familial	O
factors	O
.	O

Early	O
detection	O
of	O
disabling	O
diseases	O
prior	O
to	O
clinical	O
manifestations	O
is	O
the	O
primary	O
goal	O
of	O
newborn	O
screening	O
NS	O
.	O

Indeed	O
the	O
required	O
number	O
of	O
core	O
and	O
secondary	O
conditions	O
selected	O
for	O
screening	O
panels	O
is	O
increasing	O
in	O
many	O
countries	O
.	O

Furthermore	O
newborn	O
screening	O
can	O
lead	O
to	O
diagnosis	O
of	O
maternal	O
diseases	O
such	O
as	O
vitamin	O
B12	O
deficiency	O
or	O
3	B-DIS
-	I-DIS
MethylcrotonylCoA	I-DIS
-	O
carboxylase	O
deficiency	O
3MCC	O
.	O

NS	O
became	O
mandatory	O
in	O
Sicily	B-LOC
in	O
December	O
2017	O
.	O

Here	O
we	O
report	O
NS	O
data	O
collected	O
between	O
December	O
2017	O
and	O
April	O
2020	O
.	O

Our	O
results	O
show	O
that	O
tandem	O
mass	O
spectrometry	O
is	O
a	O
powerful	O
tool	O
for	O
discovery	O
of	O
underestimated	O
disease	O
in	O
newborns	O
and	O
their	O
family	O
members	O
.	O

Our	O
panel	O
included	O
short	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
deficiency	O
SCADD	O
.	O

Here	O
we	O
report	O
that	O
results	O
of	O
our	O
investigation	O
led	O
to	O
reassessment	O
of	O
SCADD	O
prevalence	B-EPI
in	O
our	O
population	O
.	O

The	O
infant	O
and	O
adult	O
patients	O
diagnosed	O
in	O
our	O
study	O
had	O
previously	O
not	O
shown	O
overt	O
symptoms	O
.	O

Background	O
Cardiac	B-DIS
rupture	I-DIS
CR	O
is	O
a	O
fatal	O
complication	O
of	O
ST	B-DIS
-	B-DIS
elevation	I-DIS
myocardial	O
infarction	O
STEMI	O
with	B-EPI
its	O
incidence	O
markedly	O
declined	O
in	O
the	O
recent	O
decades	O
.	O

However	O
clinical	O
features	O
of	O
CR	O
patients	O
now	O
and	O
the	O
effect	O
of	O
reperfusion	O
therapy	O
to	O
CR	O
remain	O
unclear	O
.	O

We	O
investigated	O
the	O
clinical	O
features	O
of	O
CR	O
in	O
STEMI	O
patients	O
and	O
the	O
effect	O
of	O
reperfusion	O
therapy	O
to	O
CR	O
in	O
mice	O
.	O

Methods	O
Two	O
studies	O
were	O
conducted	O
.	O

In	O
clinical	O
study	O
data	O
of	O
1456	O
STEMI	B-DIS
patients	O
admitted	O
to	O
the	O
First	O
Hospital	O
Xi'an	O
Jiaotong	O
University	O
during	O
2015.12	O
.	O

~	O
2018.12	O
.	O
were	O
analyzed	O
.	O

In	O
experimental	O
study	O
83	O
male	O
C57BL/6	O
mice	O
were	O
operated	O
to	O
induce	O
MI	O
.	O

Of	O
them	O
39	O
mice	O
were	O
permanent	O
MI	O
group-1	O
and	O
remaining	O
mice	O
received	O
reperfusion	O
after	O
1	B-STAT
h	I-STAT
ischemia	B-DIS
21	I-STAT
mice	O
group-2	O
or	O
4	O
h	O
ischemia	B-DIS
23	O
mice	O
group-3	O
.	O

All	O
operated	O
mice	O
were	O
monitored	O
up	O
to	O
day-10	O
.	O

Animals	O
were	O
inspected	O
three	O
times	O
daily	O
for	O
the	O
incidence	B-EPI
of	O
death	B-DIS
and	O
autopsy	O
was	O
done	O
for	O
all	O
mice	O
found	O
died	O
to	O
determine	O
the	O
cause	O
of	O
death	B-DIS
.	O

Results	O
CR	O
was	O
diagnosed	O
in	O
40	O
patients	O
free	B-DIS
-	I-DIS
wall	O
rupture	O
in	B-DIS
17	I-DIS
ventricular	I-DIS
septal	O
rupture	O
in	O
20	O
and	O
combined	O
locations	O
in	O
3	O
cases	O
.	O

CR	O
presented	O
in	O
19	O
patients	O
at	O
admission	O
and	O
diagnosed	O
in	O
another	O
21	O
patients	O
during	O
1	B-STAT
~	I-STAT
14	I-STAT
days	O
post	O
-	O
STEMI	O
giving	O
an	B-EPI
in	O
-	O
hospital	O
incidence	O
of	O
1.4	B-STAT
%	I-STAT
.	O

The	O
mortality	O
of	O
CR	O
patients	O
was	O
high	O
during	O
hospitalization	O
accounting	O
for	O
39	B-STAT
%	I-STAT
of	O
total	O
in	O
-	B-DIS
hospital	O
death	O
.	O

By	O
multivariate	O
logistic	O
regression	O
analysis	O
older	O
age	O
peak	O
CK	O
-	O
MB	O
and	O
peak	O
hs	O
-	O
CRP	O
were	O
independent	O
predictors	O
of	O
CR	O
post	O
-	O
STEMI	O
.	O

In	O
mice	O
with	O
non	O
-	O
reperfused	O
MI	O
17	O
animals	O
43.6	B-STAT
%	I-STAT
died	O
of	O
CR	O
that	O
occurred	O
during	O
3	O
-	O
6	O
days	O
post	O
-	O
MI	O
.	O

In	O
MI	O
mice	O
received	O
early	O
or	O
delayed	O
reperfusion	O
all	O
mice	O
survived	O
to	O
the	O
end	O
of	O
experiment	O
except	O
one	O
mouse	O
died	O
of	O
acute	B-DIS
heart	I-DIS
failure	I-DIS
.	O

Conclusion	O
CR	O
remains	O
as	O
a	O
major	O
cause	O
of	O
in	O
-	B-DIS
hospital	O
death	O
in	O
STEMI	O
patients	O
.	O

CR	O
patients	O
are	O
characterized	O
of	O
being	O
elderly	O
having	O
larger	O
infarct	B-DIS
and	O
more	O
server	O
inflammation	B-DIS
.	O

Experimentally	O
reperfusion	O
post	O
-	O
MI	O
prevented	O
CR	O
.	O

Importance	O
Although	O
several	O
single	O
-	O
center	O
studies	O
have	O
estimated	B-DIS
that	I-DIS
granuloma	O
annulare	O
may	O
account	O
for	O
approximately	B-STAT
0.1	I-STAT
%	I-STAT
to	I-STAT
0.4	I-STAT
%	I-STAT
of	O
new	O
patients	O
presenting	O
to	O
dermatologists	O
large	O
-	O
scale	O
population	B-EPI
-	O
based	B-EPI
studies	O
estimating	B-DIS
the	I-DIS
prevalence	O
and	O
incidence	O
of	O
granuloma	O
annulare	O
are	O
lacking	O
.	O

Objectives	O
To	O
estimate	O
the	O
population	O
-	B-EPI
based	O
incidence	B-EPI
and	O
prevalence	B-DIS
of	I-DIS
granuloma	O
annulare	O
in	O
the	B-LOC
United	I-LOC
States	I-LOC
and	O
to	O
identify	O
the	O
most	O
commonly	O
prescribed	O
treatments	O
.	O

Design	O
setting	O
and	O
participants	O
This	O
cross	O
-	O
sectional	O
study	O
used	O
deidentified	O
data	O
from	O
the	O
Optum	O
Clinformatics	O
Data	O
Mart	O
Database	O
from	O
January	O
12017	O
to	O
December	O
312018	O
to	O
identify	O
patients	B-DIS
with	I-DIS
granuloma	O
annulare	O
.	O

Main	O
outcomes	O
and	O
measures	O
After	O
validating	O
an	O
approach	O
to	O
classify	O
patients	O
with	O
granuloma	B-DIS
annulare	I-DIS
using	O
International	O
Statistical	O
Classification	O
of	O
Diseases	B-DIS
and	O
Related	O
Health	O
Problems	O
Tenth	O
Revision	O
codes	O
the	O
primary	O
outcomes	O
were	O
age-	O
sex-	O
and	O
race	O
/	O
ethnicity	B-EPI
-	O
specific	B-EPI
annualized	O
incidence	O
and	B-DIS
prevalence	I-DIS
estimates	O
for	O
granuloma	O
annulare	O
.	O

In	O
addition	O
treatment	O
use	O
within	O
6	O
to	O
12	O
months	O
after	O
the	O
first	O
diagnosis	O
of	O
granuloma	B-DIS
annulare	I-DIS
was	O
examined	O
.	O

Confidence	O
intervals	O
for	O
prevalence	B-EPI
and	O
incidence	B-EPI
estimates	O
were	O
computed	O
assuming	O
a	O
binomial	O
distribution	O
using	O
the	O
Wilson	B-DIS
score	O
method	O
.	O

Age-	O
sex-	O
and	O
race	O
/	B-EPI
ethnicity	O
-	B-EPI
specific	O
incidence	O
and	O
prevalence	O
estimates	O
were	O
compared	O
using	O
the	O
Ï‡2	O
test	O
.	O

Results	O
A	O
total	O
of	O
11608	O
patients	O
with	O
incident	O
granuloma	B-DIS
annulare	I-DIS
8680	O
female	O
patients	O
[	O
74.8	B-STAT
%	I-STAT
]	O
;	O
mean	O
[	O
SD	O
]	O
age	O
56.5	O
[	O
18.8	O
]	O
years	O
and	O
17862	O
patients	O
with	O
prevalent	O
granuloma	B-DIS
annulare	I-DIS
13548	O
female	O
patients	O
[	O
75.8	B-STAT
%	I-STAT
]	O
;	O
mean	O
[	O
SD	O
]	O
age	O
56.6	O
[	O
18.5	O
]	O
years	O
were	O
identified	O
during	O
the	O
study	O
period	O
.	O

The	O
overall	O
annualized	O
incidence	B-EPI
of	O
granuloma	B-DIS
annulare	I-DIS
was	O
0.04	B-STAT
%	I-STAT
or	O
37.995	B-STAT
%	I-STAT
CI	O
36.9	O
-	O
38.9	O
per	O
100000	O
and	O
the	O
overall	O
annualized	O
prevalence	B-EPI
of	O
granuloma	B-DIS
annulare	I-DIS
was	O
0.06	B-STAT
%	I-STAT
or	O
58.395	B-STAT
%	I-STAT
CI	O
57.1	O
-	O
59.5	O
per	O
100000	O
.	O

The	O
incidence	B-EPI
and	O
prevalence	B-EPI
of	O
granuloma	B-DIS
annulare	I-DIS
were	O
highest	O
in	O
the	O
fifth	O
decade	O
of	O
life	O
.	O

The	O
incidence	B-EPI
and	O
prevalence	B-EPI
of	O
granuloma	B-DIS
annulare	I-DIS
were	O
higher	O
among	O
women	O
incidence	B-EPI
female	O
to	O
male	O
ratio	O
2.81	O
;	O
prevalence	B-EPI
female	O
to	O
male	O
ratio	O
3.01	O
.	O

Within	O
6	O
months	O
of	O
their	O
first	O
diagnosis	O
4822	O
patients	O
41.5	B-STAT
%	I-STAT
filled	O
a	O
prescription	O
for	O
a	O
topical	O
corticosteroid	O
and	O
1087	O
patients	O
9.4	B-STAT
%	I-STAT
received	O
an	O
intralesional	O
injection	O
.	O

Within	O
6	O
months	O
of	O
their	O
first	O
diagnosis	O
oral	O
tetracycline	O
prescriptions	O
were	O
filled	O
by	O
820	O
patients	O
7.1	B-STAT
%	I-STAT
and	O
hydroxychloroquine	O
prescriptions	O
were	O
filled	O
by	O
268	O
patients	O
2.3	B-STAT
%	I-STAT
.	O

Conclusions	O
and	O
relevance	O
Granuloma	B-DIS
annulare	I-DIS
is	O
a	O
rare	O
disease	O
in	O
the	B-LOC
United	I-LOC
States	I-LOC
that	O
is	O
more	O
common	O
among	O
women	O
and	O
middle	O
-	O
aged	O
to	O
older	O
individuals	O
.	O

The	O
findings	O
of	O
this	O
cross	O
-	O
sectional	O
study	O
provide	O
important	O
background	O
regarding	O
the	O
basic	O
epidemiology	O
and	O
overall	O
burden	B-DIS
of	I-DIS
granuloma	O
annulare	O
in	O
the	B-LOC
United	I-LOC
States	I-LOC
.	O

Future	O
studies	O
are	O
needed	O
to	O
better	O
understand	O
the	O
association	O
of	O
granuloma	B-DIS
annulare	I-DIS
with	O
quality	O
of	O
life	O
and	O
the	O
most	O
optimal	O
treatment	O
approaches	O
for	O
this	O
condition	O
.	O

Gastrointestinal	B-DIS
symptoms	I-DIS
are	O
among	O
the	O
most	O
common	O
complaints	O
in	O
patients	O
with	O
postural	O
tachycardia	B-DIS
syndrome	I-DIS
POTS	I-DIS
.	O

In	O
some	O
cases	O
they	O
dominate	O
the	O
clinical	O
presentation	O
and	O
cause	O
substantial	O
disabilities	O
including	O
significant	O
weight	B-DIS
loss	I-DIS
and	O
malnutrition	O
that	O
require	O
the	O
use	O
of	O
invasive	O
treatment	O
to	O
support	O
caloric	O
intake	O
.	O

Multiple	O
cross	O
-	O
sectional	O
studies	O
have	O
reported	O
a	B-EPI
high	O
prevalence	B-DIS
of	I-DIS
gastrointestinal	O
symptoms	B-DIS
in	O
POTS	B-LOC
patients	B-DIS
with	I-DIS
connective	I-DIS
tissue	O
diseases	O
such	B-DIS
as	I-DIS
Ehlers	O
-	O
Danlos	O
hypermobile	O
type	O
and	O
in	O
patients	B-DIS
with	I-DIS
evidence	O
of	O
autonomic	O
neuropathy	O
.	O

Previous	O
studies	O
that	O
evaluated	O
gastric	B-DIS
motility	I-DIS
in	O
these	O
patients	O
reported	O
a	O
wide	O
range	O
of	O
abnormalities	O
particularly	O
delayed	O
gastric	O
emptying	O
.	O

The	O
pathophysiology	O
of	O
gastrointestinal	B-DIS
symptoms	I-DIS
in	O
POTS	B-DIS
is	O
likely	O
multifactorial	O
and	O
probably	O
depends	O
on	O
the	O
co	O
-	O
morbid	O
conditions	O
.	O

In	O
patients	O
with	O
POTS	B-DIS
and	O
Ehlers	B-DIS
-	I-DIS
Danlos	B-DIS
syndromes	I-DIS
structural	I-DIS
and	I-DIS
functional	O
abnormalities	O
in	O
the	O
gastrointestinal	O
connective	O
tissue	O
may	O
play	O
a	O
significant	O
role	O
whereas	B-DIS
in	I-DIS
neuropathic	I-DIS
POTS	I-DIS
the	I-DIS
gastrointestinal	O
tract	O
motility	O
and	O
gut	O
hormonal	O
secretion	O
may	O
be	O
directly	O
impaired	O
due	O
to	O
localized	O
autonomic	O
denervation	O
.	O

In	O
patients	O
with	O
normal	O
gastrointestinal	O
motility	O
but	O
persistent	O
gastrointestinal	B-DIS
symptoms	I-DIS
gastrointestinal	I-DIS
functional	I-DIS
disorders	I-DIS
should	O
be	O
considered	O
.	O

We	O
performed	O
a	O
systematic	O
review	O
of	O
the	O
literature	O
related	O
to	O
POTS	B-DIS
and	O
gastrointestinal	B-DIS
symptoms	I-DIS
have	O
proposed	O
possible	O
mechanisms	O
and	O
discussed	O
diagnosis	O
and	O
treatment	O
approaches	O
for	O
delayed	O
gastric	O
emptying	O
the	O
most	O
common	O
gastrointestinal	B-DIS
abnormality	I-DIS
reported	O
in	O
patients	O
with	O
POTS	B-DIS
.	O

The	O
aggressive	B-DIS
lymphoma	I-DIS
extranodal	I-DIS
natural	I-DIS
killer	I-DIS
/	I-DIS
T	O
-	O
cell	O
lymphoma	O
-	O
nasal	O
type	O
is	O
strongly	O
associated	O
with	O
Epstein	O
-	O
Barr	O
virus	O
EBV	O
and	O
is	O
most	O
common	O
in	O
Asia	B-LOC
and	O
in	O
South	B-LOC
and	O
Central	B-LOC
America	I-LOC
.	O

By	O
contrast	O
incidence	B-EPI
is	O
low	O
in	O
the	B-LOC
United	I-LOC
States	I-LOC
and	O
Europe	B-LOC
where	O
extranodal	B-DIS
natural	I-DIS
killer	I-DIS
/	I-DIS
T	O
-	O
cell	O
lymphoma	O
represents	O
only	B-STAT
0.2	I-STAT
%	I-STAT
-0.4	O
%	O
of	B-DIS
all	I-DIS
newly	O
diagnosed	O
non	O
-	O
Hodgkin	O
lymphomas	O
.	O

At	O
diagnosis	O
it	O
is	O
important	O
to	O
test	O
for	O
EBV	O
DNA	O
in	O
plasma	O
by	O
polymerase	O
chain	O
reaction	O
and	O
to	O
carry	O
out	O
positron	O
emission	O
tomography	O
/	O
computer	O
tomography	O
and	O
magnetic	O
resonance	O
imaging	O
of	O
the	O
nasopharynx	O
.	O

In	O
stage	O
I	O
/	O
II	O
disease	O
radiotherapy	O
is	O
the	O
most	O
important	O
treatment	O
modality	O
but	O
in	O
high	O
-	O
risk	O
stage	O
I	O
/	O
II	O
disease	O
stage	O
II	O
ag	O
60	O
y	O
elevated	O
lactate	O
dehydrogenase	O
Eastern	O
Cooperative	O
Oncology	B-DIS
Group	O
performance	O
score	O
â‰¥2	O
primary	O
tumor	O
invasion	O
it	O
should	O
be	O
combined	O
with	O
chemotherapy	O
.	O

The	O
most	O
optimal	O
responses	O
are	O
reached	O
with	O
nonmultidrug	O
resistance	O
-	O
based	O
therapy	O
eg	O
asparaginase-	O
or	O
platinum	O
-	O
based	O
therapy	O
.	O

Therapeutic	O
approaches	O
consist	O
of	O
either	O
platinum	O
-	O
based	O
concurrent	O
chemoradiotherapy	O
or	O
sequential	O
chemoradiotherapy	O
.	O

The	O
minimum	O
dose	O
of	O
radiotherapy	O
should	O
be	O
50	O
-	O
56	O
Gy	O
.	O

Treatment	O
of	O
stage	O
III	O
/	O
IV	O
disease	O
consists	O
of	O
3	O
cycles	O
of	O
chemotherapy	O
followed	O
by	O
autologous	O
hematopoietic	O
cell	O
transplantation	O
.	O

Allogeneic	B-DIS
hematopoietic	I-DIS
cell	I-DIS
transplantation	I-DIS
should	O
only	O
be	O
considered	O
in	O
case	O
of	O
relapsed	O
disease	O
or	O
after	O
difficulty	O
reaching	O
complete	O
remission	O
.	O

During	O
treatment	O
and	O
follow	O
-	O
up	O
plasma	O
EBV	O
levels	O
should	O
be	O
monitored	O
as	O
a	O
marker	B-DIS
of	O
tumor	O
load	O
.	O

Background	O
Obstructive	O
sleep	O
apnea	B-DIS
OSA	I-DIS
is	O
prevalent	O
in	O
individuals	O
with	O
Osteogenesis	B-DIS
imperfecta	I-DIS
OI	I-DIS
.	O

To	O
date	O
no	O
study	O
has	O
investigated	O
treatment	O
of	O
OSA	B-DIS
in	O
adult	O
individuals	O
with	O
OI	O
using	O
positive	O
airway	O
pressure	O
PAP	O
.	O

This	O
observational	O
pilot	O
study	O
examined	O
the	O
adherence	O
of	O
adults	O
with	O
OI	O
to	O
treatment	O
of	O
OSA	B-DIS
with	O
PAP	O
therapy	O
and	O
the	O
evolution	O
of	O
self	O
-	O
experienced	O
sleepiness	B-DIS
and	O
depression	O
symptoms	O
before	O
and	O
after	O
treatment	O
.	O

Methods	O
We	O
included	O
20	O
patients	O
with	O
a	O
mean	O
age	O
of	O
51	O
years	O
who	O
represented	O
varying	O
severity	O
of	O
OI	B-DIS
and	O
displayed	O
an	O
apnea	B-DIS
and	O
hypopnea	B-DIS
index	O
â‰¥	O
5	O
/sleeping	O
hour	O
as	O
recorded	O
by	O
an	O
overnight	O
polysomnography	O
.	O

PAP	O
therapy	O
was	O
proposed	O
to	O
all	O
patients	O
.	O

Epworth	O
Sleepiness	O
Scale	O
ESS	O
questionnaire	O
to	O
evaluate	O
daytime	B-DIS
sleepiness	I-DIS
and	O
a	O
validated	O
self	B-DIS
-	I-DIS
rating	O
depression	O
questionnaire	O
to	O
identify	B-DIS
possible	O
depression	O
were	O
completed	O
prior	O
to	O
PAP	O
therapy	O
and	O
repeated	O
after	O
a	O
minimum	O
of	O
one	O
year	O
.	O

The	O
datasets	O
supporting	O
the	O
conclusions	O
of	O
this	O
article	O
are	O
included	O
within	O
the	O
article	O
.	O

Results	O
From	O
the	O
20	O
patients	O
15	O
initiated	O
PAP	O
therapy	O
and	O
two	O
patients	O
later	O
interrupted	O
it	O
.	O

The	O
mean	O
PAP	O
follow	O
-	O
up	O
period	O
was	O
1230	O
days	O
.	O

At	O
baseline	O
an	O
abnormally	O
high	O
ESS	O
score	O
was	O
reported	O
by	O
29	B-STAT
%	I-STAT
of	O
the	O
respondents	O
and	O
an	O
abnormally	O
high	O
number	O
of	O
symptoms	O
suggesting	O
depression	B-DIS
by	O
29	B-STAT
%	I-STAT
.	O

Follow	O
-	O
up	O
questionnaires	O
were	O
completed	O
by	O
60	B-STAT
%	I-STAT
of	O
the	O
patients	O
of	O
whom	O
83	B-STAT
%	I-STAT
were	O
adherent	O
to	O
PAP	O
treatment	O
.	O

ESS	O
score	O
and	O
depression	B-DIS
symptoms	O
did	O
not	O
decrease	O
significantly	O
with	O
PAP	O
therapy	O
.	O

Conclusions	O
Patients	O
with	O
OI	B-DIS
accepted	O
well	O
PAP	O
therapy	O
and	O
remained	O
compliant	O
.	O

Sleepiness	B-DIS
and	O
depression	B-DIS
persisted	O
unaltered	O
despite	O
good	O
PAP	O
adherence	O
.	O

These	O
unexpectedly	O
poor	O
improvements	O
in	O
symptoms	O
by	O
PAP	O
therapy	O
may	O
be	O
due	O
to	O
subjective	O
depression	B-DIS
symptoms	O
and	O
the	O
complexity	O
of	O
factors	O
underlying	O
persisting	O
sleepiness	B-DIS
in	O
OI	B-DIS
.	O

Further	O
research	O
is	O
needed	O
to	O
confirm	O
this	O
novel	O
finding	O
.	O

Coagulation	B-DIS
factor	O
X	O
F10	O
amplifies	O
the	O
clotting	O
reaction	O
in	O
the	O
middle	O
of	O
the	O
coagulation	O
cascade	O
and	O
thus	O
F10	O
deficiency	O
leads	O
to	O
a	O
bleeding	B-DIS
tendency	O
.	O

Isolated	O
acquired	O
F10	B-DIS
deficiency	I-DIS
is	O
widely	O
recognized	O
in	O
patients	O
with	O
immunoglobulin	O
light	O
-	O
chain	O
amyloidosis	O
or	O
plasma	O
cell	O
dyscrasias	O
.	O

However	O
its	O
occurrence	O
as	O
an	O
autoimmune	B-DIS
disorder	I-DIS
is	O
extremely	O
rare	O
.	O

The	O
Japanese	O
Collaborative	O
Research	O
Group	O
has	O
been	O
conducting	O
a	O
nationwide	O
survey	O
on	O
autoimmune	B-DIS
coagulation	I-DIS
factor	O
deficiencies	O
AiCFDs	O
starting	O
in	O
the	O
last	O
decade	O
;	O
we	O
recently	O
identified	O
three	O
patients	O
with	O
autoimmune	B-DIS
F10	I-DIS
deficiency	I-DIS
AiF10D	I-DIS
.	O

Furthermore	O
an	O
extensive	O
literature	O
search	O
was	O
performed	O
confirming	O
26	O
AiF10D	O
and	O
28	O
possible	O
cases	O
.	O

Our	O
study	O
revealed	O
that	O
AiF10D	O
patients	O
were	O
younger	O
than	O
patients	O
with	O
other	O
AiCFDs	O
;	O
AiF10D	O
patients	O
included	O
children	O
and	O
were	O
predominantly	O
male	O
.	O

AiF10D	O
was	O
confirmed	O
as	O
a	O
severe	O
type	O
of	O
bleeding	B-DIS
diathesis	O
although	O
its	O
mortality	O
rate	O
was	O
not	O
high	O
.	O

As	O
AiF10D	O
patients	O
showed	O
only	O
low	O
F10	O
inhibitor	O
titers	O
they	O
were	O
considered	O
to	O
have	O
nonneutralizing	O
anti	O
-	O
F10	O
autoantibodies	O
rather	O
than	O
their	O
neutralizing	O
counterparts	O
.	O

Accordingly	O
immunological	O
anti	O
-	O
F10	O
antibody	O
detection	O
is	O
highly	O
recommended	O
.	O

Hemostatic	O
and	O
immunosuppressive	O
therapies	O
may	O
help	O
arrest	O
bleeding	B-DIS
and	O
eliminate	O
anti	O
-	O
F10	O
antibodies	O
leading	O
to	O
a	O
high	O
recovery	O
rate	O
.	O

However	O
further	O
investigation	O
is	O
necessary	O
to	O
understand	O
the	O
basic	O
characteristics	O
and	O
proper	O
management	O
of	O
AiF10D	O
owing	O
to	O
the	O
limited	O
number	O
of	O
patients	O
.	O

Background	O
Down	B-DIS
syndrome	I-DIS
is	O
the	O
most	O
common	O
chromosomal	B-DIS
disorder	I-DIS
at	O
birth	O
and	O
is	O
often	O
accompanied	O
by	O
structural	O
birth	B-DIS
defects	I-DIS
.	O

Current	O
data	O
on	O
major	O
structural	B-DIS
defects	I-DIS
in	O
this	O
population	O
are	O
limited	O
.	O

Methods	O
States	O
and	O
territorial	O
population	O
-	O
based	O
surveillance	O
programs	O
submitted	O
data	O
on	O
identified	O
cases	B-DIS
of	I-DIS
Down	O
syndrome	O
and	O
identified	B-DIS
structural	I-DIS
birth	O
defects	O
during	O
2013	O
-	O
2017	O
.	O

We	O
estimated	O
prevalence	B-EPI
by	O
program	O
type	O
and	O
maternal	O
and	O
infant	O
characteristics	O
.	O

Among	O
programs	O
with	O
active	O
case	O
ascertainment	O
we	O
estimated	O
the	O
prevalence	B-EPI
of	O
birth	B-DIS
defects	I-DIS
by	O
organ	O
system	O
and	O
for	O
specific	O
defects	O
by	O
maternal	O
age	O
<	O
35	O
â‰¥35	O
and	O
infant	O
sex	O
.	O

Results	O
We	O
identified	O
13376	O
cases	O
of	O
Down	B-DIS
syndrome	I-DIS
.	O

Prevalence	B-EPI
among	O
all	O
programs	O
was	O
12.7	O
per	O
10000	O
live	O
births	O
.	O

Among	O
these	O
children	O
75	B-STAT
%	I-STAT
had	O
at	O
least	O
one	O
reported	O
co	O
-	B-DIS
occurring	I-DIS
birth	O
defect	O
diagnosis	O
code	O
.	O

Among	O
6210	O
cases	O
identified	O
by	O
active	O
programs	O
66	B-STAT
%	I-STAT
had	O
a	O
cardiovascular	B-DIS
defect	I-DIS
with	O
septal	B-DIS
defects	I-DIS
being	O
the	O
most	O
common	O
atrial	O
32.5	B-STAT
%	I-STAT
ventricular	O
20.6	B-STAT
%	I-STAT
and	O
atrioventricular	O
17.4	B-STAT
%	I-STAT
.	O

Defect	O
prevalence	B-EPI
differed	O
by	O
infant	O
sex	O
more	O
frequently	O
than	O
by	O
maternal	O
age	O
.	O

For	O
example	O
atrioventricular	B-DIS
septal	I-DIS
defects	I-DIS
were	O
more	O
common	O
in	O
female	O
children	O
20.1	B-STAT
%	I-STAT
vs.	O
15.1	B-STAT
%	I-STAT
while	O
limb	O
deficiencies	O
were	O
more	O
prevalent	O
in	O
male	O
children	O
0.4	B-STAT
%	I-STAT
vs.	O
0.1	B-STAT
%	I-STAT
.	O

Conclusions	O
Our	O
study	O
provides	O
updated	O
prevalence	B-EPI
estimates	O
for	O
structural	B-DIS
defects	I-DIS
including	I-DIS
rare	I-DIS
defects	I-DIS
among	O
children	O
with	O
Down	B-DIS
syndrome	I-DIS
using	O
one	O
of	O
the	O
largest	O
and	O
most	O
recent	O
cohorts	O
to	O
date	O
.	O

These	O
data	O
may	O
aid	O
clinical	O
care	O
and	O
surveillance	O
.	O

Pyridoxine	B-DIS
-	I-DIS
dependent	O
epilepsy	O
PDE	O
is	O
a	O
potentially	B-DIS
treatable	I-DIS
vitamin	I-DIS
-	O
responsive	O
epileptic	O
encephalopathy	O
.	O

The	O
most	O
prevalent	O
form	O
of	O
PDE	O
is	O
due	O
to	O
an	O
underlying	O
genetic	O
defect	O
in	O
ALDH7A1	O
encoding	O
Antiquitin	O
ATQ	O
an	O
enzyme	O
with	O
Î±	O
-	O
aminoadipic	O
semialdehyde	O
dehydrogenase	O
AASADH	O
activity	O
which	O
facilitates	O
cerebral	O
lysine	O
degradation	O
.	O

Devastating	O
outcomes	O
including	O
intellectual	B-DIS
disability	I-DIS
and	O
significant	O
developmental	O
delays	O
are	O
still	O
observed	O
in	O
75	B-STAT
%	I-STAT
to	I-STAT
80	I-STAT
%	I-STAT
of	O
pyridoxine	O
responsive	O
individuals	O
with	O
good	O
seizure	B-DIS
control	O
potentially	O
attributable	O
to	O
the	O
accumulation	O
of	O
toxic	O
intermediates	O
Î±	O
-	O
aminoadipic	O
semialdehyde	O
AASA	O
and	O
its	O
cyclic	O
form	O
Î”	O
1	O
<	O
/s	O
-piperideine-6	O
-	O
carboxylate	O
P6C	O
in	O
plasma	O
urine	O
and	O
CSF	O
.	O

Thus	O
adjunct	O
treatment	O
strategies	O
incorporating	O
lysine	O
restriction	O
and	O
arginine	O
supplementation	O
separately	O
or	O
in	O
combination	O
with	O
pyridoxine	O
have	O
been	O
attempted	O
to	O
enhance	O
seizure	B-DIS
control	O
and	O
improve	O
cognitive	O
function	O
.	O

We	O
describe	O
a	O
4	O
year	O
old	O
girl	O
with	O
classical	O
PDE	O
who	O
demonstrated	O
significant	O
improvements	O
in	O
clinical	O
neurological	O
and	O
developmental	O
outcomes	O
including	O
absence	O
of	O
clinical	O
seizures	B-DIS
and	O
cessation	O
of	O
antiepileptic	O
medications	O
since	O
age	O
3	O
months	O
normalisation	O
of	O
EEG	O
significant	O
improvement	O
in	O
the	O
white	O
matter	O
signal	O
throughout	O
the	O
cerebrum	O
on	O
neuroimaging	O
and	O
significant	O
reduction	O
in	O
urine	O
P6C	O
and	O
pipecolic	O
acid	O
levels	O
post-	O
combined	O
therapy	O
with	O
lysine	O
restricted	O
diet	O
in	O
conjunction	O
with	O
pyridoxine	O
and	O
folinic	O
acid	O
.	O

Lysine	O
restriction	O
was	O
well	O
tolerated	O
with	O
impressive	O
compliance	O
and	O
plasma	O
lysine	O
levels	O
remained	O
within	O
the	O
lower	O
reference	O
ranges	O
;	O
mean	O
level	O
70	O
Î¼mol	O
/	O
L	O
ref	O
range	O
52	O
-	O
196	O
Î¼mol	O
/	O
L	O
.	O

This	O
case	O
further	O
emphasizes	O
the	O
benefit	O
of	O
early	O
dietary	O
intervention	O
as	O
an	O
effective	O
adjunct	O
in	O
the	O
management	O
of	O
PDE	O
.	O

Purpose	O
To	O
compare	O
clinical	O
outcomes	O
between	O
pars	B-DIS
plana	I-DIS
vitrectomy	I-DIS
PPV	O
scleral	B-DIS
buckling	I-DIS
SB	I-DIS
and	O
PPV+SB	O
for	O
rhegmatogenous	O
retinal	B-DIS
detachment	I-DIS
in	O
the	O
Japan	O
-	O
RD	O
Registry	O
.	O

Methods	O
This	O
is	O
a	O
nation	O
-	O
wide	O
multicenter	O
observational	O
study	O
based	O
on	O
the	O
registry	O
data	O
between	O
2016	O
and	O
2017	O
.	O

The	O
failure	O
levels	O
were	O
defined	O
as	O
Level	O
1	O
a	O
failure	O
of	O
retinal	B-DIS
detachment	I-DIS
repair	O
Level	O
2	O
remaining	O
silicone	O
oil	O
and	O
Level	O
3	O
multiple	O
surgeries	O
to	O
achieve	O
reattachment	O
.	O

We	O
compared	O
cases	O
treated	O
by	O
SB	O
or	O
PPV	O
in	O
the	O
subgroup	O
of	O
simple	O
rhegmatogenous	O
retinal	B-DIS
detachment	I-DIS
using	O
multivariate	O
Cox	O
proportional	O
hazard	O
models	O
.	O

Results	O
A	O
total	O
of	O
2775	O
cases	O
were	O
included	O
.	O

Overall	O
6	O
months	O
any	O
levels	O
of	O
failure	O
in	O
total	O
SB	O
PPV	O
and	O
PPV+SB	O
were	O
9.2	B-STAT
%	I-STAT
n	O
=	O
2566.9	B-STAT
%	I-STAT
n	O
=	O
488.2	B-STAT
%	I-STAT
n	O
=	O
157	O
and	O
21.3	B-STAT
%	I-STAT
n	O
=	O
51	O
respectively	O
.	O

Poor	O
visual	O
acuity	O
at	O
baseline	O
in	O
SB	O
and	O
inferior	B-DIS
rhegmatogenous	I-DIS
retinal	I-DIS
detachment	I-DIS
and	O
larger	O
retinal	B-DIS
tear	I-DIS
in	O
PPV	O
were	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
failure	O
.	O

Pars	O
plana	O
vitrectomy	O
was	O
associated	O
with	O
a	O
higher	O
chance	O
of	O
achieving	O
primary	O
success	O
in	O
cases	O
with	O
simple	O
RRD	O
especially	O
for	O
cases	O
with	O
superior	O
RRD	O
adjusted	O
hazard	O
ratio	O
3.6195	B-STAT
%	I-STAT
confidence	O
interval	O
2.22	O
-	O
5.94	O
P	O
<	O
0.001	O
.	O

Conclusion	O
In	O
this	O
nationwide	O
study	O
surgical	O
anatomic	O
outcomes	O
were	O
equally	O
successful	O
in	O
either	O
SB	O
or	O
PPV	O
.	O

There	O
were	O
different	O
baseline	O
characteristics	O
associated	O
with	O
primary	O
success	O
between	O
SB	O
and	O
PPV	O
.	O

Summary	O
Emerging	O
and	O
re	O
-	B-DIS
emerging	I-DIS
infectious	O
disease	O
in	O
otorhinolaryngology	O
ENT	O
are	O
an	O
area	O
of	O
growing	O
epidemiological	O
and	O
clinical	O
interest	O
.	O

The	O
aim	O
of	O
this	O
section	O
is	O
to	O
comprehensively	O
report	O
on	O
the	O
epidemiology	O
of	O
key	O
infectious	B-DIS
disease	I-DIS
in	O
otorhinolaryngology	O
reporting	O
on	O
their	O
burden	O
at	O
the	O
national	O
and	O
international	O
level	O
expanding	O
of	O
the	O
need	O
of	O
promoting	O
and	O
implementing	O
preventive	O
interventions	O
and	O
the	O
rationale	O
of	O
applying	O
evidence	O
-	O
based	O
effective	O
and	O
cost-	O
effective	O
diagnostic	O
curative	O
and	O
preventive	O
approaches	O
.	O

In	O
particular	O
we	O
focus	O
on	O
i	O
ENT	O
viral	O
infections	B-DIS
HIV	I-DIS
Epstein	I-DIS
-	I-DIS
Barr	B-DIS
virus	I-DIS
Human	I-DIS
Papilloma	O
virus	O
retrieving	O
the	O
available	O
evidence	O
on	O
their	O
oncogenic	O
potential	O
;	O
ii	O
typical	O
and	O
atypical	O
mycobacteria	O
infections	O
;	O
iii	B-DIS
non	I-DIS
-	O
specific	O
granulomatous	O
lymphadenopathy	O
;	O
iv	B-DIS
emerging	I-DIS
paediatric	O
ENT	O
infectious	O
diseases	O
and	O
the	O
prevention	O
of	O
their	O
complications	O
;	O
v	O
the	O
growing	O
burden	O
of	O
antimicrobial	O
resistance	O
in	O
ENT	O
and	O
the	O
strategies	O
for	O
its	O
control	O
in	O
different	O
clinical	O
settings	O
.	O

We	O
conclude	O
by	O
outlining	O
knowledge	O
gaps	O
and	O
action	O
needed	O
in	O
ENT	O
infectious	B-DIS
diseases	I-DIS
research	O
and	O
clinical	O
practice	O
and	O
we	O
make	O
references	O
to	O
economic	O
analysis	O
in	O
the	O
field	O
of	O
ENT	O
infectious	B-DIS
diseases	I-DIS
prevention	O
and	O
care	O
.	O

BACKGROUND	O
Vascular	O
type	O
of	O
Ehlers	B-DIS
-	I-DIS
Danlos	I-DIS
syndrome	O
vEDS	O
is	O
a	B-DIS
rare	I-DIS
connective	I-DIS
tissue	O
disorder	O
associated	O
with	O
a	B-EPI
high	O
prevalence	O
rate	O
of	O
aortic	O
dissection	O
AD	O
.	O

The	O
coexistence	O
of	O
a	O
pregnancy	O
raises	O
these	O
rates	O
and	O
the	O
diagnostic	O
complexity	O
of	O
the	O
situation	O
.	O

In	O
this	O
article	O
we	O
present	O
a	O
different	O
initial	O
diagnostic	O
approach	O
to	O
an	O
acute	B-DIS
aortic	I-DIS
syndrome	I-DIS
.	O

CASE	O
REPORT	O
A	O
young	O
pregnant	O
woman	O
29th	O
week	O
gestation	O
with	O
vEDS	O
was	O
admitted	O
to	O
our	O
clinic	O
due	O
to	O
sudden	O
tearing	O
back	O
pain	B-DIS
radiating	O
to	O
the	O
left	O
arm	O
.	O

Four	O
years	O
ago	O
the	O
same	O
patient	O
underwent	O
a	O
surgical	O
aortic	O
valve	O
reconstruction	O
and	O
replace	O
of	O
the	O
ascending	O
and	O
proximal	O
arch	O
of	O
the	O
aorta	O
because	O
of	O
an	O
acute	O
Standford	O
A	O
AD	O
.	O

The	O
clinical	O
laboratory	O
as	O
well	O
as	O
transthoracic	O
echocardiographic	O
findings	O
did	O
not	O
reveal	O
any	O
objective	O
signs	O
of	O
an	O
acute	B-DIS
aortic	I-DIS
syndrome	I-DIS
.	O

Due	O
to	O
the	O
relative	O
contraindications	O
against	O
computed	O
tomography	O
imaging	O
due	O
to	O
pregnancy	O
we	O
conducted	O
a	O
transesophageal	O
echocardiography	O
which	O
revealed	O
acute	O
progress	O
of	O
pre	O
-	O
existing	O
AD	O
.	O

A	O
follow	O
-	O
up	O
computed	O
tomography	O
could	O
verify	O
our	O
findings	O
showing	O
a	O
Standford	O
B	O
dissection	O
which	O
was	O
treated	O
conservatively	O
.	O

After	O
2	O
weeks	O
due	O
to	O
a	O
distal	O
progression	O
of	O
dissection	O
our	O
patient	O
underwent	O
a	O
cesarean	O
section	O
.	O

In	O
absence	O
of	O
new	O
clinical	O
findings	O
the	O
young	O
patient	O
was	O
discharged	O
the	O
following	O
week	O
.	O

CONCLUSIONS	O
Patients	O
with	O
vEDS	O
are	O
at	O
high	O
risk	O
of	O
an	O
AD	O
and	O
other	O
life	O
-	O
threatening	O
complications	O
especially	O
during	O
pregnancy	O
.	O

According	O
to	O
the	O
guidelines	O
of	O
European	O
Society	O
of	O
Cardiology	O
ESC	O
vEDS	O
-	O
patients	O
should	O
be	O
thoroughly	O
screened	O
.	O

In	O
the	O
case	O
of	O
pregnancy	O
physicians	O
should	O
consider	O
frequent	O
follow	O
-	O
up	O
examinations	O
and	O
be	O
prepared	O
for	O
diagnosis	O
and	O
treatment	O
of	O
the	O
potential	O
complications	O
.	O

Purpose	O
VACTERL	O
association	O
is	O
a	O
rare	O
and	O
complex	O
condition	O
of	O
congenital	B-DIS
malformations	I-DIS
often	O
requiring	O
repeated	O
surgery	O
and	O
entailing	O
various	O
physical	O
sequelae	O
.	O

Due	O
to	O
scarcity	O
of	O
knowledge	O
the	O
study	O
aim	O
was	O
to	O
investigate	O
self	O
-	O
reported	O
health	O
-	O
related	O
quality	B-DIS
of	I-DIS
life	O
HRQoL	O
anxiety	O
depression	O
and	O
self	O
-	O
concept	O
in	O
children	O
and	O
adolescents	B-DIS
with	O
VACTERL	B-DIS
association	O
and	O
self	O
-	O
reported	O
anxiety	O
and	O
depression	O
in	O
their	O
parents	O
.	O

Methods	O
Patients	O
aged	O
8	O
-	O
17	O
years	O
with	O
VACTERL	O
association	O
and	O
their	O
parents	O
were	O
recruited	O
from	O
three	O
of	O
four	O
Swedish	O
paediatric	O
surgical	O
centres	O
during	O
2015	O
-	O
2019	O
.	O

The	O
well	O
-	O
established	O
validated	O
questionnaires	O
DISABKIDS	O
Beck	O
Youth	O
Inventories	B-DIS
Beck	O
Anxiety	O
Inventory	O
and	B-DIS
Beck	O
Depression	O
Inventory	O
were	O
sent	O
to	O
the	O
families	O
.	O

Data	O
were	O
analysed	O
using	O
descriptives	O
t	O
tests	O
and	O
multivariable	O
analysis	O
.	O

Results	O
were	O
compared	O
with	O
norm	O
groups	O
and	O
reference	O
samples	O
.	O

Results	O
The	O
questionnaires	O
were	O
returned	O
by	O
40	O
patients	O
38	O
mothers	O
and	O
33	O
fathers	O
.	O

The	O
mean	O
HRQoL	O
was	O
M	O
=	O
80.4	O
comparable	O
to	O
children	O
with	O
asthma	O
M	O
=	O
80.2	O
and	O
diabetes	B-DIS
M	O
=	O
79.5	O
.	O

Self	O
-	O
reported	O
psychological	O
well	O
-	O
being	O
was	O
comparable	O
to	O
the	O
norm	O
group	O
of	O
Swedish	O
school	O
children	O
and	O
was	O
significantly	O
higher	O
than	O
a	O
clinical	O
sample	O
.	O

Factors	O
negatively	O
influencing	O
children	O
's	O
HRQoL	O
and	O
psychological	O
well	O
-	O
being	O
were	O
identified	O
.	O

The	O
parents	O
'	O
self	O
-	O
reports	B-DIS
of	O
anxiety	B-DIS
and	O
depression	O
were	O
comparable	O
to	O
non	O
-	O
clinical	O
samples	O
.	O

Conclusions	O
Although	O
children	O
and	O
adolescents	O
with	O
VACTERL	O
association	O
reported	O
similar	O
HRQoL	O
to	O
those	O
of	O
European	O
children	O
with	O
chronic	O
conditions	O
their	O
psychological	O
well	O
-	O
being	O
was	O
comparable	O
to	O
Swedish	O
school	O
children	O
in	O
general	O
.	O

Nevertheless	O
some	O
individuals	O
among	O
both	O
children	O
and	O
parents	O
were	O
in	O
need	O
of	O
extra	O
support	O
.	O

This	O
attained	O
knowledge	O
is	O
valuable	O
when	O
counselling	O
parents	O
regarding	O
the	O
prognosis	O
for	O
children	O
with	O
VACTERL	O
association	O
.	O

Usher	B-DIS
syndrome	I-DIS
the	O
most	O
prevalent	O
cause	O
of	O
combined	O
hereditary	B-DIS
vision	I-DIS
and	O
hearing	B-DIS
impairment	I-DIS
is	O
clinically	O
and	O
genetically	O
heterogeneous	O
.	O

Moreover	O
several	O
conditions	O
with	O
phenotypes	O
overlapping	O
Usher	B-DIS
syndrome	I-DIS
have	O
been	O
described	O
.	O

This	O
makes	O
the	O
molecular	O
diagnosis	O
of	O
hereditary	B-DIS
deaf	I-DIS
-	O
blindness	O
challenging	O
.	O

Here	O
we	O
performed	O
exome	O
sequencing	O
and	O
analysis	O
on	O
7	O
Mexican	O
and	O
52	O
Iranian	O
probands	O
with	O
combined	O
retinal	B-DIS
degeneration	I-DIS
and	O
hearing	B-DIS
impairment	I-DIS
without	O
intellectual	B-DIS
disability	I-DIS
.	O

Clinical	O
assessment	O
involved	O
ophthalmological	O
examination	O
and	O
hearing	B-DIS
loss	I-DIS
questionnaire	O
.	O

Usher	B-DIS
syndrome	I-DIS
most	O
frequently	O
due	O
to	O
biallelic	O
variants	O
in	O
MYO7A	O
USH1B	B-DIS
in	O
16	O
probands	O
USH2A	O
17	O
probands	O
and	O
ADGRV1	O
USH2C	O
in	O
7	O
probands	O
was	O
diagnosed	O
in	O
44	O
of	O
5975	B-STAT
%	I-STAT
unrelated	O
probands	O
.	O

Almost	O
half	O
of	O
the	O
identified	O
variants	O
were	O
novel	O
.	O

Nine	O
of	O
5915	B-STAT
%	I-STAT
probands	O
displayed	O
other	O
genetic	O
entities	O
with	O
dual	B-DIS
sensory	I-DIS
impairment	I-DIS
including	O
AlstrÃ¶m	O
syndrome	O
3	O
patients	O
cone	B-DIS
-	I-DIS
rod	O
dystrophy	B-DIS
and	I-DIS
hearing	O
loss	O
12	O
probands	B-DIS
and	I-DIS
Heimler	O
syndrome	O
1	O
patient	O
.	O

Unexpected	O
findings	O
included	O
one	O
proband	O
each	O
with	O
Scheie	B-DIS
syndrome	I-DIS
coenzyme	O
Q10	O
deficiency	O
and	O
pseudoxanthoma	B-DIS
elasticum	I-DIS
.	O

In	O
four	O
probands	O
including	O
three	O
Usher	B-DIS
cases	O
dual	B-DIS
sensory	I-DIS
impairment	I-DIS
was	O
either	O
modified	O
/	O
aggravated	O
or	O
caused	O
by	O
variants	O
in	O
distinct	O
genes	O
associated	B-DIS
with	I-DIS
retinal	O
degeneration	B-DIS
and/or	I-DIS
hearing	O
loss	O
.	O

The	O
overall	O
diagnostic	O
yield	O
of	O
whole	O
exome	O
analysis	O
in	O
our	O
deaf	O
-	O
blind	O
cohort	O
was	O
92	B-STAT
%	I-STAT
.	O

Two	B-STAT
3	I-STAT
%	I-STAT
probands	O
were	O
partially	O
solved	O
and	O
only	B-STAT
35	I-STAT
%	I-STAT
remained	O
without	O
any	O
molecular	O
diagnosis	O
.	O

In	O
many	O
cases	O
the	O
molecular	O
diagnosis	O
is	O
important	O
to	O
guide	O
genetic	O
counseling	O
to	O
support	O
prognostic	O
outcomes	O
and	O
decisions	O
with	O
currently	O
available	O
and	O
evolving	O
treatment	O
modalities	O
.	O

Epidemiological	O
data	O
on	O
the	O
14	O
cases	O
of	O
adrenal	B-DIS
cortical	I-DIS
tumour	I-DIS
registered	O
with	O
the	O
Manchester	O
Children	O
's	O
Tumour	B-DIS
Registry	O
from	O
1954	O
and	O
1985	O
are	O
presented	O
.	O

The	O
incidence	B-EPI
of	O
adrenal	B-DIS
cortical	I-DIS
carcinomas	I-DIS
was	O
0.3	B-STAT
%	I-STAT
mainly	O
in	O
girls	O
most	O
of	O
whom	O
presented	O
with	O
virilisation	B-DIS
.	O

The	O
incidence	B-EPI
of	O
neoplastic	B-DIS
disease	I-DIS
among	O
close	O
relatives	O
was	O
ascertained	O
but	O
except	O
in	O
siblings	O
this	O
was	O
not	O
significantly	O
higher	O
than	O
would	O
be	O
expected	O
.	O

Evidence	O
from	O
extended	O
pedigrees	O
however	O
indicates	O
that	O
at	O
least	O
four	O
of	O
the	O
children	O
could	O
be	O
members	O
of	O
families	O
with	O
the	O
SBLA	B-DIS
sarcoma	I-DIS
breast	I-DIS
and	O
brain	O
tumour	B-DIS
leukaemia	I-DIS
laryngeal	I-DIS
and	O
lung	B-DIS
cancer	I-DIS
and	O
adrenal	B-DIS
cortical	I-DIS
carcinoma	I-DIS
cancer	I-DIS
family	O
syndrome	O
and	O
that	O
other	O
relatives	O
may	O
be	O
at	O
risk	O
of	O
developing	O
such	O
neoplasms	B-DIS
.	O

Herpes	B-DIS
simplex	I-DIS
virus	O
types	O
1	B-STAT
HSV-1	I-STAT
and	I-STAT
2	I-STAT
HSV-2	O
are	O
highly	O
prevalent	O
viruses	O
capable	O
of	O
establishing	O
lifelong	O
infection	B-DIS
.	O

Genital	O
herpes	B-DIS
in	O
women	O
of	O
childbearing	O
age	O
represents	O
a	O
major	O
risk	O
for	O
mother	O
-	O
to	O
-	O
child	B-DIS
transmission	I-DIS
MTCT	O
of	O
HSV	O
infection	B-DIS
with	I-DIS
primary	I-DIS
and	I-DIS
first	O
-	O
episode	O
genital	O
HSV	O
infections	O
posing	O
the	O
highest	O
risk	O
.	O

The	O
advent	O
of	O
antiviral	O
therapy	O
with	O
parenteral	O
acyclovir	O
has	O
led	O
to	O
significant	O
improvement	O
in	O
neonatal	O
HSV	B-DIS
disease	I-DIS
mortality	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
improve	O
the	O
clinician	O
's	O
ability	O
to	O
identify	O
infants	O
at	O
increased	O
risk	O
for	O
HSV	B-DIS
infection	I-DIS
and	O
prevent	O
MTCT	O
and	O
to	O
develop	O
novel	O
antiviral	O
agents	O
with	O
increased	O
efficacy	O
in	O
infants	O
with	O
HSV	B-DIS
infection	I-DIS
.	O

Charcot	B-DIS
-	I-DIS
Marie	O
-	O
Tooth	O
disease	O
CMT	O
is	B-DIS
a	I-DIS
common	O
inherited	O
peripheral	O
neuropathy	B-STAT
affecting	I-STAT
up	I-STAT
to	O
1	O
in	O
1214	O
of	O
the	O
general	O
population	O
with	O
more	O
than	O
60	O
nuclear	O
genes	O
implicated	O
in	O
its	O
pathogenesis	O
.	O

Traditional	O
molecular	O
diagnostic	O
pathways	O
based	O
on	O
relative	O
prevalence	B-EPI
and	O
clinical	O
phenotyping	O
are	O
limited	O
by	O
long	O
turnaround	O
time	O
population	O
-	B-EPI
specific	O
prevalence	O
of	O
causative	O
variants	O
and	O
inability	O
to	O
assess	O
multiple	O
co	O
-	O
existing	O
variants	O
.	O

In	O
this	O
study	O
a	O
CMT	B-DIS
gene	O
panel	O
comprising	O
27	O
genes	O
was	O
used	O
to	O
uncover	O
the	O
pathogenic	O
mutations	O
in	O
two	O
index	O
patients	O
.	O

The	O
first	O
patient	O
is	O
a	O
15	O
-	O
year	O
-	O
old	B-DIS
boy	O
born	O
of	O
consanguineous	O
parents	O
who	O
has	O
had	O
frequent	O
trips	O
and	O
falls	O
since	O
infancy	O
and	O
was	O
later	O
found	O
to	O
have	O
inverted	O
champagne	O
bottle	O
appearance	O
of	O
bilateral	O
legs	O
and	O
foot	O
drop	O
.	O

His	O
elder	O
sister	O
is	O
similarly	O
affected	O
.	O

The	O
second	O
patient	O
is	O
a	O
37	O
-	O
year	O
-	O
old	O
woman	O
referred	O
for	O
pre	O
-	O
pregnancy	O
genetic	O
diagnosis	O
.	O

During	O
early	O
adulthood	O
she	O
developed	O
progressive	O
lower	B-DIS
limb	I-DIS
weakness	I-DIS
difficulties	I-DIS
in	O
tip	O
-	O
toe	O
walking	O
and	O
thinning	O
of	O
calf	O
muscles	O
.	O

Both	O
patients	O
are	O
clinically	O
compatible	O
with	O
CMT	B-DIS
have	O
undergone	O
multiple	O
genetic	O
testings	O
and	O
have	O
not	O
previously	O
received	O
a	O
definitive	O
genetic	O
diagnosis	O
.	O

Patients	O
1	B-STAT
and	I-STAT
2	I-STAT
were	O
found	O
to	O
have	O
pathogenic	O
homozygous	O
HSPB1	O
NM_001540c.25	O
A	O
p.	O
G84R	O
variant	O
and	O
heterozygous	O
GDAP1	O
NM_018972c.35	O
T	O
p.	O
R120W	O
variant	O
respectively	O
.	O

Advantages	O
and	O
limitations	O
of	O
the	O
current	O
approach	O
are	O
discussed	O
.	O

Background	O
Gastric	O
enterochromaffin	O
-	O
like	O
cell	O
ECL	O
tumours	O
can	O
occur	O
in	O
patients	B-DIS
with	I-DIS
multiple	I-DIS
endocrine	I-DIS
neoplasia	I-DIS
type	I-DIS
1	O
MEN1	O
especially	O
in	O
those	O
affected	B-DIS
by	I-DIS
Zollinger	I-DIS
Ellison	O
syndrome	O
ZES	O
.	O

Since	O
the	O
prevalence	B-EPI
of	O
ECL	O
lesions	O
is	O
not	O
well	O
defined	O
yet	O
the	O
present	O
study	O
evaluated	O
the	O
presence	O
and	O
extent	O
of	O
ECL	O
lesions	O
in	O
MEN1	B-DIS
patients	O
with	O
and	O
without	O
ZES	O
.	O

Methods	O
Multiple	O
endocrine	B-DIS
neoplasia	I-DIS
type	O
1	O
patients	O
being	O
part	O
of	O
a	O
regular	O
screening	O
program	O
2014	O
-	O
2018	O
underwent	O
gastroduodenoscopies	O
with	O
biopsies	O
of	O
the	O
stomach	O
and	O
determination	O
of	O
serum	O
gastrin	O
and	O
chromogranin	O
A	O
levels	O
.	O

Haematoxylin-	O
and	O
immunostaining	O
with	O
chromogranin	O
A	O
gastrin	O
and	O
VMAT	O
I	O
and	O
II	O
vesicular	O
monoamine	O
transporter	O
I	O
and	O
II	O
of	O
the	O
biopsies	O
were	O
performed	O
.	O

Results	O
Thirty	O
-	B-DIS
eight	O
MEN1	O
patients	O
of	O
whom	O
1642	B-STAT
%	I-STAT
were	O
diagnosed	O
and	O
treated	O
earlier	O
for	O
ZES	O
were	O
analysed	O
.	O

In	O
ten	O
of	O
1662.5	B-STAT
%	I-STAT
ZES	O
patients	O
a	O
locally	O
scattered	O
mixed	O
image	O
of	O
diffuse	O
linear	O
and	O
micronodular	O
mild	O
hyperplasia	O
was	O
present	O
.	O

In	O
addition	O
two	O
of	O
these	O
patients	O
13	B-STAT
%	I-STAT
showed	O
small	O
max	O
1.5	O
mm	O
in	O
size	O
intramucosal	O
ECL	O
tumours	O
.	O

Neither	O
ECL	O
changes	O
nor	O
tumours	B-DIS
were	O
found	O
in	O
MEN1	B-DIS
patients	O
without	O
ZES	O
n	O
=	O
22	O
.	O

In	O
MEN1	B-DIS
/	O
ZES	O
patients	O
the	O
median	O
serum	O
gastrin	O
level	O
was	O
significantly	O
elevated	O
compared	B-DIS
to	O
MEN1	O
patients	O
without	O
ZES	O
206	O
pg	O
/	O
ml	O
vs.	O
30.5	O
pg	O
/	O
ml	O
p	O
<	O
.001	O
.	O

A	O
subgroup	O
analysis	O
of	O
the	O
serum	O
gastrin	O
and	O
chromogranin	O
A	O
levels	O
of	O
MEN1	B-DIS
/	O
ZES	O
patients	O
with	O
or	B-DIS
without	I-DIS
ECL	O
hyperplasia	O
did	O
not	O
show	O
significant	O
differences	O
gastrin	O
level	O
p	O
=	O
.302	O
chromogranin	O
A	O
p	O
=	O
.464	O
.	O

Conclusion	O
Enterochromaffin	B-DIS
-	I-DIS
like	I-DIS
cell	I-DIS
hyperplasia	I-DIS
and	I-DIS
gastric	O
carcinoids	O
occur	O
only	B-DIS
in	O
MEN1	O
patients	O
with	O
ZES	O
but	O
less	O
frequently	O
than	O
reported	O
.	O

Congenital	B-DIS
lung	I-DIS
agenesis	I-DIS
is	O
an	O
extremely	O
rare	O
condition	O
with	O
an	O
estimated	O
prevalence	B-EPI
of	O
34	O
in	O
1000000	O
live	O
births	O
.	O

It	O
is	O
often	O
associated	O
with	O
other	O
congenital	B-DIS
malformations	I-DIS
of	O
the	O
skeletal	O
cardiovascular	O
urogenital	O
and	O
gastrointestinal	O
systems	O
.	O

We	O
discuss	O
the	O
case	O
of	O
a	O
5	O
-	O
month	O
-	O
old	O
who	O
presented	O
with	O
increasing	O
stridor	O
over	O
1	O
month	O
.	O

Imaging	O
revealed	O
right	B-DIS
lung	I-DIS
agenesis	I-DIS
complete	O
dextromalposition	O
of	O
heart	O
and	O
compression	O
of	O
distal	O
trachea	O
.	O

An	O
intrathoracic	O
saline	O
tissue	O
expander	O
was	O
placed	O
which	O
marked	O
improved	O
distal	O
tracheal	B-DIS
stenosis	I-DIS
.	O

In	O
patients	O
who	O
are	O
symptomatic	O
it	O
becomes	O
imperative	O
to	O
perform	O
surgeries	O
to	O
increase	O
survival	O
as	O
was	O
the	O
case	O
in	O
this	O
patient	O
.	O

A	O
novel	O
coronavirus	O
SARS	O
-	O
CoV-2	B-DIS
causing	I-DIS
Coronavirus	I-DIS
disease	I-DIS
2019	O
COVID-19	O
has	O
entered	O
the	O
human	O
population	O
and	O
has	O
spread	O
rapidly	O
around	O
the	O
world	O
in	O
the	O
first	O
half	O
of	O
2020	O
causing	O
a	B-DIS
global	O
pandemic	O
.	O

The	O
virus	O
uses	O
its	O
spike	O
glycoprotein	O
receptor	O
-	O
binding	O
domain	O
to	O
interact	O
with	O
host	O
cell	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
ACE2	O
sites	O
to	O
initiate	O
a	O
cascade	O
of	O
events	O
that	O
culminate	B-DIS
in	I-DIS
severe	O
acute	O
respiratory	O
syndrome	O
in	O
some	O
individuals	O
.	O

In	O
efforts	O
to	O
curtail	O
viral	O
spread	O
authorities	O
initiated	O
far	O
-	O
reaching	O
lockdowns	O
that	O
have	O
disrupted	O
global	O
economies	O
.	O

The	O
scientific	O
and	O
medical	O
communities	O
are	O
mounting	O
serious	O
efforts	O
to	O
limit	O
this	O
pandemic	B-DIS
and	O
subsequent	O
waves	O
of	O
viral	O
spread	O
by	O
developing	O
preventative	O
vaccines	O
and	O
repurposing	O
existing	O
drugs	O
as	O
potential	O
therapies	O
.	O

In	O
this	O
review	O
we	O
focus	O
on	O
the	O
latest	O
developments	O
in	O
COVID-19	O
vaccine	O
development	O
including	O
results	O
of	O
the	O
first	O
Phase	O
I	O
clinical	O
trials	O
and	O
describe	O
a	O
number	O
of	O
the	O
early	O
candidates	O
that	O
are	O
emerging	O
in	O
the	O
field	O
.	O

We	O
seek	O
to	O
provide	O
a	O
balanced	O
coverage	O
of	O
the	O
seven	O
main	O
platforms	O
used	O
in	O
vaccine	O
development	O
that	O
will	O
lead	O
to	O
a	O
desired	O
target	O
product	O
profile	O
for	O
the	O
`	O
`	O
ideal	O
''	O
vaccine	O
.	O

Using	O
tales	O
of	O
past	O
vaccine	O
discovery	O
efforts	O
that	O
have	O
taken	O
many	O
years	O
or	O
that	O
have	O
failed	O
we	O
temper	O
over	O
exuberant	O
enthusiasm	O
with	O
cautious	O
optimism	O
that	O
the	O
global	O
medical	O
community	O
will	O
reach	O
the	O
elusive	O
target	O
to	O
treat	O
COVID-19	O
and	O
end	O
the	O
pandemic	B-DIS
.	O

Objective	O
This	O
study	O
was	O
undertaken	O
to	O
measure	O
the	O
incidence	B-EPI
and	O
prevalence	B-EPI
of	O
active	O
psychogenic	B-DIS
nonepileptic	I-DIS
seizures	I-DIS
PNES	O
in	O
a	O
Norwegian	O
county	O
.	O

Methods	O
Using	O
the	O
Norwegian	O
patient	O
registry	O
we	O
identified	O
patients	O
in	O
MÃ¸re	O
and	O
Romsdal	B-LOC
County	I-LOC
in	O
Norway	B-LOC
diagnosed	O
with	O
F44.5	O
conversion	O
disorder	O
with	O
seizures	B-DIS
or	O
convulsions	B-DIS
or	O
R56.8	O
convulsions	B-DIS
not	O
elsewhere	O
classified	O
in	O
the	O
period	O
January	O
2010	O
to	O
January	O
2020	O
.	O

A	O
review	O
of	O
the	O
patients	O
'	O
medical	O
records	O
and	O
an	O
assessment	O
of	O
diagnostic	O
validity	O
were	O
performed	O
.	O

PNES	O
were	O
diagnosed	O
according	O
to	O
the	O
recommendations	O
by	O
the	O
International	O
League	O
Against	O
Epilepsy	B-DIS
Nonepileptic	I-DIS
Seizures	I-DIS
Task	O
Force	O
.	O

Point	O
prevalence	B-EPI
of	O
PNES	O
on	O
January	O
12020	O
and	O
incidence	B-EPI
rates	O
for	O
the	O
period	O
2010	O
-	O
2019	O
were	O
determined	O
.	O

Results	O
Based	O
on	O
PNES	O
within	O
the	O
past	O
5	O
years	O
we	O
found	O
a	O
PNES	O
prevalence	B-EPI
of	O
23.8/100000	B-STAT
95	I-STAT
%	I-STAT
confidence	O
interval	O
[	O
CI	O
]	O
=	O
17.9	O
-	O
29.6	O
including	O
all	O
levels	O
of	O
diagnostic	O
certainty	O
.	O

For	O
the	O
highest	O
level	O
of	O
diagnostic	O
certainty	O
video	O
-	O
electroencephalographically	O
confirmed	B-EPI
the	O
prevalence	B-STAT
was	O
10.6/100000	O
95	B-STAT
%	I-STAT
CI	O
=	O
6.7	O
-	O
14.5	O
.	O

The	O
highest	O
prevalence	B-EPI
was	O
found	O
in	O
the	O
age	O
group	O
15	O
-	O
19	O
years	O
at	O
59.5/100000	B-STAT
95	I-STAT
%	I-STAT
CI	O
=	O
22.6	O
-	O
96.3	O
.	O

The	O
mean	O
annual	O
incidence	B-EPI
rate	O
between	O
2010	O
and	O
2019	O
was	O
3.1/100	B-STAT
000	B-STAT
/	O
year	O
95	B-STAT
%	I-STAT
CI	O
=	O
2.4	O
-	O
3.7	O
.	O

Significance	O
We	O
report	O
for	O
the	O
first	O
time	O
a	O
population	O
-	O
based	O
estimate	O
of	B-EPI
the	O
prevalence	O
of	O
PNES	O
.	O

Our	O
findings	O
suggest	O
that	O
the	O
prevalence	B-EPI
of	O
PNES	B-DIS
is	O
within	O
the	O
range	O
of	O
estimates	O
from	O
non	O
-	O
population	O
-	O
based	O
data	O
.	O

We	O
found	O
a	O
strikingly	O
high	O
prevalence	B-EPI
of	O
PNES	O
in	O
the	O
15	O
-	O
19	O
-	O
year	O
age	O
group	O
.	O

Ogilvie	B-DIS
syndrome	I-DIS
is	O
a	O
clinical	O
condition	O
in	O
which	O
there	O
is	O
a	O
colorectal	B-DIS
distention	I-DIS
in	O
the	O
absence	O
of	O
mechanical	O
obstacles	O
.	O

Early	O
diagnosis	O
and	O
appropriate	O
therapy	O
significantly	O
reduce	O
mortality	O
.	O

The	O
incidence	B-EPI
of	O
this	O
is	O
not	O
known	O
.	O

This	O
paper	O
presents	O
the	O
course	O
of	O
diagnosis	O
and	O
treatment	O
both	O
conservative	O
and	O
operational	O
of	O
an	O
82	O
year	O
old	O
patient	O
with	O
pulmonary	B-DIS
embolism	I-DIS
burdened	O
with	O
coronary	B-DIS
artery	I-DIS
disease	I-DIS
hypertension	I-DIS
heart	I-DIS
failure	I-DIS
and	O
chronic	B-DIS
kidney	I-DIS
failure	I-DIS
in	O
which	O
the	O
hospital	O
diagnosed	O
Ogilvie	B-DIS
syndrome	I-DIS
.	O

The	O
establishing	O
of	O
46	O
chromosomes	O
as	O
the	O
normal	O
complement	O
in	O
man	O
and	O
the	O
report	O
of	O
the	O
sex	O
chromatin	O
bodies	O
in	O
buccal	O
smears	O
were	O
followed	O
by	O
reports	O
of	O
trisomies	B-DIS
and	O
other	O
abnormal	O
patterns	O
of	O
the	O
X	O
and	O
Y	O
chromosomes	O
in	O
Klinefelter	B-DIS
's	O
and	O
Turner	B-DIS
's	I-DIS
syndromes	I-DIS
.	O

Abnormal	B-DIS
autosomal	I-DIS
complements	O
were	O
described	O
in	O
mongolism	B-DIS
in	O
the	O
E	B-DIS
-	I-DIS
trisomy	O
syndrome	B-DIS
the	I-DIS
D	O
-	O
trisomy	B-DIS
syndrome	I-DIS
in	I-DIS
the	I-DIS
Sturge	I-DIS
-	I-DIS
Weber	I-DIS
syndrome	I-DIS
Waldenstrom	B-DIS
's	I-DIS
macroglobulinemia	I-DIS
benign	O
congenital	O
hypotonia	O
atrial	B-DIS
septal	I-DIS
defect	O
and	O
in	O
the	O
schizoid	O
personality	O
.	O

Certain	O
of	O
these	O
conditions	O
as	O
well	O
as	O
the	O
`	O
`	O
oral	O
-	O
facial	O
-	O
digital	O
''	O
syndrome	O
were	O
also	O
found	O
to	B-DIS
exist	O
as	O
partial	O
trisomies	O
.	O

The	O
mechanism	O
of	O
a	O
trisomy	B-DIS
is	O
one	O
of	O
non	O
-	O
disjunction	O
and	O
of	O
partial	O
trisomy	O
translocation	O
or	O
insertion	O
.	O

Two	O
cases	O
of	O
the	O
partial	O
trisomy	O
in	O
the	O
E	O
group	O
are	O
described	O
;	O
these	O
are	O
of	O
especial	O
interest	O
because	O
of	O
the	O
familial	O
incidence	B-EPI
longer	O
survival	O
and	O
male	O
sex	O
occurrence	O
features	O
which	O
are	O
rarely	O
seen	O
in	O
the	O
full	O
E	B-DIS
-	I-DIS
trisomy	O
syndrome	O
.	O

We	O
examined	O
the	O
potential	O
benefits	O
of	O
neuroimaging	O
measurements	O
across	O
the	O
first	O
5	O
years	O
of	O
life	O
in	O
detecting	O
early	O
comorbid	O
or	O
etiological	O
signs	O
of	O
autism	B-DIS
spectrum	I-DIS
disorder	I-DIS
ASD	I-DIS
.	O

In	O
particular	O
we	O
analyzed	O
the	O
prevalence	B-EPI
of	O
neuroradiologic	O
findings	O
in	O
routine	O
magnetic	O
resonance	O
imaging	O
MRI	O
scans	O
of	O
a	O
group	O
of	O
117	O
ASD	O
children	O
younger	O
than	O
5	O
years	O
old	O
.	O

These	O
data	O
were	O
compared	O
to	O
those	O
reported	O
in	O
typically	O
developing	O
TD	B-DIS
children	O
.	O

MRI	O
findings	O
in	O
children	O
with	O
ASD	B-DIS
were	O
analyzed	O
in	O
relation	O
to	O
their	O
cognitive	O
level	O
severity	O
of	O
autistic	B-DIS
symptoms	I-DIS
and	O
the	O
presence	O
of	O
electroencephalogram	O
EEG	O
abnormalities	O
.	O

The	O
MRI	O
was	O
rated	O
abnormal	O
in	O
55	B-STAT
%	I-STAT
of	O
children	O
with	O
ASD	B-DIS
with	O
a	O
significant	O
prevalence	B-EPI
in	O
the	O
high	O
-	O
functioning	O
subgroup	O
compared	B-DIS
to	O
TD	O
children	O
.	O

We	O
report	O
significant	O
incidental	O
findings	O
of	O
mega	O
cisterna	O
magna	O
ventricular	B-DIS
anomalies	I-DIS
and	O
abnormal	B-DIS
white	I-DIS
matter	I-DIS
signal	I-DIS
intensity	O
in	O
ASD	B-DIS
without	O
significant	O
associations	O
between	O
these	O
MRI	O
findings	O
and	O
EEG	O
features	O
.	O

Based	O
on	O
these	O
results	O
we	O
discuss	O
the	O
role	O
that	O
brain	O
MRI	O
may	O
play	O
in	O
the	O
diagnostic	O
procedure	O
of	O
ASD	B-DIS
.	O

Purpose	O
The	O
eye	O
and	O
its	O
adnexal	O
structures	O
can	O
give	O
rise	O
to	O
first	O
or	O
consecutive	O
primary	B-DIS
malignancies	I-DIS
or	O
to	O
encounter	O
metastasis	B-DIS
.	O

Our	O
aim	O
was	O
to	O
define	O
the	O
characteristics	O
of	O
the	O
second	O
primary	O
neoplasms	B-DIS
affecting	O
the	O
eye	O
and	O
its	O
adnexa	B-DIS
and	O
find	O
the	O
risk	O
modifying	O
factors	O
for	O
them	O
after	O
malignancies	O
elsewhere	O
in	O
the	O
body	O
.	O

Methods	O
We	O
have	O
queried	O
the	O
Surveillance	O
Epidemiology	O
and	O
End	O
-	O
Results	O
`	O
`	O
SEER	O
''	O
-9	O
program	O
of	O
the	B-DIS
National	O
Cancer	O
Institute	O
for	B-DIS
the	I-DIS
malignancies	I-DIS
of	I-DIS
the	O
eye	O
and	B-DIS
its	O
adnexa	O
that	O
occurred	O
between	O
1973	O
and	O
2015	O
.	O

The	O
malignancies	B-DIS
were	O
ordered	O
chronologically	O
according	O
to	O
their	O
incidence	B-EPI
first	O
or	O
second	O
primary	B-DIS
malignancies	I-DIS
.	O

The	O
tumors	B-DIS
were	O
classified	O
according	O
to	O
ICD	O
-	O
O-3	O
classification	O
.	O

Standardized	O
incidence	B-EPI
ratios	O
SIR	B-DIS
and	O
survival	O
probabilities	O
were	O
calculated	O
for	O
subgroups	O
.	O

Results	O
Among	O
3578950	O
cancer	O
patients	O
1203	O
experienced	O
a	O
second	O
malignancies	B-DIS
of	I-DIS
the	I-DIS
eye	I-DIS
and	O
its	O
adnexa	B-DIS
.	O

The	O
first	O
malignancy	B-DIS
was	O
diagnosed	O
between	O
50	O
and	O
69	O
years	O
of	O
age	O
in	O
58.94	B-STAT
%	I-STAT
of	O
them	O
.	O

The	O
eyelid	B-DIS
showed	O
280	O
events	O
while	O
50	O
in	O
lacrimal	O
gland	O
181	O
in	O
the	O
orbit	O
21	O
in	O
the	O
overlapping	O
lesions	O
15	O
in	O
optic	B-DIS
nerve	I-DIS
148	I-DIS
in	O
the	O
conjunctiva	O
9	O
in	O
the	O
cornea	B-DIS
6	O
in	O
the	O
Retina	O
379	O
in	O
the	O
choroid	O
and	O
93	O
in	O
the	O
ciliary	O
body	O
.	O

The	O
SIR	O
of	O
a	O
second	O
malignancy	B-DIS
after	O
a	O
prior	O
non	B-DIS
-	I-DIS
Hodgkin	O
lymphoma	O
was	O
2.42	O
and	O
in	O
case	O
of	B-DIS
previous	I-DIS
skin	O
carcinomas	O
it	O
was	B-DIS
3.02	O
melanoma	O
of	O
skin	O
and	O
2.13	O
and	O
1.58	O
in	B-DIS
oral	I-DIS
cavity	O
/	O
pharynx	O
malignancies	O
.	O

The	O
second	O
ocular	B-DIS
and	I-DIS
adnexal	I-DIS
neoplasms	I-DIS
increased	O
steadily	O
over	O
the	O
5	O
-	O
year	O
periods	O
on	O
contrary	O
to	O
first	B-DIS
primary	O
neoplasms	O
.	O

The	O
survival	O
of	O
patients	O
affected	O
with	O
first	O
ocular	B-DIS
and	I-DIS
adnexal	I-DIS
neoplasms	I-DIS
was	O
significantly	O
higher	O
than	O
those	O
with	O
second	O
ocular	B-DIS
and	I-DIS
adnexal	I-DIS
neoplasms	I-DIS
.	O

On	O
the	O
other	O
side	O
second	O
primary	O
ocular	O
and	O
adnexal	B-DIS
tumors	I-DIS
showed	O
a	O
better	O
survival	O
than	O
second	O
primary	B-DIS
malignancies	I-DIS
elsewhere	O
.	O

Conclusions	O
The	O
epidemiological	O
differences	O
between	O
first	O
and	O
second	O
ocular	B-DIS
and	I-DIS
adnexal	I-DIS
primaries	O
suggest	O
different	O
underlying	O
mechanisms	O
.	O

Careful	O
ocular	O
examination	O
should	O
be	O
integrated	O
in	O
the	O
long	O
-	O
term	O
follow	O
-	B-DIS
up	O
plan	O
of	O
cancer	O
patients	O
.	O

Special	O
attention	O
should	O
be	O
given	O
to	O
patients	O
with	O
non	B-DIS
-	I-DIS
Hodgkin	I-DIS
's	O
lymphoma	B-DIS
and	O
melanoma	O
as	O
first	O
primary	O
.	O

In	O
this	O
study	O
analysis	O
of	O
soil	O
water	O
and	O
plant	O
residue	O
samples	O
is	O
presented	O
to	O
evaluate	O
the	O
contamination	O
levels	O
and	O
possible	O
health	O
risks	O
.	O

Hexachlorocyclohexane	O
HCH	O
is	O
a	O
persistent	O
organic	O
pollutant	O
used	O
as	O
a	O
pesticide	O
in	O
agricultural	O
sector	O
for	O
pest	O
control	O
in	O
order	O
to	O
obtain	O
higher	O
productivity	O
.	O

For	O
analysis	O
soil	O
water	O
and	O
crop	O
residue	O
samples	O
were	O
collected	O
from	O
different	O
agricultural	O
areas	O
of	O
the	O
northern	O
Punjab	B-LOC
region	O
of	O
Pakistan	B-LOC
.	O

The	O
investigation	O
of	O
the	O
samples	O
shows	O
significant	O
levels	O
of	O
HCH	O
residues	O
in	O
all	O
types	O
of	O
samples	O
.	O

Gas	O
chromatography	O
-	O
mass	O
spectrometry	O
analysis	O
was	O
used	O
to	O
assess	O
the	O
higher	O
residue	O
levels	O
of	O
HCH	O
in	O
the	O
samples	O
.	O

The	O
concentration	O
of	O
HCH	O
residues	O
detected	O
in	O
samples	O
ranged	O
from	O
2.43	O
to	O
8.88	O
Âµg	O
/	O
g	O
in	O
soil	O
nd	O
-5.87	O
Âµg	O
/	O
l	O
in	O
water	O
and	O
nd	O
-	O
4.87	O
Âµg	O
/	O
g	O
in	O
plants	O
.	O

The	O
presence	O
of	O
HCH	O
residues	O
in	O
soil	O
water	O
and	O
plant	O
samples	O
was	O
beyond	O
the	O
recommended	O
quality	O
guidelines	O
.	O

Human	O
health	O
risk	O
was	O
evaluated	O
for	O
cancer	B-DIS
and	O
non	O
-	O
cancer	O
risks	O
through	O
dietary	O
and	O
non	O
-	O
dietary	O
exposure	O
routes	O
.	O

The	O
hazard	O
index	O
was	O
H	O
1	O
in	O
children	O
and	O
HI	O
<	O
1	O
in	O
adults	O
while	O
the	O
non	O
-	O
dietary	O
incremental	O
lifetime	O
cancer	O
risks	O
ILCR	O
were	O
beyond	O
the	O
internationally	O
acceptable	O
limit	B-STAT
of	I-STAT
1	I-STAT
Ã—	O
10	O
-5	O
<	O
/s	O
.	O

Hence	O
results	O
of	O
the	O
present	O
investigation	O
concluded	O
the	O
presence	O
of	O
high	O
levels	O
of	O
HCH	O
residues	O
in	O
samples	O
and	O
pose	O
high	O
health	O
risk	O
to	O
the	O
inhabitants	O
.	O

These	O
findings	O
are	O
alarming	O
and	O
apprise	O
the	O
concerned	O
departments	O
for	O
the	O
remediation	O
of	O
contamination	O
and	O
proper	O
implementation	O
of	O
environmental	O
laws	O
in	O
the	O
area	O
.	O

Ehlers	B-DIS
-	I-DIS
Danlos	I-DIS
Syndrome	O
EDS	O
is	O
a	O
family	B-DIS
of	I-DIS
multisystemic	I-DIS
hereditary	I-DIS
connective	I-DIS
tissue	O
disorders	O
now	O
comprised	O
of	O
13	O
recognized	O
subtypes	O
classical	O
classical	O
-	O
like	O
cardiac	O
-	O
valvular	O
vascular	B-DIS
hypermobile	I-DIS
arthrochlasia	I-DIS
dermosparaxis	I-DIS
kyphoscoliotic	I-DIS
brittle	O
cornea	O
syndrome	O
spondylodysplastic	O
musculocontractural	O
myopathic	O
and	O
periodontal	O
as	O
designated	O
by	O
the	O
most	O
recent	O
2017	O
International	O
classification	O
system	O
.	O

Clinical	O
presentation	O
of	O
this	O
disease	O
can	O
range	O
from	O
mild	O
manifestations	O
including	O
skin	B-DIS
hyperextensibility	I-DIS
and	O
joint	O
hypermobility	O
to	O
more	O
severe	O
complications	O
such	O
as	O
vascular	O
and	O
organ	O
rupture	O
.	O

While	O
there	O
may	O
be	O
accompanying	O
inflammation	B-DIS
in	O
some	O
of	O
the	O
subtypes	O
of	O
EDS	O
the	O
pathogenic	O
mechanisms	O
have	O
not	O
been	O
clearly	O
defined	O
.	O

Thorough	O
evaluation	O
incorporates	O
clinical	O
examination	O
family	O
history	O
laboratory	O
testing	O
and	O
imaging	O
.	O

In	O
recent	O
years	O
studies	O
have	O
identified	O
multiple	O
gene	O
variants	O
involved	O
in	O
the	O
pathogenesis	O
of	O
specific	O
EDS	O
subtypes	O
as	O
well	O
as	O
elaborate	O
clinical	O
diagnostic	O
criteria	O
and	O
classification	O
models	O
used	O
to	O
differentiate	O
overlapping	O
conditions	O
.	O

The	O
differential	O
diagnosis	O
of	O
EDS	O
includes	O
hypermobility	B-DIS
spectrum	I-DIS
disorders	I-DIS
Marfan	I-DIS
syndrome	I-DIS
Loey	I-DIS
-	I-DIS
Dietz	I-DIS
syndrome	I-DIS
Cutis	I-DIS
laxa	I-DIS
syndromes	O
autosomal	B-DIS
dominant	I-DIS
polycystic	I-DIS
kidney	O
disease	B-DIS
osteogenesis	I-DIS
Imperfecta	I-DIS
Type	I-DIS
1	I-DIS
fibromyalgia	O
depression	B-DIS
and	I-DIS
chronic	I-DIS
fatigue	O
syndrome	O
.	O

Surgical	O
treatment	O
is	O
reserved	O
for	O
complications	O
or	O
emergencies	O
involving	O
vascular	O
or	O
orthopedic	O
injury	O
because	O
of	O
the	O
risk	O
of	O
poor	O
wound	O
healing	O
.	O

Management	O
techniques	O
each	O
have	O
their	O
own	O
consequences	O
and	O
benefits	O
which	O
will	O
also	O
be	O
discussed	O
in	O
this	O
review	O
article	O
.	O

Patients	O
affected	O
by	O
this	O
spectrum	O
of	O
disorders	O
are	O
impacted	O
both	O
phenotypically	O
and	O
psychosocially	O
diminishing	O
their	O
quality	O
of	O
life	O
.	O

Background	O
and	O
Objectives	O
The	O
incidence	B-EPI
of	O
diverticulitis	B-DIS
is	O
increasing	O
in	O
western	O
countries	O
.	O

Complicated	O
diverticulitis	B-DIS
is	O
defined	O
as	O
diverticulitis	B-DIS
associated	O
with	O
localized	O
or	O
generalized	O
perforation	B-DIS
localized	O
or	O
distant	O
abscess	O
fistula	O
stricture	O
or	O
obstruction	B-DIS
.	O

Colonic	B-DIS
symptomatic	I-DIS
strictures	I-DIS
are	O
often	O
treated	O
with	O
segmental	O
colectomy	O
.	O

The	O
aim	O
of	O
our	O
study	O
is	O
to	O
report	O
our	O
experience	O
with	O
Self	O
Expandable	O
Metal	O
Stents	O
SEMS	O
placement	O
to	O
relieve	O
sigmoid	B-DIS
obstruction	I-DIS
secondary	O
to	O
diverticulitis	B-DIS
either	O
as	O
a	O
permanent	O
solution	O
or	O
as	O
a	O
bridge	O
to	O
elective	O
colectomy	O
.	O

Material	O
and	O
Methods	O
From	O
January	O
2016	O
to	O
December	O
201821	O
patients	O
underwent	O
SEMS	O
placement	O
for	O
sigmoid	B-DIS
obstruction	I-DIS
secondary	O
to	O
diverticulitis	B-DIS
at	O
our	O
institution	O
.	O

In	O
four	O
patients	O
with	O
poor	O
general	O
conditions	O
SEMS	O
was	O
considered	O
the	O
definitive	O
form	O
of	O
treatment	O
.	O

In	O
17	O
patients	O
the	O
stent	O
was	O
placed	O
as	O
bridge	O
to	O
elective	O
colectomy	O
.	O

Data	O
were	O
prospectively	O
collected	O
and	O
retrospectively	O
analyzed	O
.	O

Primary	O
outcomes	O
were	O
postoperative	O
mortality	O
and	O
morbidity	O
after	O
SEMS	O
and	O
subsequent	O
elective	O
colectomy	O
.	O

Results	O
There	O
was	O
no	O
mortality	O
or	O
major	O
morbidity	O
after	O
SEMS	O
placement	O
or	O
subsequent	O
elective	O
colectomy	O
.	O

No	O
stoma	B-DIS
was	O
performed	O
.	O

Conclusions	O
Placement	O
of	O
Colorectal	B-DIS
Self	O
Expandable	O
Stent	O
represents	O
a	O
useful	O
tool	O
to	O
relieve	O
obstruction	B-DIS
in	O
patients	O
with	O
left	B-DIS
-	I-DIS
sided	I-DIS
colonic	O
diverticulitis	O
.	O

SEMS	O
placement	O
makes	O
it	O
possible	O
to	O
transform	O
an	O
emergency	O
clinical	O
condition	O
into	O
an	O
elective	O
condition	O
giving	O
time	O
to	O
resolve	O
the	O
inflammation	B-DIS
and	O
the	O
infection	B-DIS
inevitably	O
associated	O
with	O
complicated	O
diverticulitis	B-DIS
.	O

Introduction	O
Cerebellar	B-DIS
degeneration	I-DIS
has	O
been	O
associated	O
in	O
patients	O
with	O
epilepsy	B-DIS
though	O
the	O
exact	O
pathogenic	O
mechanisms	O
are	O
not	O
understood	O
.	O

The	O
aim	O
of	O
this	O
systematic	O
review	O
was	O
to	O
identify	O
the	O
prevalence	B-EPI
of	O
cerebellar	B-DIS
degeneration	I-DIS
in	O
patients	O
with	O
epilepsy	B-DIS
and	O
identify	O
any	O
pathogenic	O
mechanisms	O
.	O

Methodology	O
A	O
systematic	O
computer	O
-	O
based	O
literature	O
search	O
was	O
conducted	O
using	O
the	O
PubMed	O
database	O
.	O

Data	O
extracted	O
included	O
prevalence	B-EPI
clinical	O
neuroradiological	O
and	O
neuropathological	O
characteristics	O
of	O
patients	O
with	O
epilepsy	B-DIS
and	O
cerebellar	B-DIS
degeneration	I-DIS
.	O

Results	O
We	O
identified	O
three	O
consistent	O
predictors	O
of	O
cerebellar	B-DIS
degeneration	I-DIS
in	O
the	O
context	O
of	O
epilepsy	B-DIS
in	O
our	O
review	O
temporal	B-DIS
lobe	I-DIS
epilepsy	I-DIS
poor	O
seizure	B-DIS
control	O
and	O
phenytoin	O
as	O
the	O
treatment	O
modality	O
.	O

Whole	O
brain	O
and	O
hippocampal	O
atrophy	B-DIS
were	O
also	O
identified	O
in	O
patients	O
with	O
epilepsy	B-DIS
.	O

Conclusions	O
Cerebellar	B-DIS
degeneration	I-DIS
is	O
prevalent	O
in	O
patients	O
with	O
epilepsy	B-DIS
.	O

Further	O
prospective	O
studies	O
are	O
required	O
to	O
confirm	O
if	O
the	O
predictors	O
identified	O
in	O
this	O
review	O
are	O
indeed	O
linked	O
to	O
cerebellar	B-DIS
degeneration	I-DIS
and	O
to	O
establish	O
the	O
pathogenic	O
mechanisms	O
that	O
result	O
in	O
cerebellar	B-DIS
insult	I-DIS
.	O

Background	O
A	O
higher	O
risk	O
of	O
developing	O
dementia	B-DIS
is	O
observed	O
in	O
patients	O
with	O
atrial	B-DIS
fibrillation	I-DIS
AF	O
.	O

Results	O
are	O
inconsistent	O
regarding	O
the	O
risk	O
of	O
dementia	B-DIS
when	O
patients	O
with	O
AF	O
use	O
different	O
anticoagulants	O
.	O

We	O
aimed	O
to	O
investigate	O
the	O
risk	O
of	O
dementia	B-DIS
in	O
patients	O
with	O
AF	O
receiving	O
non	O
-	O
vitamin	O
K	O
antagonist	O
oral	O
anticoagulants	O
NOACs	O
compared	O
with	O
those	O
receiving	O
warfarin	O
.	O

Methods	O
and	O
Results	O
We	O
conducted	O
a	O
nationwide	O
population	O
-	O
based	O
cohort	O
study	O
of	O
incident	O
cases	O
using	O
the	O
Taiwan	O
National	O
Health	O
Insurance	O
Research	O
Database	O
.	O

We	O
initially	O
enlisted	O
all	O
incident	O
cases	O
of	O
AF	B-DIS
and	O
then	O
selected	O
those	O
treated	O
with	O
either	O
NOACs	O
or	O
warfarin	O
for	O
at	O
least	O
90	O
days	O
between	O
2012	O
and	O
2016	O
.	O

First	B-DIS
-	O
ever	O
diagnosis	B-DIS
of	O
dementia	O
was	O
the	O
primary	O
outcome	O
.	O

We	O
performed	O
propensity	O
score	O
matching	O
to	O
minimize	O
the	O
difference	O
between	O
each	O
cohort	O
.	O

We	O
used	O
the	O
Fine	O
and	O
Gray	O
competing	O
risk	O
regression	O
model	O
to	O
calculate	O
the	O
hazard	O
ratio	O
HR	O
for	O
dementia	B-DIS
.	O

We	O
recruited	O
12068	O
patients	O
with	O
AF	B-DIS
6034	O
patients	O
in	O
each	O
cohort	O
.	O

The	O
mean	O
follow	O
-	O
up	O
time	O
was	O
3.27	O
and	O
3.08	O
years	O
in	O
the	O
groups	O
using	O
NOACs	O
and	O
warfarin	O
respectively	O
.	O

Compared	O
with	O
the	O
HR	O
for	O
the	O
group	O
using	O
warfarin	O
the	O
HR	O
for	O
dementia	B-DIS
was	O
0.8295	B-STAT
%	I-STAT
CI	O
0.73	O
-	O
0.92	O
;	O
P	O
=	O
0.0004	O
in	O
the	O
group	O
using	O
NOACs	O
.	O

Subgroup	O
analysis	O
demonstrated	O
that	O
users	O
of	O
NOAC	O
aged	O
65	O
to	O
74	O
years	O
with	O
a	O
high	O
risk	O
of	O
stroke	B-DIS
or	O
bleeding	B-DIS
were	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
dementia	B-DIS
than	O
users	O
of	O
warfarin	O
with	O
similar	O
characteristics	O
.	O

Conclusions	O
Patients	O
with	O
AF	O
using	O
NOACs	O
were	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
dementia	B-DIS
than	O
those	O
using	O
warfarin	O
.	O

Further	O
randomized	O
clinical	O
trials	O
are	O
greatly	O
needed	O
to	O
prove	O
these	O
findings	O
.	O

Clinical	O
/	O
methodological	B-DIS
issue	I-DIS
Brain	O
tumors	O
are	O
the	O
most	O
common	B-DIS
solid	O
tumors	O
in	O
childhood	O
and	O
the	O
most	B-DIS
frequent	I-DIS
cancer	I-DIS
after	O
leukemia	O
.	O

The	O
incidence	B-EPI
is	O
continuously	O
increasing	O
.	O

The	O
WHO	O
classification	O
of	O
brain	B-DIS
tumors	I-DIS
valid	O
since	O
2016	O
is	O
now	O
based	O
on	O
the	O
combination	O
of	O
histological	O
and	O
molecular	O
genetic	O
diagnostics	O
.	O

Standard	O
radiological	O
methods	O
Diagnostics	O
are	O
mainly	O
performed	O
with	O
magnetic	O
resonance	O
imaging	O
MRI	O
;	O
only	O
in	O
emergencies	O
with	O
computed	O
tomography	O
CT	O
.	O

Methodological	O
innovations	O
Diffusion	O
and	O
susceptibility	O
weighted	O
and	O
dynamic	O
contrast	O
-	O
enhanced	O
imaging	O
and	O
spectroscopy	O
are	O
used	O
.	O

Performance	O
Improved	O
diagnosis	O
regarding	O
dignity	O
size	O
determination	O
adjacency	O
assessment	O
and	O
morphological	O
description	O
of	O
tumor	B-DIS
composition	O
.	O

Achievements	O
Modern	O
MRI	O
with	O
functional	O
techniques	O
is	O
now	O
the	O
gold	O
standard	O
for	O
differential	O
diagnosis	O
and	O
staging	O
of	O
central	O
nervous	O
system	O
CNS	O
tumors	B-DIS
in	O
pediatrics	O
.	O

Introduction	O
Tinea	B-DIS
capitis	I-DIS
is	O
the	O
most	O
common	O
form	O
of	O
dermatophytosis	B-DIS
among	O
children	O
contributing	O
significantly	O
to	O
the	O
global	O
burden	O
of	O
skin	O
and	O
hair	B-DIS
infections	I-DIS
.	O

However	O
an	O
accurate	O
account	O
of	O
its	O
burden	O
in	O
Africa	B-LOC
where	O
most	O
cases	O
are	O
thought	O
to	O
occur	O
is	O
lacking	O
.	O

We	O
aim	O
to	O
systematically	O
evaluate	O
the	O
burden	O
aetiology	O
and	O
epidemiological	O
trend	O
of	O
tinea	B-DIS
capitis	I-DIS
among	O
children	O
over	O
a	O
30	O
-	O
year	O
period	O
in	O
Africa	B-LOC
.	O

Methods	O
and	O
analysis	O
A	O
systematic	O
review	O
will	O
be	O
conducted	O
using	O
Embase	O
PubMed	O
African	O
Journals	O
Online	O
Web	O
of	O
Science	O
and	O
the	O
Cochrane	O
Library	O
of	O
Systematic	O
Review	O
.	O

These	O
resources	O
will	O
be	O
used	O
to	O
identify	O
studies	O
published	O
between	O
1990	O
and	O
December	O
2020	O
which	O
report	O
the	O
prevalence	B-EPI
aetiology	O
and	O
trend	O
of	O
tinea	B-DIS
capitis	I-DIS
among	O
children	O
younger	O
than	O
18	O
years	O
in	O
Africa	B-LOC
.	O

Articles	O
in	O
English	O
and	O
French	O
will	O
be	O
considered	O
.	O

Two	O
independent	O
reviewers	O
will	O
screen	O
the	O
articles	O
for	O
eligibility	O
and	O
any	O
discrepancies	O
will	O
be	O
resolved	O
by	O
discussion	O
and	O
consensus	O
between	O
the	O
authors	O
.	O

Methodological	O
quality	O
of	O
all	O
studies	O
will	O
be	O
assessed	O
and	O
critically	O
appraised	O
.	O

We	O
will	O
perform	O
a	O
metaregression	O
to	O
assess	O
the	O
impact	O
of	O
study	O
characteristics	O
on	O
heterogeneity	O
and	O
also	O
to	O
correct	O
the	O
meta	O
-	O
analytical	O
estimates	O
for	O
biases	O
.	O

A	O
qualitative	O
synthesis	O
will	O
be	O
performed	O
and	O
STATA	O
V.16.0	O
software	O
will	O
be	O
used	O
to	O
estimate	O
the	O
pooled	O
prevalence	B-EPI
and	O
aetiology	O
of	O
tinea	B-DIS
capitis	I-DIS
.	O

The	O
Mann	O
-	O
Kendall	O
trend	O
test	O
will	O
be	O
use	O
to	O
evaluate	O
the	O
trend	O
in	B-EPI
the	O
prevalence	B-DIS
of	I-DIS
tinea	O
capitis	O
over	O
the	O
study	O
period	O
.	O

Ethics	O
and	O
dissemination	O
Ethical	O
approval	O
from	O
an	O
institutional	O
review	O
board	O
or	O
research	O
ethics	O
committee	O
is	O
not	O
required	O
for	O
this	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
.	O

The	O
results	O
will	O
be	O
published	O
in	O
a	O
peer	O
-	O
reviewed	O
journal	O
and	O
presented	O
in	O
conferences	O
.	O

The	O
Arab	O
population	O
encompasses	O
over	O
420	O
million	O
people	O
characterized	O
by	O
genetic	O
admixture	O
and	O
a	O
consequent	O
rich	O
genetic	O
diversity	O
.	O

A	O
number	O
of	O
genetic	O
diseases	O
have	O
been	O
reported	O
for	O
the	O
first	O
time	O
from	O
the	O
population	O
.	O

Additionally	O
a	O
high	O
prevalence	B-EPI
of	O
some	O
genetic	O
diseases	O
including	O
autosomal	B-DIS
recessive	I-DIS
disorders	I-DIS
such	O
as	O
hemoglobinopathies	B-DIS
and	O
familial	O
mediterranean	O
fever	B-DIS
have	O
been	O
found	O
in	O
the	O
population	O
and	O
across	O
the	O
region	O
.	O

There	O
is	O
a	O
paucity	O
of	O
databases	O
cataloguing	O
genetic	O
variants	O
of	O
clinical	O
relevance	O
from	O
the	O
population	O
.	O

The	O
availability	O
of	O
such	O
a	O
catalog	O
could	O
have	O
implications	O
in	O
precise	O
diagnosis	O
genetic	O
epidemiology	O
and	O
prevention	O
of	O
disease	O
.	O

To	O
fill	O
in	O
the	O
gap	O
we	O
have	O
compiled	O
DALIA	O
a	O
comprehensive	O
compendium	O
of	O
genetic	O
variants	O
reported	O
in	O
literature	O
and	O
implicated	O
in	O
genetic	O
diseases	O
reported	O
from	O
the	O
Arab	O
population	O
.	O

The	O
database	O
aims	O
to	O
act	O
as	O
an	O
effective	O
resource	O
for	O
population	O
-	O
scale	O
and	O
sub	O
-	O
population	O
specific	O
variant	O
analyses	O
enabling	O
a	O
ready	O
reference	O
aiding	O
clinical	O
interpretation	O
of	O
genetic	O
variants	O
genetic	O
epidemiology	O
as	O
well	O
as	O
facilitating	O
rapid	O
screening	O
and	O
a	O
quick	O
reference	O
for	O
evaluating	O
evidence	O
on	O
genetic	O
diseases	O
.	O

We	O
have	O
studied	O
36	O
patients	O
with	O
HPRT	B-DIS
deficiency	O
25	O
with	O
Lesch	B-DIS
-	I-DIS
Nyhan	O
syndrome	O
and	O
11	O
with	O
partial	O
HPRT	O
deficiency	B-STAT
grades	I-STAT
1	I-STAT
to	O
3	O
.	O

Patients	O
diagnosed	O
with	O
HPRT	B-DIS
deficiency	I-DIS
have	O
increased	O
50	B-STAT
%	I-STAT
since	O
2000	O
.	O

The	O
most	O
relevant	O
recent	O
advances	O
have	O
been	O
made	O
in	O
molecular	O
diagnosis	O
.	O

Nevertheless	O
enzyme	O
determinations	O
are	O
still	O
essential	O
for	O
the	O
diagnosis	O
of	O
HPRT	B-DIS
deficiency	I-DIS
.	O

Therapy	O
for	O
the	O
neurological	O
manifestations	O
of	O
HPRT	B-DIS
deficiency	I-DIS
has	O
not	O
advanced	O
.	O

Allopurinol	O
remains	O
the	O
drug	O
of	O
choice	O
to	O
diminish	O
uric	O
acid	O
overproduction	O
but	O
the	O
optimal	O
allopurinol	O
dose	O
must	O
be	O
established	O
in	O
each	O
patient	O
to	O
prevent	O
xanthine	O
or	O
uric	O
acid	O
urolithiasis	O
a	O
process	O
aided	O
by	O
sequential	O
determination	O
of	O
urinary	O
oxypurines	O
and	O
uric	O
acid	O
.	O

BACKGROUNDMost	O
patients	O
with	O
isolated	O
methylmalonic	B-DIS
acidemia	I-DIS
MMA	I-DIS
/propionic	O
acidemia	B-DIS
PA	O
presenting	O
during	O
the	O
neonatal	O
period	O
with	O
acute	O
metabolic	O
distress	O
are	O
at	O
risk	O
for	O
death	B-DIS
and	O
significant	O
neurodevelopmental	B-DIS
disability	I-DIS
.	O

The	O
nationwide	O
newborn	O
screening	O
for	O
MMA	O
/	O
PA	O
has	O
been	O
in	O
place	O
in	O
Taiwan	B-LOC
from	O
January	O
2000	O
and	O
data	O
was	O
collected	O
until	O
December	O
2016	O
.	O

RESULTSDuring	O
the	O
study	O
period	O
3155263	O
newborns	O
were	O
screened	O
.	O

The	O
overall	O
incidence	B-EPI
of	O
MMA	O
mutase	O
type	O
cases	O
was	O
1/121356	B-STAT
n	O
=	O
261	O
cobalamin	O
B	O
was	O
detected	O
and	O
that	O
for	O
PA	O
cases	O
n	O
=	O
4	O
was	O
1/788816	B-STAT
.	O

The	O
time	O
of	O
referral	O
is	O
8.8	O
days	O
for	O
MMA	O
patients	O
and	O
7.5	O
days	O
for	O
PA	O
patients	O
.	O

The	O
MMA	O
mutase	O
type	O
patients	O
have	O
higher	O
AST	O
ALT	O
and	O
NH3	O
values	O
as	O
well	O
as	O
a	O
lower	O
pH	O
value	O
p	O
<	O
0.05	O
.	O

The	O
mean	O
age	O
for	O
liver	O
transplantation	O
LT	O
is	O
402	O
days	O
range	O
from	O
0.6	O
-	O
6.7	O
yr	O
with	O
16	O
out	O
of	O
20	O
cases	O
80.0	B-STAT
%	I-STAT
using	O
living	O
donors	O
.	O

The	O
mean	O
admission	O
length	O
shortened	O
from	O
90.6	O
days	O
/	O
year	O
pre	O
-	O
LT	O
to	O
5.3	O
days	O
/	O
year	O
at	O
3rd	O
year	O
post	O
-	O
LT	O
p	O
<	O
0.0005	O
.	O

Similarly	O
the	O
tube	O
feeding	O
ratio	O
decreased	O
from	O
67.8	O
to	O
0.50	B-STAT
%	I-STAT
p	O
<	O
0.00005	O
.	O

The	O
anxiety	B-DIS
level	O
of	O
the	O
caregiver	O
was	O
reduced	O
from	O
33.4	O
to	O
27.2	O
after	O
LT	O
p	O
=	O
0.001	O
and	O
the	O
DQ	O
/	O
IQ	O
performance	O
of	O
the	O
patients	O
was	O
improved	O
after	O
LT	O
from	O
50	O
to	O
60.1	O
p	O
=	O
0.07	O
.	O

CONCLUSIONMMA	O
/	O
PA	O
patients	O
with	O
LT	O
do	O
survive	O
and	O
have	O
reduced	O
admission	O
time	O
reduced	O
tube	O
feeding	O
and	O
the	O
caregiver	O
is	O
less	O
anxious	O
.	O

Background	O
Intestinal	B-DIS
malrotation	I-DIS
is	O
a	O
potentially	O
life	O
-	B-DIS
threatening	I-DIS
congenital	O
anomaly	O
due	O
to	O
the	O
risk	O
of	B-DIS
developing	I-DIS
midgut	O
volvulus	O
.	O

The	O
reported	O
incidence	B-EPI
is	O
0.2	B-STAT
%	I-STAT
-1	O
%	O
and	O
both	O
apparently	O
hereditary	B-DIS
and	O
sporadic	O
cases	O
have	O
been	O
reported	O
.	O

Intestinal	B-DIS
malrotation	I-DIS
is	O
associated	O
with	O
a	O
few	O
syndromes	O
with	O
known	O
genotype	O
but	O
the	O
genetic	O
contribution	O
in	O
isolated	O
intestinal	B-DIS
malrotation	I-DIS
has	O
not	O
yet	O
been	O
reported	O
.	O

Rare	O
copy	O
number	O
variants	O
CNVs	O
have	O
been	O
implicated	O
in	O
many	O
congenital	B-DIS
anomalies	I-DIS
and	O
hence	O
we	O
sought	O
to	O
investigate	O
the	O
potential	O
contribution	O
of	O
rare	O
CNVs	O
in	O
intestinal	B-DIS
malrotation	I-DIS
.	O

Methods	O
Analysis	O
of	O
array	O
comparative	O
genomic	O
hybridization	O
aCGH	O
data	O
from	O
47	O
patients	O
with	O
symptomatic	O
intestinal	B-DIS
malrotation	I-DIS
was	O
performed	O
.	O

Results	O
We	O
identified	O
six	O
rare	O
CNVs	O
in	O
five	O
patients	O
.	O

Five	O
CNVs	O
involved	O
syndrome	O
loci	O
7q11.23	B-DIS
microduplication	I-DIS
16p13.11	I-DIS
microduplication	I-DIS
18q	I-DIS
terminal	I-DIS
deletion	I-DIS
HDAC8	O
Cornelia	B-DIS
de	I-DIS
Lange	I-DIS
syndrome	I-DIS
type	O
5	O
and	O
FOXF1	O
as	O
well	O
as	O
one	O
intragenic	O
deletion	O
in	O
GALNT14	O
not	O
previously	O
implicated	O
in	O
human	B-DIS
disease	I-DIS
.	O

Conclusion	O
In	O
the	O
present	O
study	O
we	O
identified	O
rare	O
CNVs	O
contributing	O
pathogenic	O
or	O
potentially	O
pathogenic	O
alleles	O
in	O
five	O
patients	O
with	O
syndromic	B-DIS
intestinal	I-DIS
malrotation	I-DIS
suggesting	O
that	O
CNV	O
screening	O
is	O
indicated	O
in	O
intestinal	B-DIS
malrotation	I-DIS
with	O
associated	O
malformations	B-DIS
or	O
neurological	B-DIS
involvements	I-DIS
.	O

In	O
addition	O
we	O
identified	O
intestinal	B-DIS
malrotation	I-DIS
in	O
two	O
known	O
syndromes	O
Cornelia	B-DIS
de	I-DIS
Lange	I-DIS
type	I-DIS
5	I-DIS
and	I-DIS
18q	I-DIS
terminal	I-DIS
deletion	I-DIS
syndrome	I-DIS
that	O
has	O
not	O
previously	O
been	O
associated	O
with	O
gastrointestinal	B-DIS
malformations	I-DIS
.	O

Background	O
Electrophysiological	O
examination	O
plays	O
an	O
important	O
role	O
in	O
the	O
diagnosis	O
of	O
X	O
-	B-DIS
linked	I-DIS
Charcot	I-DIS
-	O
Marie	O
-	O
Tooth	B-DIS
disease	I-DIS
CMTX1	I-DIS
with	O
transient	O
central	O
nervous	O
system	O
deficits	O
.	O

However	O
the	O
electrophysiological	O
features	O
are	O
seldom	O
reported	O
.	O

Methods	O
We	O
reviewed	O
and	O
analyzed	O
published	O
reports	O
to	O
determine	O
the	O
electrophysiological	O
features	O
of	O
CMTX1	B-DIS
patients	O
with	O
transient	O
central	B-DIS
nervous	I-DIS
system	I-DIS
deficits	I-DIS
.	O

Results	O
A	O
total	O
of	O
21	O
CMTX1	B-DIS
patients	O
with	O
transient	O
central	B-DIS
nervous	I-DIS
system	I-DIS
deficits	I-DIS
were	O
found	O
in	O
17	O
published	O
case	O
reports	O
/	O
series	O
.	O

The	O
age	O
of	O
onset	O
ranged	O
from	O
0.5	O
to	O
18	O
years	O
mean	O
12.02	O
Â±	O
0.78	O
years	O
.	O

All	O
patients	O
were	O
male	O
.	O

Recurrent	O
episodes	O
of	O
central	O
nervous	O
system	O
deficits	O
were	O
reported	O
in	O
all	O
21	O
cases	O
and	O
resolved	O
in	O
periods	O
ranging	O
from	O
several	O
minutes	O
to	O
3	O
days	O
.	O

All	O
20	O
patients	O
who	O
had	O
MRIs	O
at	O
presentation	O
had	O
bilaterally	O
symmetrical	O
abnormal	O
T2	O
/	O
Diffusion	O
signals	O
in	O
the	O
white	O
matter	O
without	O
enhancement	O
of	O
gadolinium	O
.	O

All	O
subsequent	O
MRIs	O
showed	O
improvement	O
or	O
were	O
within	O
normal	O
limits	O
.	O

The	O
median	O
motor	O
nerve	O
conduction	O
velocity	O
MNCV	O
motor	O
latencies	O
and	O
compound	O
muscle	O
action	O
potential	O
CMAP	O
amplitude	O
were	O
the	O
most	O
commonly	O
measurable	O
electrophysiological	O
parameters	O
85.7	B-STAT
%	I-STAT
.	O

All	O
cases	O
that	O
had	O
MNCV	O
at	O
presentation	O
had	O
slower	O
and	O
significantly	O
decreased	O
MNCV	O
compared	O
with	O
the	O
normal	O
value	O
34.1	O
Â±	O
1.10	O
m	O
/	O
s	O
vs.	O
46.8Â±2.05	O
m	O
/	O
s	O
P	O
<	O
0.0001	O
;	O
95	B-STAT
%	I-STAT
CI	O
-17.4	O
to	O
-7.92	O
.	O

The	O
average	O
variations	O
of	O
MNCV	O
in	O
median	O
nerve	O
ulnar	O
nerve	O
peroneal	O
nerve	O
and	O
tibial	O
nerve	O
were	O
22.0	B-STAT
Â±	I-STAT
5.96	I-STAT
%	I-STAT
27.6	B-STAT
Â±	I-STAT
11.9	I-STAT
%	I-STAT
25.9	O
Â±	O
4.36	B-STAT
%	I-STAT
and	O
27.3	B-STAT
Â±	I-STAT
4.30	I-STAT
%	I-STAT
respectively	O
.	O

All	O
cases	O
with	O
measured	O
sensory	O
nerve	O
conduction	O
velocity	O
SNCV	O
at	O
presentation	O
had	O
slower	O
and	O
significantly	O
decreased	O
SNCV	O
compared	O
with	O
the	O
normal	O
value	O
35.3	O
Â±	O
1.33	O
m	O
/	O
s	O
vs.	O
47.7	O
Â±	O
2.40	O
m	O
/	O
s	O
P	O
<	O
0.001	O
;	O
95	B-STAT
%	I-STAT
CI	O
-18.2	O
to	O
-6.46	O
.	O

The	O
average	O
variations	O
of	O
SNCV	O
in	O
median	O
nerve	O
ulnar	O
nerve	O
and	O
sural	O
nerve	O
were	O
19.9	B-STAT
Â±	I-STAT
8.24	I-STAT
%	I-STAT
25.2	B-STAT
Â±	I-STAT
7.75	I-STAT
%	I-STAT
and	O
23.2	O
Â±	O
3.95	O
%	O
respectively	O
.	O

Conclusion	O
This	O
case	O
series	O
serves	O
as	O
a	O
reminder	O
that	O
electrophysiological	O
examination	O
should	O
be	O
included	O
in	O
the	O
diagnosis	O
of	O
recurrent	O
and	O
episodic	O
neurological	B-DIS
deficit	I-DIS
with	O
white	B-DIS
matter	I-DIS
lesions	I-DIS
.	O

Median	O
MNCV	O
is	O
a	O
sensitive	O
and	O
valuable	O
parameter	O
to	O
support	O
the	O
diagnosis	O
of	O
CMTX1	O
with	O
transient	O
central	O
nervous	B-DIS
system	I-DIS
deficits	I-DIS
.	O

Adenylosuccinate	O
lyase	O
ADSL	B-DIS
deficiency	I-DIS
is	O
a	O
defect	O
of	O
purine	O
metabolism	O
affecting	O
purinosome	O
assembly	O
and	O
reducing	O
metabolite	O
fluxes	O
through	O
purine	O
de	O
novo	O
synthesis	O
and	O
purine	O
nucleotide	O
recycling	O
pathways	O
.	O

Biochemically	O
this	O
defect	O
manifests	O
by	O
the	O
presence	O
in	O
the	O
biologic	O
fluids	O
of	O
two	O
dephosphorylated	O
substrates	O
of	O
ADSL	O
enzyme	O
succinylaminoimidazole	O
carboxamide	O
riboside	O
SAICAr	O
and	O
succinyladenosine	O
S	O
-	O
Ado	O
.	O

More	O
than	O
80	O
individuals	O
with	O
ADSL	B-DIS
deficiency	I-DIS
have	O
been	O
identified	O
but	O
incidence	B-EPI
of	O
the	O
disease	O
remains	O
unknown	O
.	O

The	O
disorder	B-DIS
shows	O
a	O
wide	O
spectrum	O
of	O
symptoms	O
from	O
slowly	O
to	O
rapidly	O
progressing	O
forms	O
.	O

The	O
fatal	O
neonatal	O
form	O
has	O
onset	O
from	O
birth	O
and	O
presents	O
with	O
fatal	O
neonatal	O
encephalopathy	B-DIS
with	O
a	O
lack	O
of	O
spontaneous	O
movement	B-DIS
respiratory	I-DIS
failure	I-DIS
and	O
intractable	O
seizures	B-DIS
resulting	O
in	O
early	O
death	B-DIS
within	O
the	O
first	O
weeks	O
of	O
life	O
.	O

Patients	O
with	O
type	O
I	O
severe	O
form	O
present	O
with	O
a	O
purely	O
neurologic	O
clinical	O
picture	O
characterized	O
by	O
severe	O
psychomotor	B-DIS
retardation	I-DIS
microcephaly	I-DIS
early	O
onset	O
of	O
seizures	B-DIS
and	O
autistic	B-DIS
features	O
.	O

A	O
more	O
slowly	O
progressing	O
form	O
has	O
also	O
been	O
described	O
type	O
II	O
moderate	O
or	O
mild	O
form	O
as	O
having	O
later	O
onset	O
usually	O
within	O
the	O
first	O
years	O
of	O
life	O
slight	O
to	O
moderate	O
psychomotor	B-DIS
retardation	I-DIS
and	O
transient	O
contact	O
disturbances	O
.	O

Diagnosis	O
is	O
facilitated	O
by	O
demonstration	O
of	O
SAICAr	O
and	O
S	O
-	O
Ado	O
in	O
extracellular	O
fluids	O
such	O
as	O
plasma	O
cerebrospinal	O
fluid	O
and/or	O
followed	O
by	O
genomic	O
and/or	O
cDNA	O
sequencing	O
and	O
characterization	O
of	O
mutant	O
proteins	O
.	O

Over	O
50	O
ADSL	O
mutations	O
have	O
been	O
identified	O
and	O
their	O
effects	O
on	O
protein	O
biogenesis	O
structural	O
stability	O
and	O
activity	O
as	O
well	O
as	O
on	O
purinosome	O
assembly	O
were	O
characterized	O
.	O

To	O
date	O
there	O
is	O
no	O
specific	O
and	O
effective	O
therapy	O
for	O
ADSL	B-DIS
deficiency	I-DIS
.	O

Objective	O
Classic	O
congenital	B-DIS
adrenal	I-DIS
hyperplasia	I-DIS
CAH	I-DIS
secondary	O
to	O
21	B-DIS
-	I-DIS
hydroxylase	O
deficiency	O
is	O
characterized	O
by	O
increased	O
prenatal	O
adrenal	O
androgen	O
secretion	O
.	O

There	O
are	O
a	O
small	O
number	O
of	O
reports	O
in	O
the	O
literature	O
showing	O
higher	O
birth	O
weight	O
and	O
length	O
in	O
CAH	O
newborns	O
.	O

Methods	O
We	O
analyzed	O
birth	O
weight	O
and	O
length	O
data	O
of	O
116	O
German	O
newborns	O
48	O
boys	O
68	O
girls	O
with	O
classic	O
CAH	B-DIS
who	O
were	O
born	O
during	O
the	O
period	O
from	O
1990	O
to	O
2017	O
.	O

All	O
children	O
have	O
been	O
followed	O
or	O
are	O
currently	O
treated	O
as	O
outpatients	O
in	O
our	O
clinic	O
.	O

All	O
children	O
were	O
born	O
at	O
term	O
.	O

The	O
mothers	O
were	O
healthy	O
and	O
their	O
pregnancies	O
were	O
uneventful	O
.	O

The	O
diagnosis	O
of	O
CAH	O
was	O
confirmed	O
by	O
molecular	O
analyses	O
of	O
the	O
CYP21A2	O
gene	O
.	O

Birth	O
data	O
were	O
calculated	O
as	O
standard	O
deviation	O
SD	O
scores	O
according	O
to	O
German	O
reference	O
values	O
.	O

Results	O
Weight	O
and	O
length	O
in	O
male	O
CAH	B-DIS
newborns	O
mean	O
Â±	O
SD	O
3601Â±576	O
g	O
;	O
52.4Â±2.85	O
cm	O
were	O
significantly	O
higher	O
than	O
in	O
female	O
CAH	O
newborns	O
3347Â±442	O
g	O
;	O
51.2Â±2.55	O
cm	O
but	O
male	O
-	O
female	O
differences	O
in	B-DIS
the	O
CAH	O
cohort	O
were	O
lost	O
when	O
the	O
data	O
were	O
converted	O
into	O
SD	O
scores	O
.	O

The	O
birth	O
sizes	O
of	O
the	O
CAH	B-DIS
newborns	O
did	O
not	O
differ	O
from	O
the	O
reference	O
group	O
.	O

The	O
birth	O
sizes	O
also	O
did	O
not	O
differ	O
between	O
the	O
different	O
CAH	O
genotypes	O
.	O

Maternal	O
age	O
mode	O
of	O
delivery	O
and	O
maternal	O
parity	O
had	O
no	O
influence	O
on	O
birth	O
size	O
.	O

Conclusion	O
Our	O
data	O
show	O
that	O
prenatal	O
hyperandrogenism	B-DIS
does	O
not	O
affect	O
fetal	O
growth	O
.	O

Little	O
information	O
is	O
available	O
on	O
the	O
prevalence	B-EPI
geographic	O
distribution	O
and	O
mutation	O
spectrum	O
of	O
genetic	O
skeletal	B-DIS
disorders	I-DIS
GSDs	I-DIS
in	O
China	B-LOC
.	O

This	O
study	O
systematically	O
reviewed	O
GSDs	B-DIS
as	O
defined	O
in	O
`	O
`	O
Nosology	B-DIS
and	O
Classification	O
of	O
genetic	O
skeletal	B-DIS
disorders	I-DIS
2010	O
version	O
`	O
`	O
using	O
Chinese	O
biomedical	O
literature	O
published	O
over	O
the	O
past	O
34	O
years	O
from	O
1978	O
to	O
2012	O
.	O

In	O
total	O
16099	O
GSDs	B-DIS
have	O
been	O
reported	O
.	O

The	O
most	O
frequently	O
reported	O
disorders	O
were	O
Marfan	B-DIS
syndrome	I-DIS
osteogenesis	I-DIS
imperfecta	I-DIS
fibrous	I-DIS
dysplasia	I-DIS
mucopolysaccharidosis	I-DIS
multiple	O
cartilaginous	B-DIS
exostoses	I-DIS
neurofibromatosis	I-DIS
type	I-DIS
1	I-DIS
NF1	I-DIS
osteopetrosis	I-DIS
achondroplasia	I-DIS
enchondromatosis	I-DIS
Ollier	I-DIS
and	O
osteopoikilosis	B-DIS
accounting	O
for	O
76.5	B-STAT
%	I-STAT
12312	O
cases	O
of	O
the	O
total	O
cases	O
.	O

Five	O
groups	O
group	O
81214	O
1821	O
defined	O
by	O
`	O
`	O
Nosology	B-DIS
and	O
Classification	O
of	O
genetic	O
skeletal	B-DIS
disorders	I-DIS
''	O
have	O
not	O
been	O
reported	O
in	O
the	O
Chinese	O
biomedical	O
literature	O
.	O

Gene	O
mutation	O
testing	O
was	O
performed	O
in	O
only	O
a	O
minor	O
portion	O
of	O
the	O
16099	O
cases	O
of	O
GSDs	B-DIS
187	O
cases	O
1.16	B-STAT
%	I-STAT
.	O

In	O
total	O
37	O
genes	O
for	O
41	O
different	O
GSDs	B-DIS
were	O
reported	O
in	O
Chinese	O
biomedical	O
literature	O
including	O
43	O
novel	O
mutations	O
.	O

This	O
review	O
revealed	O
a	O
significant	O
imbalance	O
in	O
rare	O
disease	O
identification	O
in	O
terms	O
of	O
geographic	O
regions	O
and	O
hospital	O
levels	O
suggesting	O
the	O
need	O
to	O
create	O
a	O
national	O
multi	O
-	O
level	O
network	O
to	O
meet	O
the	O
specific	O
challenge	O
of	O
care	O
for	O
rare	O
diseases	O
in	O
China	B-LOC
.	O

The	O
hierarchical	O
information	O
flow	O
through	O
DNA	O
-	O
RNA	O
-	O
protein	O
-	O
metabolite	O
collectively	O
referred	O
to	O
as	O
'	O
molecular	O
fingerprint	O
'	O
defines	O
both	O
health	O
and	O
disease	O
.	O

Environment	O
and	O
food	O
quality	O
and	O
quantity	O
are	O
the	O
key	O
factors	O
known	O
to	O
affect	O
the	O
health	O
of	O
an	O
individual	O
.	O

The	O
fundamental	O
concepts	O
are	O
that	O
the	O
transition	O
from	O
a	O
healthy	O
condition	O
to	O
a	O
disease	O
phenotype	O
must	O
occur	O
by	O
concurrent	O
alterations	O
in	O
the	O
genome	O
expression	O
or	O
by	O
differences	O
in	O
protein	O
synthesis	O
function	O
and	O
metabolites	O
.	O

In	O
other	O
words	O
the	O
dietary	O
components	O
directly	O
or	O
indirectly	O
modulate	O
the	O
molecular	O
fingerprint	O
and	O
understanding	O
of	O
which	O
is	O
dealt	O
with	O
nutrigenomics	O
.	O

Although	O
the	O
fundamental	O
principles	O
of	O
nutrigenomics	O
remain	O
similar	O
to	O
that	O
of	O
traditional	O
research	O
a	O
collection	O
of	O
comprehensive	O
targeted	O
/	O
untargeted	O
data	O
sets	O
in	O
the	O
context	O
of	O
nutrition	O
offers	O
the	O
unique	O
advantage	O
of	O
understanding	O
complex	O
metabolic	O
networks	O
to	O
provide	O
a	O
mechanistic	O
understanding	O
of	O
data	O
from	O
epidemiological	O
and	O
intervention	O
studies	O
.	O

In	O
this	O
review	O
the	O
challenges	O
and	O
opportunities	O
of	O
nutrigenomic	O
tools	O
in	O
addressing	O
the	O
nutritional	O
problems	O
of	O
public	O
health	O
importance	O
are	O
discussed	O
.	O

The	O
application	O
of	O
nutrigenomic	O
tools	O
provided	O
numerous	O
leads	O
on	O
biomarkers	O
of	O
nutrient	O
intake	O
undernutrition	O
metabolic	B-DIS
syndrome	I-DIS
and	O
its	O
complications	O
.	O

Importantly	O
nutrigenomic	O
studies	O
also	O
led	O
to	O
the	O
discovery	O
of	O
the	O
association	O
of	O
multiple	O
genetic	O
polymorphisms	O
in	O
relation	O
to	O
the	O
variability	O
of	O
micronutrient	O
absorption	O
and	O
metabolism	O
providing	O
a	O
potential	O
opportunity	O
for	O
further	O
research	O
toward	O
setting	O
personalized	O
dietary	O
recommendations	O
for	O
individuals	O
and	O
population	O
subgroups	O
.	O

Inherited	O
epidermolysis	B-DIS
bullosa	I-DIS
is	O
a	O
group	O
of	O
genetic	O
diseases	O
characterized	O
by	O
skin	O
fragility	O
and	O
blistering	O
on	O
the	O
skin	O
and	O
mucous	O
membranes	O
in	O
response	O
to	O
minimal	O
trauma	B-DIS
.	O

Epidermolysis	B-DIS
bullosa	I-DIS
is	O
clinically	O
and	O
genetically	O
very	O
heterogeneous	O
being	O
classified	O
into	O
four	O
main	O
types	O
according	O
to	O
the	O
layer	O
of	O
skin	O
in	O
which	O
blistering	O
occurs	O
epidermolysis	B-DIS
bullosa	I-DIS
simplex	I-DIS
intraepidermal	B-DIS
junctional	I-DIS
epidermolysis	I-DIS
bullosa	I-DIS
within	O
the	O
lamina	O
lucida	O
of	O
the	O
basement	O
membrane	O
dystrophic	O
epidermolysis	O
bullosa	O
below	O
the	O
basement	O
membrane	O
and	O
Kindler	B-DIS
epidermolysis	I-DIS
bullosa	I-DIS
mixed	O
skin	O
cleavage	O
pattern	O
.	O

Furthermore	O
epidermolysis	B-DIS
bullosa	I-DIS
is	O
stratified	O
into	O
several	O
subtypes	O
which	O
consider	O
the	O
clinical	O
characteristics	O
the	O
distribution	O
of	O
the	O
blisters	O
and	O
the	O
severity	O
of	O
cutaneous	B-DIS
and	I-DIS
extracutaneous	I-DIS
signs	I-DIS
.	O

Pathogenic	O
variants	O
in	O
at	O
least	O
16	O
genes	O
that	O
encode	O
proteins	O
essential	O
for	O
the	O
integrity	O
and	O
adhesion	O
of	O
skin	O
layers	O
have	O
already	O
been	O
associated	O
with	O
different	O
subtypes	O
of	O
epidermolysis	B-DIS
bullosa	I-DIS
.	O

The	O
marked	O
heterogeneity	O
of	O
the	O
disease	O
which	O
includes	O
phenotypes	O
with	O
a	O
broad	O
spectrum	O
of	O
severity	O
and	O
many	O
causal	O
genes	O
hinders	O
its	O
classification	O
and	O
diagnosis	O
.	O

For	O
this	O
reason	O
dermatologists	O
and	O
geneticists	O
regularly	O
review	O
and	O
update	O
the	O
classification	O
criteria	O
.	O

This	O
review	O
aimed	O
to	O
update	O
the	O
state	O
of	O
the	O
art	O
on	O
inherited	O
epidermolysis	B-DIS
bullosa	I-DIS
with	O
a	O
special	O
focus	O
on	O
the	O
associated	O
clinical	O
and	O
genetic	O
aspects	O
presenting	O
data	O
from	O
the	O
most	O
recent	O
reclassification	O
consensus	O
published	O
in	O
2020	O
.	O

Background	O
Little	O
is	O
known	O
about	O
the	O
surgical	O
conditions	O
affecting	O
the	O
pediatric	O
population	O
in	O
low	O
-	O
income	O
countries	O
.	O

In	O
this	O
article	O
we	O
describe	O
the	O
epidemiology	O
of	O
pediatric	O
surgical	O
diseases	O
observed	O
in	O
Mutoyi	B-LOC
hospital	O
a	O
first	O
-	O
level	O
hospital	O
in	O
Burundi	B-LOC
.	O

Methods	O
and	O
Findings	O
We	O
retrospectively	O
reviewed	O
the	O
records	O
of	O
all	O
children	O
0	O
-	O
14	O
years	O
admitted	O
to	O
the	O
Surgery	O
ward	O
from	O
January	O
2017	O
to	O
December	O
2017	O
.	O

We	O
also	O
reviewed	O
the	O
records	O
of	O
all	O
the	O
patients	O
admitted	O
to	O
the	O
Neonatology	B-LOC
ward	O
in	O
2017	O
and	O
among	O
them	O
we	O
selected	O
the	O
ones	O
in	O
which	O
a	O
surgical	O
diagnosis	O
was	O
present	O
.	O

Five	O
hundred	O
twenty	O
-	O
eight	O
children	O
were	O
admitted	O
to	O
the	O
surgical	O
ward	O
during	O
the	O
study	O
period	O
.	O

The	O
most	O
common	O
conditions	O
requiring	O
hospitalization	O
were	O
abscesses	O
29.09	B-STAT
%	I-STAT
fractures	B-DIS
13.59	B-STAT
%	I-STAT
osteomyelitis	B-DIS
9.76	B-STAT
%	I-STAT
burns	B-DIS
5.40	B-STAT
%	I-STAT
and	O
head	B-DIS
injuries	I-DIS
4.36	B-STAT
%	I-STAT
.	O

The	O
average	O
length	O
of	O
stay	O
was	O
16	O
days	O
.	O

Fifty	O
-	O
six	O
newborns	O
were	O
admitted	O
to	O
the	O
Neonatology	B-LOC
ward	O
for	O
a	O
surgical	O
condition	O
;	O
29	B-STAT
%	I-STAT
of	O
them	O
had	B-DIS
an	O
abscess	O
.	O

Conclusions	O
Conditions	O
requiring	O
surgical	O
care	O
are	O
frequent	O
in	O
Burundian	O
children	O
and	O
have	O
a	O
completely	O
different	O
spectrum	O
from	O
the	O
western	O
ones	O
.	O

This	O
is	O
due	O
on	O
one	O
side	O
to	O
an	O
under	O
-	O
diagnosis	O
of	O
certain	O
conditions	O
caused	O
by	O
the	O
lack	O
of	O
diagnostic	O
tools	O
and	O
on	O
the	O
other	O
to	O
the	O
living	O
conditions	O
of	O
the	O
population	O
.	O

This	O
difference	O
should	O
lead	O
to	O
intervention	O
plans	O
tailored	O
on	O
the	O
actual	O
necessities	O
of	O
the	O
country	O
and	O
not	O
on	O
the	O
western	O
ones	O
.	O

Both	O
axial	B-DIS
spondyloarthritis	I-DIS
axSpA	O
and	O
idiopathic	B-DIS
inflammatory	I-DIS
myopathy	I-DIS
IIM	I-DIS
are	O
infrequent	O
and	O
their	O
coexistence	O
is	O
even	O
rarer	O
;	O
there	O
are	O
a	O
few	O
reported	O
cases	O
in	O
the	O
literature	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
their	O
association	O
and	O
clinical	O
and	O
laboratory	O
features	O
in	O
our	O
patients	O
.	O

The	O
clinical	O
data	O
of	O
patients	O
with	O
axSpA	B-DIS
and	O
IIM	B-DIS
diagnosed	O
in	O
China	B-LOC
-	O
Japan	O
Friendship	O
Hospital	O
from	O
July	O
2015	O
to	O
February	O
2019	O
were	O
retrospectively	O
analyzed	O
.	O

This	O
study	O
included	O
7	O
patients	O
with	O
axSpA	O
who	O
met	O
the	O
IIM	B-DIS
criteria	O
including	O
3	O
males	O
and	O
4	O
females	O
.	O

The	O
age	O
of	O
onset	O
was	O
16	O
to	O
39	O
years	O
.	O

Four	O
patients	O
were	O
HLA	O
-	O
B27	O
positive	O
and	O
three	O
were	O
negative	O
.	O

All	O
patients	O
were	O
first	O
diagnosed	O
as	O
axSpA	O
and	O
then	O
IIM	B-DIS
was	O
detected	O
after	O
0.5	O
-	O
20	O
years	O
mean	O
Â±	O
SD	O
9.9	O
Â±	O
5.0	O
years	O
.	O

After	O
being	O
diagnosed	O
to	O
have	O
axSpA	B-DIS
and	O
IIM	B-DIS
those	O
patients	O
were	O
given	O
prednisone	O
and	O
immunosuppressant	O
drugs	O
and	O
their	O
symptoms	O
gradually	O
improved	O
.	O

Our	O
study	O
provides	O
further	O
evidence	O
of	O
the	O
coexistence	O
of	O
IIM	B-DIS
with	O
axSpA	B-DIS
.	O

In	O
patients	O
with	O
axSpA	B-DIS
who	O
have	O
skin	B-DIS
rash	I-DIS
interstitial	I-DIS
lung	I-DIS
disease	I-DIS
ILD	I-DIS
myalgia	I-DIS
or	O
muscle	B-DIS
weakness	I-DIS
we	O
should	O
suspect	O
that	O
they	O
may	O
have	O
IIM	B-DIS
.	O

Purpose	O
Kabuki	B-DIS
syndrome	I-DIS
KS	I-DIS
OMIM	I-DIS
147920	I-DIS
and	O
300867	O
is	O
a	O
rare	O
genetic	O
disorder	O
characterized	O
by	O
specific	O
facial	O
features	O
intellectual	B-DIS
disability	I-DIS
and	O
various	O
malformations	B-DIS
.	O

Immunopathological	O
manifestations	O
seem	O
prevalent	O
and	O
increase	O
the	O
morbimortality	O
.	O

To	O
assess	O
the	O
frequency	O
and	O
severity	O
of	O
the	O
manifestations	O
we	O
measured	O
the	O
prevalence	B-EPI
of	O
immunopathological	O
manifestations	O
as	O
well	O
as	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
KS	B-LOC
individuals	O
from	O
a	O
registry	O
.	O

Methods	O
Data	O
were	O
for	O
177	O
KS	O
individuals	O
with	O
KDM6A	O
or	O
KMT2D	O
pathogenic	O
variants	O
.	O

Questionnaires	O
to	O
clinicians	O
were	O
used	O
to	O
assess	O
the	O
presence	O
of	O
immunodeficiency	B-DIS
and	I-DIS
autoimmune	I-DIS
diseases	I-DIS
both	O
on	O
a	O
clinical	O
and	O
biological	O
basis	O
.	O

Results	O
Overall	O
44.1	B-STAT
%	I-STAT
78/177	B-STAT
and	O
58.2	B-STAT
%	I-STAT
46/79	B-STAT
of	O
KS	B-LOC
individuals	O
exhibited	O
infection	B-DIS
susceptibility	O
and	O
hypogammaglobulinemia	B-DIS
respectively	O
;	O
13.6	B-STAT
%	I-STAT
24/177	B-STAT
had	O
autoimmune	B-DIS
disease	I-DIS
AID	O
;	O
25.6	B-STAT
%	I-STAT
[	O
11/43	B-STAT
]	O
in	O
adults	O
5.6	B-STAT
%	I-STAT
10/177	B-STAT
with	O
â‰¥2	O
AID	O
manifestations	O
.	O

The	O
most	O
frequent	O
AID	O
manifestations	O
were	O
immune	O
thrombocytopenic	O
purpura	B-DIS
7.3	B-STAT
%	I-STAT
[	O
13/177	B-STAT
]	O
and	O
autoimmune	B-DIS
hemolytic	I-DIS
anemia	I-DIS
4.0	B-STAT
%	I-STAT
[	O
7/177	B-STAT
]	O
.	O

Among	O
nonhematological	O
manifestations	O
vitiligo	B-DIS
was	O
frequent	O
.	O

Immune	O
thrombocytopenic	B-DIS
purpura	I-DIS
was	O
frequent	O
with	O
missense	O
versus	O
other	O
types	O
of	O
variants	O
p	O
=	O
0.027	O
.	O

Conclusion	O
The	O
high	O
prevalence	B-EPI
of	O
immunopathological	O
manifestations	O
in	O
KS	B-LOC
demonstrates	O
the	O
importance	O
of	O
systematic	O
screening	O
and	O
efficient	O
preventive	O
management	O
of	O
these	O
treatable	O
and	O
sometimes	O
life	O
-	O
threatening	O
conditions	O
.	O

Background	O
&	O
methods	O
Blastocystis	B-DIS
sp	O
.	O

is	O
one	O
of	O
the	O
most	O
prevalent	O
unicellular	O
eukaryote	O
of	O
the	O
human	O
large	O
intestine	O
in	O
Chile	B-LOC
and	O
worldwide	O
.	O

It	O
is	O
classified	O
in	O
subtypes	O
STs	O
where	O
using	O
the	O
polymorphic	O
sequences	O
of	O
its	O
18S	O
rRNA	O
genes	O
currently	O
recognizes	O
22	O
.	O

STs	O
1	B-STAT
-	I-STAT
9	I-STAT
and	O
ST12	O
have	O
been	O
reported	O
in	O
humans	O
.	O

It	O
has	O
been	O
hypothesized	O
that	O
different	O
STs	O
of	O
Blastocystis	B-DIS
sp	O
.	O

differentially	O
affect	O
the	O
clinical	O
severity	O
of	O
the	O
digestive	B-DIS
disease	I-DIS
in	O
Irritable	B-DIS
Bowel	I-DIS
Syndrome	I-DIS
IBS	I-DIS
patients	O
but	O
more	O
studies	O
ar4e	O
needed	O
to	O
establish	O
this	O
statement	O
.	O

To	O
contribute	O
in	O
the	O
elucidation	O
of	O
the	O
potential	O
relationship	O
between	O
Blastocystis	B-DIS
sp	O
.	O

subtypes	O
and	O
IBS	O
severity	O
37	O
IBS	O
patient	O
fecal	O
samples	O
were	O
collected	O
at	O
hospitals	O
in	O
Santiago	B-LOC
Chile	I-LOC
and	O
were	O
screened	O
for	O
the	O
presence	O
of	O
vacuolated	O
forms	O
of	O
Blastocystis	B-DIS
sp	O
.	O

by	O
using	O
conventional	O
microscopy	O
.	O

Positive	O
samples	O
were	O
submitted	O
to	O
PCR	O
and	O
sequencing	O
for	O
determining	O
STs	O
.	O

The	O
same	O
procedure	O
was	O
performed	O
in	O
fecal	O
samples	O
from	O
five	O
non	O
-	B-DIS
IBS	O
Blastocystis	O
sp	O
.	O

carriers	O
for	O
preliminary	O
comparative	O
purpose	O
.	O

Results	O
and	O
discussion	O
Four	O
out	O
of	O
the	O
37	O
samples	O
from	O
the	O
IBS	B-DIS
patients	O
were	O
found	O
positive	O
for	O
Blastocystis	B-DIS
sp	O
.	O

10.81	B-STAT
%	I-STAT
by	O
using	O
microscopy	O
.	O

The	O
presence	O
of	O
this	O
microorganism	O
in	O
these	O
four	O
samples	O
were	O
confirmed	O
by	O
PCR	O
and	O
sequencing	O
.	O

Subtypes	O
and	O
their	O
respective	O
closest	O
match	O
alleles	O
were	O
searched	O
and	O
the	O
ST1	O
ST2	O
and	O
ST4	O
subtypes	O
were	O
found	O
in	O
these	O
patients	O
.	O

ST4	O
subtype	O
is	O
scarcely	O
detected	O
in	O
South	B-LOC
America	I-LOC
countries	O
being	O
reported	O
previously	O
only	O
in	O
Colombia	B-LOC
and	O
Brazil	B-LOC
.	O

In	O
this	O
ST4	O
subtype	O
we	O
determined	O
the	O
allele	O
42	O
which	O
is	O
the	O
most	O
frequent	O
allele	O
observed	O
in	O
human	O
Blastocystis	B-DIS
isolates	O
.	O

In	O
the	O
non	B-DIS
-	O
IBS	O
individuals	O
'	O
carriers	O
three	O
subtypes	O
were	O
found	O
ST1	O
ST2	O
and	O
ST3	O
even	O
belonging	O
to	O
the	O
same	O
family	O
group	O
.	O

Closest	O
match	O
alleles	O
212	O
and	O
34	O
here	O
detected	O
were	O
also	O
commonly	O
reported	O
globally	O
.	O

Instead	O
of	O
the	O
small	O
number	O
of	O
IBS	B-DIS
patients	O
studied	O
here	O
the	O
frequency	O
of	O
blastocystosis	O
detected	O
10.81	B-STAT
%	I-STAT
was	O
lower	O
than	O
the	O
prevalence	B-EPI
of	O
Blastocystis	B-DIS
sp	O
.	O

infections	B-DIS
described	O
for	O
the	O
Chilean	O
general	O
population	O
30.4	B-STAT
%	I-STAT
.	O

In	O
Chile	B-LOC
clear	O
correlation	O
of	O
Blastocystis	B-DIS
sp	O
.	O

subtypes	O
and	O
IBS	O
severity	O
is	O
still	O
lacking	O
with	O
this	O
study	O
but	O
it	O
may	O
lead	O
and	O
contribute	O
to	O
a	O
better	O
understanding	O
of	O
its	O
pathogenicity	O
and	O
worldwide	O
epidemiology	O
.	O

Background	O
The	O
incidence	B-EPI
of	O
contralateral	B-DIS
occult	I-DIS
hernia	I-DIS
COH	O
varies	O
from	O
4.2	B-STAT
%	I-STAT
to	O
57.5	B-STAT
%	I-STAT
.	O

Total	O
extraperitoneal	O
TEP	O
gives	O
us	O
opportunity	O
to	O
visualize	O
contralateral	B-DIS
groin	I-DIS
for	O
occult	B-DIS
hernia	I-DIS
and	O
its	O
simultaneous	O
repair	O
.	O

Ultrasonography	O
USG	O
helps	O
to	O
diagnose	O
occult	B-DIS
hernia	I-DIS
preoperatively	O
with	O
detection	O
rate	O
of	O
96.6	B-STAT
%	I-STAT
with	O
specificity	O
84.4	B-STAT
%	I-STAT
.	O

Objective	O
The	O
aims	O
of	O
this	O
study	O
were	O
to	O
identify	O
the	O
incidence	B-EPI
of	O
contralateral	B-DIS
occult	I-DIS
inguinal	I-DIS
hernia	I-DIS
in	O
clinically	O
diagnosed	O
unilateral	O
inguinal	B-DIS
hernia	I-DIS
patients	O
using	O
USG	O
as	O
diagnostic	O
modality	O
and	O
to	O
compare	O
the	O
clinical	O
outcomes	O
of	O
unilateral	O
TEP	O
vs.	O
bilateral	O
TEP	O
with	O
respect	O
to	O
pain	B-DIS
duration	O
of	O
hospital	O
stay	O
time	O
for	O
return	O
to	O
normal	O
work	O
and	O
postoperative	O
complications	O
.	O

Setting	O
and	O
design	O
This	O
was	O
a	O
prospective	O
observational	O
single	O
-	O
center	O
study	O
.	O

Materials	O
and	O
methods	O
A	O
total	O
of	O
30	O
male	O
patients	O
were	O
included	O
in	O
the	O
study	O
who	O
was	O
having	O
clinically	O
diagnosed	O
unilateral	O
hernia	B-DIS
.	O

All	O
patients	O
were	O
assessed	O
by	O
USG	O
for	O
contralateral	B-DIS
occult	I-DIS
inguinal	I-DIS
hernia	I-DIS
.	O

Results	O
Incidence	B-EPI
of	O
COH	O
was	O
10	B-STAT
%	I-STAT
two	B-STAT
6.7	I-STAT
%	I-STAT
had	O
indirect	O
defect	O
and	O
13.3	B-STAT
%	I-STAT
had	O
direct	O
defect	O
.	O

Two	B-STAT
6.7	I-STAT
%	I-STAT
patients	O
underwent	O
bilateral	O
TEP	O
and	O
2893.3	B-STAT
%	I-STAT
underwent	O
unilateral	O
TEP	O
.	O

No	O
significant	O
difference	O
was	O
observed	O
in	O
terms	O
of	O
mean	O
duration	O
of	O
hospital	O
stay	O
duration	O
of	O
surgery	O
and	O
visual	O
analog	O
scale	O
score	O
for	O
pain	B-DIS
in	O
both	O
unilateral	O
and	O
bilateral	O
TEP	O
.	O

The	O
mean	O
for	O
resuming	O
daily	O
work	O
in	O
unilateral	O
TEP	O
was	O
4.86	O
Â±	O
0.833	O
days	O
and	O
in	O
bilateral	O
TEP	O
the	O
mean	O
was	O
7.50	O
Â±	O
0.70	O
days	O
and	O
this	O
showed	O
statistically	O
significant	O
difference	O
P	O
<	O
0.001	O
.	O

Conclusion	O
Patients	O
with	O
COH	O
should	O
be	O
counselled	O
for	O
synchronous	O
repair	O
as	O
there	O
is	O
no	O
significant	O
difference	O
in	O
clinical	O
outcomes	O
of	O
unilateral	O
and	O
bilateral	O
TEP	O
.	O

On	O
the	O
basis	O
of	O
this	O
pilot	O
study	O
it	O
can	O
be	O
concluded	O
that	O
preoperative	O
USG	O
is	O
mandatory	O
for	O
diagnosis	O
and	O
simultaneous	O
management	O
of	O
preexisting	O
contralateral	B-DIS
hernia	I-DIS
.	O

Background	O
Charcot	B-DIS
-	I-DIS
Marie	O
-	O
Tooth	O
disease	O
Type	O
2A	B-DIS
CMT2A	I-DIS
presents	O
with	O
optic	O
atrophy	O
in	O
a	O
subset	O
of	B-EPI
patients	O
but	O
the	O
prevalence	B-DIS
and	I-DIS
severity	O
of	O
optic	O
nerve	O
involvement	O
in	B-DIS
relation	O
to	O
other	O
CMT	O
subtypes	O
has	O
not	O
been	O
explored	O
.	O

Methods	O
Patients	O
with	O
genetically	O
confirmed	O
CMT2A	O
n	O
=	O
5	O
CMT1A	O
n	O
=	O
9	O
and	O
CMTX1	O
n	O
=	O
10	O
underwent	O
high-	B-LOC
and	O
low	O
-	O
contrast	O
acuity	O
testing	O
using	O
Sloan	O
letter	O
charts	O
and	O
circumpapillary	O
retinal	O
nerve	O
fiber	O
layer	O
RNFL	O
and	O
macular	B-DIS
total	I-DIS
retinal	O
RNFL	O
and	O
ganglion	O
cell	O
layer	O
/	O
inner	O
plexiform	O
layer	O
thickness	O
was	O
measured	O
using	O
spectral	O
domain	O
optical	O
coherence	O
tomography	O
OCT	O
.	O

We	O
used	O
age-	O
and	O
gender	O
-	O
adjusted	O
linear	O
regression	O
to	O
compare	O
contrast	O
acuity	O
and	O
retinal	O
thickness	B-DIS
between	O
CMT	O
groups	O
.	O

Results	O
One	B-STAT
of	I-STAT
5	I-STAT
patients	O
with	O
CMT2A	B-DIS
had	O
optic	B-DIS
nerve	I-DIS
atrophy	I-DIS
binocular	O
high	O
-	O
contrast	O
acuity	B-STAT
equivalent	O
20/160	O
mean	O
circumpapillary	O
RNFL	O
47.5	O
Î¼m	O
.	O

The	O
other	O
patients	O
with	O
CMT2A	B-DIS
had	O
normal	O
high-	O
and	O
low	O
-	O
contrast	O
acuity	B-DIS
and	I-DIS
retinal	O
thickness	O
and	O
there	O
were	O
no	O
significant	O
differences	O
between	O
patients	B-DIS
with	I-DIS
CMT2A	O
CMT1A	O
and	O
CMTX1	O
.	O

Conclusions	O
Optic	B-DIS
atrophy	I-DIS
occurs	O
in	O
some	O
patients	O
with	O
CMT2A	B-DIS
but	O
in	O
others	O
there	O
is	O
no	O
discernible	O
optic	B-DIS
nerve	I-DIS
involvement	O
.	O

This	O
suggests	O
that	O
optic	B-DIS
neuropathy	I-DIS
is	O
specific	O
to	O
certain	O
MFN2	O
mutations	O
in	O
CMT2A	B-DIS
and	O
that	O
low	O
-	O
contrast	O
acuity	O
or	O
OCT	O
is	O
of	O
limited	O
value	O
as	O
a	O
disease	O
-	O
wide	O
biomarker	O
.	O

Background	O
Congenital	B-DIS
malformations	I-DIS
involving	O
the	O
MÃ¼llerian	O
ducts	O
are	O
observed	O
in	O
around	B-STAT
5	I-STAT
%	I-STAT
of	O
infertile	O
women	O
.	O

Complete	O
aplasia	B-DIS
of	I-DIS
the	I-DIS
uterus	I-DIS
cervix	I-DIS
and	O
upper	O
vagina	O
also	O
termed	O
MÃ¼llerian	O
aplasia	B-DIS
or	O
Mayer	B-DIS
-	I-DIS
Rokitansky	I-DIS
-	O
Kuster	O
-	O
Hauser	B-EPI
MRKH	O
syndrome	O
occurs	B-STAT
with	I-STAT
an	I-STAT
incidence	O
of	O
around	O
1	O
in	O
4500	O
female	O
births	O
and	O
occurs	O
in	O
both	O
isolated	O
and	O
syndromic	O
forms	O
.	O

Previous	O
reports	O
have	O
suggested	O
that	O
a	O
proportion	O
of	O
cases	O
especially	O
syndromic	O
cases	O
are	O
caused	O
by	O
variation	O
in	O
copy	O
number	O
at	O
different	O
genomic	O
loci	O
.	O

Methods	O
In	O
order	O
to	O
obtain	O
an	O
overview	O
of	O
the	O
contribution	O
of	O
copy	O
number	O
variation	O
to	O
both	O
isolated	O
and	O
syndromic	O
forms	O
of	O
MÃ¼llerian	O
aplasia	B-DIS
copy	O
number	O
assays	O
were	O
performed	O
in	O
a	O
series	O
of	O
63	O
cases	O
of	O
which	O
25	O
were	O
syndromic	O
and	O
38	O
isolated	O
.	O

Results	O
A	O
high	O
incidence	B-EPI
9/6314	B-STAT
%	I-STAT
of	O
recurrent	O
copy	O
number	O
variants	O
in	O
this	O
cohort	O
is	O
reported	O
here	O
.	O

These	O
comprised	O
four	O
cases	O
of	O
microdeletion	O
at	O
16p11.2	O
an	O
autism	B-DIS
susceptibility	O
locus	O
not	O
previously	O
associated	O
with	O
MÃ¼llerian	O
aplasia	B-DIS
four	O
cases	O
of	O
microdeletion	O
at	O
17q12	O
and	O
one	O
case	O
of	O
a	O
distal	O
22q11.2	B-DIS
microdeletion	I-DIS
.	O

Microdeletions	B-DIS
at	O
16p11.2	O
and	O
17q12	O
were	O
found	O
in	O
4/38	B-STAT
10.5	I-STAT
%	I-STAT
cases	O
with	O
isolated	O
MÃ¼llerian	O
aplasia	B-DIS
and	O
at	O
16p11.2	O
17q12	O
and	O
22q11.2	B-DIS
distal	O
in	O
5/25	B-STAT
cases	O
20	B-STAT
%	I-STAT
with	O
syndromic	O
MÃ¼llerian	O
aplasia	B-DIS
.	O

Conclusion	O
The	O
finding	O
of	O
microdeletion	O
at	O
16p11.2	O
in	O
2/385	B-STAT
%	I-STAT
of	O
isolated	O
and	O
2/258	B-STAT
%	I-STAT
of	O
syndromic	O
cases	O
suggests	O
a	O
significant	O
contribution	O
of	O
this	O
copy	O
number	O
variant	O
alone	O
to	O
the	O
pathogenesis	O
of	O
MÃ¼llerian	O
aplasia	B-DIS
.	O

Overall	O
the	O
high	O
incidence	B-EPI
of	O
recurrent	O
copy	O
number	O
variants	O
in	O
all	O
forms	O
of	O
MÃ¼llerian	O
aplasia	B-DIS
has	O
implications	O
for	O
the	O
understanding	O
of	O
the	O
aetiopathogenesis	O
of	O
the	O
condition	O
and	O
for	O
genetic	O
counselling	O
in	O
families	O
affected	O
by	O
it	O
.	O

Purpose	O
We	O
investigated	O
the	O
prevalence	B-EPI
of	O
Modic	O
changes	O
MCs	O
and	O
associated	O
pathologies	O
in	O
pediatric	O
patients	O
.	O

Methods	O
A	O
total	O
of	O
368	O
MRI	O
obtained	O
for	O
240	O
male	O
and	O
128	O
female	O
patients	O
under	O
the	O
age	O
of	O
18	O
years	O
with	O
complaints	B-DIS
of	I-DIS
low	I-DIS
back	I-DIS
/	I-DIS
leg	O
pain	O
were	O
retrospectively	O
examined	O
.	O

All	O
changes	O
in	O
signal	O
intensity	O
in	O
the	O
vertebral	O
endplate	O
and	O
subchondral	O
bone	O
on	O
MRI	O
were	O
defined	O
as	O
MCs	O
.	O

We	O
investigated	O
the	O
relationship	O
between	O
MCs	O
and	O
underlying	O
diseases	O
including	O
lumbar	B-DIS
spondylolysis	I-DIS
/	O
spondylolisthesis	O
and	O
conditions	O
of	O
the	O
growth	O
plate	O
in	O
cases	O
with	O
MCs	O
.	O

The	O
degree	O
of	O
disc	B-DIS
degeneration	I-DIS
in	O
patients	O
with	O
MCs	O
was	O
evaluated	O
using	O
the	O
Pfirrmann	O
grading	O
system	O
.	O

Results	O
MCs	O
were	O
identified	O
in	O
six	O
patients	O
1.6	B-STAT
%	I-STAT
.	O

In	O
five	O
of	O
the	O
six	O
patients	O
the	O
signal	O
intensity	O
changes	O
were	O
localized	O
to	O
the	O
anterosuperior	O
endplate	O
of	O
the	O
affected	O
vertebra	O
;	O
the	O
MCs	O
were	O
associated	O
with	O
anterior	O
apophyseal	O
ring	O
fracture	B-DIS
and	O
an	O
open	O
growth	O
plate	O
in	O
all	O
these	O
cases	O
.	O

Disc	O
degeneration	O
was	O
classified	O
as	O
Pfirrmann	O
grade	O
I	O
in	O
three	O
patients	O
and	O
grade	O
II	O
and	O
III	O
in	O
one	O
patient	O
each	O
.	O

One	O
patient	O
had	O
type	O
I	O
changes	O
associated	O
with	O
grade	O
IV	O
disc	O
degeneration	O
and	O
herniation	B-DIS
and	O
no	O
sign	O
of	O
an	O
open	O
growth	O
plate	O
.	O

Conclusion	O
The	O
prevalence	B-EPI
of	O
MCs	O
in	O
pediatrics	O
patients	O
was	O
much	O
lower	O
than	O
the	O
rates	O
reported	O
in	O
adults	O
.	O

Most	O
MCs	O
were	O
associated	O
with	O
an	O
anterior	O
apophyseal	O
ring	O
fracture	B-DIS
.	O

If	O
Modic	O
type	O
changes	O
are	O
seen	O
in	O
immature	O
vertebrae	O
of	O
pediatric	O
patients	O
growth	O
plate	O
lesions	O
such	O
as	O
apophyseal	O
ring	O
fractures	B-DIS
should	O
be	O
considered	O
.	O

Level	O
of	O
evidence	O
Diagnostic	O
individual	O
l	O
cross	O
-	O
sectional	O
studies	O
with	O
consistently	O
applied	O
reference	O
standard	O
and	O
blinding	O
.	O

Allogeneic	O
islet	O
transplantation	O
is	O
a	O
standard	O
of	O
care	O
treatment	O
for	O
patients	O
with	O
labile	O
type	O
1	O
diabetes	B-DIS
in	O
many	O
countries	O
around	O
the	O
world	O
including	O
Japan	B-LOC
the	O
United	B-LOC
Kingdom	I-LOC
Australia	O
much	O
of	O
continental	O
Europe	B-LOC
and	O
parts	O
of	O
Canada	B-LOC
.	O

The	B-LOC
United	I-LOC
States	I-LOC
is	O
now	O
endorsing	O
islet	O
cell	O
treatment	O
for	O
type	O
1	O
diabetes	B-DIS
but	O
the	O
FDA	O
has	O
chosen	O
to	O
consider	O
islets	O
as	O
a	O
biologic	O
that	O
requires	O
licensure	O
making	O
the	O
universal	O
implementation	O
of	O
the	O
procedure	O
in	O
the	O
clinic	O
very	O
challenging	O
and	O
opening	O
the	O
manufacture	O
of	O
islet	O
grafts	O
to	O
private	O
companies	O
.	O

The	O
commercialization	O
of	O
human	O
tissues	O
raises	O
significant	O
legal	O
and	O
ethical	O
issues	O
and	O
ironically	O
leads	O
to	O
a	O
situation	O
where	O
treatments	O
developed	O
as	O
a	O
result	O
of	O
the	O
scientific	O
and	O
economic	O
efforts	O
of	O
academia	O
over	O
several	O
decades	O
become	O
exploited	O
exclusively	O
by	O
for	O
-	O
profit	O
entities	O
.	O

Congenital	B-DIS
hypothyroidism	I-DIS
CH	I-DIS
is	O
a	O
highly	O
prevalent	O
but	O
treatable	O
neonatal	O
endocrine	B-DIS
disorder	I-DIS
.	O

Thyroid	B-DIS
dyshormonogenesis	I-DIS
is	O
the	O
main	O
cause	O
of	O
congenital	B-DIS
hypothyroidism	I-DIS
in	O
Chinese	O
CH	O
patients	O
and	O
DUOX2	O
is	O
the	O
most	O
frequent	O
mutated	O
gene	O
involved	O
in	O
H2O2	O
production	O
.	O

In	O
humans	O
the	O
primary	O
sources	O
for	O
H2O2	O
production	O
are	O
DUOX1	O
and	O
DUOX2	O
while	O
in	O
zebrafish	O
there	O
is	O
only	O
a	O
single	O
orthologue	O
for	O
DUOX1	O
and	O
DUOX2	B-LOC
.	O

In	O
this	O
study	O
duox	O
mutant	O
zebrafish	O
were	O
generated	O
through	O
knockdown	O
duox	O
by	O
morpholino	O
or	O
knockout	O
duox	O
by	O
CRISPR	O
Cas9	O
.	O

The	O
associated	O
phenotypes	O
were	O
investigated	O
and	O
rescued	O
by	O
thyroxine	O
T4	O
treatment	O
.	O

Mutant	O
zebrafish	O
displayed	O
hypothyroid	B-DIS
phenotypes	O
including	O
growth	O
retardation	B-DIS
goiter	I-DIS
and	O
infertility	B-DIS
.	O

Homozygous	O
mutants	O
in	O
adults	O
also	O
displayed	O
extrathyroidal	B-DIS
abnormal	O
phenotypes	O
including	O
lacking	O
barbels	O
pigmentation	O
defects	O
erythema	O
in	O
the	O
opercular	O
region	O
ragged	O
fins	O
and	O
delayed	O
scales	O
.	O

All	O
these	O
abnormal	O
phenotypes	O
can	O
be	O
rescued	O
by	O
10	O
nM	O
T4	O
treatment	O
.	O

Strikingly	O
the	O
fertility	O
of	O
zebrafish	O
was	O
dependent	O
on	O
thyroid	O
hormone	O
;	O
T4	O
treatment	O
should	O
be	O
continued	O
and	O
can	O
not	O
be	O
stopped	O
over	O
2	O
weeks	O
in	O
hypothyroid	B-DIS
zebrafish	O
in	O
order	O
to	O
achieve	O
fertility	O
.	O

Thyroid	O
hormones	O
played	O
a	O
role	O
in	O
the	O
developing	O
and	O
maturing	O
of	O
reproductive	O
cells	O
.	O

Our	O
work	O
indicated	O
that	O
duox	O
mutant	O
zebrafish	O
may	O
provide	O
a	O
model	O
for	O
human	O
congenital	B-DIS
hypothyroidism	I-DIS
.	O

Congenital	O
factor	O
X	O
FX	B-DIS
deficiency	I-DIS
is	O
a	O
rare	O
bleeding	B-DIS
disorder	O
with	O
an	O
incidence	B-EPI
of	O
one	O
in	O
one	O
million	O
.	O

The	O
proband	O
a	O
2	B-DIS
-	O
year	O
-	O
old	B-DIS
girl	O
exhibited	O
easy	O
bruising	O
and	B-DIS
a	I-DIS
history	I-DIS
of	O
umbilical	O
cord	O
bleeding	O
at	O
birth	O
.	O

Prothrombin	O
time	O
40	O
s	O
and	O
activated	O
partial	O
thromboplastin	O
time	O
65.0	O
s	O
were	O
prolonged	O
.	O

Marked	O
declines	B-DIS
in	I-DIS
FX	I-DIS
activity	I-DIS
<	O
1	B-STAT
%	I-STAT
and	O
FX	O
antigen	O
levels	O
5	B-STAT
%	I-STAT
were	O
also	O
observed	O
.	O

Genetic	O
analysis	O
of	O
the	O
proband	O
identified	O
two	O
types	O
of	O
single	O
-	O
base	B-DIS
substitutions	I-DIS
c.35	O
A	O
p.	O
Gly118Asp	O
and	O
c.130	O
A	O
p.	O
Gly435Ser	O
indicating	O
compound	B-DIS
heterozygous	I-DIS
congenital	I-DIS
FX	O
deficiency	O
.	O

Genetic	O
analysis	O
of	O
family	O
members	O
revealed	O
that	O
her	O
father	O
and	O
older	O
sister	O
5	O
-	O
year	O
-	O
old	O
were	O
also	O
heterozygous	O
for	O
p.	O
Gly118Asp	O
and	O
that	O
her	O
mother	O
was	O
heterozygous	O
for	O
p.	O
Gly435Ser	O
.	O

To	O
improve	O
the	O
bleeding	B-DIS
tendency	O
the	O
proband	O
received	O
regular	O
replacement	O
of	O
500	O
units	O
of	O
PPSB	O
-	O
HT	O
a	O
prothrombin	O
complex	O
concentrate	O
PCC	O
.	O

Following	O
continued	O
regular	O
replacement	O
of	O
500	O
units	O
of	O
PPSB	O
-	O
HT	O
once	O
per	O
week	O
the	O
proband	O
has	O
exhibited	B-DIS
no	O
bleeding	O
tendencies	O
and	O
no	B-DIS
new	O
bruises	O
have	O
been	O
observed	O
.	O

There	O
are	O
no	O
previous	O
report	O
of	O
the	O
use	O
of	O
PPSB	O
-	O
HT	O
for	O
regular	O
FX	O
replacement	O
.	O

Regular	O
replacement	O
therapy	O
with	O
PPSB	O
-	O
HT	O
may	O
be	O
an	O
effective	O
method	O
for	O
preventative	O
control	B-DIS
of	O
bleeding	O
tendencies	B-DIS
in	I-DIS
FX	O
deficiency	O
.	O

The	O
relationship	O
between	O
smoking	O
and	O
illness	O
perceptions	O
among	O
congenital	B-DIS
heart	I-DIS
disease	I-DIS
CHD	O
survivors	O
is	O
unknown	O
.	O

The	O
primary	O
aims	O
of	O
the	O
present	O
study	O
were	O
to	O
compare	O
the	O
smoking	O
prevalence	B-EPI
among	O
CHD	B-DIS
survivors	O
to	O
a	O
nationally	O
representative	O
U.S.	B-LOC
sample	O
and	O
examine	O
the	O
relationship	O
between	O
smoking	O
and	O
illness	O
perceptions	O
.	O

CHD	B-DIS
survivors	O
N	O
=	O
744	O
from	O
six	O
U.S.	B-LOC
sites	O
participated	O
in	O
the	O
study	O
.	O

The	O
smoking	O
prevalence	B-EPI
among	O
CHD	O
survivors	O
9.3	B-STAT
%	I-STAT
was	O
lower	O
than	O
the	O
general	O
population	O
15.3	B-STAT
%	I-STAT
.	O

However	O
23.3	B-STAT
%	I-STAT
of	O
CHD	B-DIS
survivors	O
with	O
severe	O
functional	O
limitations	O
smoked	O
.	O

Smoking	O
prevalence	B-EPI
differed	O
by	O
U.S.	B-LOC
region	O
with	O
a	O
greater	O
proportion	O
of	O
those	O
attending	O
CHD	O
care	O
in	O
the	O
Midwest	B-LOC
reporting	O
smoking	O
11.8	B-STAT
%	I-STAT
.	O

The	O
illness	O
perception	O
dimensions	O
of	O
Concern	O
and	O
Emotional	O
Response	O
were	O
independently	O
associated	O
with	O
smoking	O
.	O

Differences	O
in	O
illness	O
perceptions	O
enhance	O
our	O
understanding	O
of	O
smoking	O
among	O
CHD	O
survivors	O
and	O
may	O
guide	O
interventions	O
promoting	O
positive	O
health	O
behaviors	O
.	O

The	O
protocol	O
for	O
the	O
study	O
from	O
which	O
the	O
present	O
analyses	O
were	O
conducted	O
was	O
recorded	O
at	O
ClinicalTrials.gov	O
NCT02150603	O
.	O

West	B-LOC
Nile	I-LOC
virus	O
WNV	B-DIS
is	O
a	O
zoonotic	O
mosquito	B-DIS
-	I-DIS
borne	O
flavivirus	O
that	O
is	O
harbored	O
and	O
amplified	O
by	O
wild	O
birds	O
via	O
the	O
enzootic	O
transmission	O
cycle	O
.	O

Wide	O
range	O
of	O
hosts	O
are	O
found	O
to	O
be	O
susceptible	O
to	O
WNV	B-DIS
infection	I-DIS
including	O
mammals	O
amphibians	O
and	O
reptiles	O
across	O
the	O
world	O
.	O

Several	O
studies	O
have	O
demonstrated	O
that	O
WNV	B-DIS
was	O
present	O
in	O
the	O
Malaysian	O
Orang	O
Asli	O
and	O
captive	O
birds	O
.	O

However	O
no	O
data	O
are	O
available	O
on	O
the	O
WNV	B-DIS
prevalence	B-EPI
in	O
wild	O
birds	O
found	O
in	O
Malaysia	B-LOC
.	O

Therefore	O
this	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
serological	O
and	O
molecular	O
prevalence	B-EPI
of	O
WNV	B-DIS
in	O
wild	O
birds	O
in	O
selected	O
areas	O
in	O
the	B-LOC
West	I-LOC
Coast	I-LOC
of	O
Peninsular	O
Malaysia	B-LOC
.	O

Two	O
types	O
of	O
wild	O
birds	O
were	O
screened	O
namely	O
migratory	O
and	O
resident	O
birds	O
in	O
order	O
to	O
explore	O
any	O
possibility	O
of	O
WNV	B-DIS
transmission	O
from	O
the	O
migratory	O
birds	O
to	O
the	O
resident	O
birds	O
.	O

Thus	O
a	O
cross	O
-	O
sectional	O
study	O
was	O
conducted	O
at	O
the	O
migratory	O
birds	O
sanctuary	O
located	O
in	O
Kuala	B-LOC
Gula	I-LOC
Perak	I-LOC
and	O
Kapar	O
Selangor	O
by	O
catching	O
163	O
migratory	O
birds	O
and	O
97	O
resident	O
birds	O
from	O
Kuala	B-LOC
Gula	I-LOC
and	O
Parit	O
Buntar	O
Perak	O
at	O
different	O
time	O
between	O
2016	O
and	O
2017	O
Total	O
n	O
=	O
260	O
.	O

Blood	O
and	O
oropharyngeal	O
swabs	O
were	O
collected	O
for	O
serological	O
and	O
molecular	O
analysis	O
respectively	O
.	O

Serum	O
were	O
screened	O
for	O
WNV	B-DIS
antibodies	O
using	O
a	O
commercial	O
competitive	O
ELISA	O
c	O
-	O
ELISA	O
ID	O
Screen	O
Â®	O
West	O
Nile	O
Competition	O
Multi	O
-	O
species	O
ELISA	O
ID	O
VET	O
Montpellier	B-LOC
France	B-LOC
and	B-DIS
cross	O
-	B-DIS
reactivity	O
towards	O
Japanese	O
Encephalitis	O
virus	O
JEV	O
was	O
also	O
carried	O
out	O
using	O
the	O
JEV	O
-	O
double	O
antigen	O
sandwich	O
DAS	O
ELISA	O
.	O

Oropharyngeal	B-DIS
swabs	O
were	O
subjected	O
to	O
one	O
-	O
step	O
RT	O
-	B-DIS
PCR	O
to	O
detect	O
WNV	O
RNA	O
in	O
which	O
positive	O
reactions	O
were	O
subsequently	O
sequenced	O
.	O

WNV	B-DIS
seropositive	O
rate	O
of	O
18.71	B-STAT
%	I-STAT
29/155	B-STAT
at	O
95	B-STAT
%	I-STAT
CI	O
0.131	O
to	O
0.260	O
and	O
molecular	O
prevalence	B-EPI
of	O
15.2	B-STAT
%	I-STAT
16/105	B-STAT
at	O
95	B-STAT
%	I-STAT
CI	O
0.092	O
to	O
0.239	O
were	O
demonstrated	O
in	O
migratory	O
and	O
resident	O
wild	O
birds	O
found	O
in	O
West	B-LOC
Coast	I-LOC
Malaysia	B-LOC
.	O

Phylogenetic	O
analyses	O
of	O
the	O
16	O
WNV	B-DIS
isolates	O
found	O
in	O
this	O
study	O
revealed	O
that	O
the	O
local	O
strains	O
have	O
99	B-STAT
%	I-STAT
similarity	O
to	O
the	O
strains	O
from	O
South	B-LOC
Africa	I-LOC
and	O
were	O
clustered	O
under	O
lineage	O
2	O
.	O

Evidence	O
of	O
WNV	B-DIS
infection	I-DIS
in	O
resident	O
and	O
migratory	O
birds	O
were	O
demonstrated	O
in	O
this	O
study	O
.	O

As	O
a	O
summary	O
intervention	O
between	O
migratory	O
birds	O
resident	O
birds	O
and	O
mosquitoes	O
might	O
cause	O
the	O
introduction	O
and	O
maintenance	O
of	O
WNV	B-DIS
in	O
Malaysia	B-LOC
however	O
the	O
assumption	O
could	O
be	O
further	O
proven	O
by	O
studying	O
the	O
infection	B-DIS
dynamics	O
in	O
the	O
mosquitoes	O
present	O
in	O
the	O
studied	O
areas	O
.	O

Takotsubo	B-DIS
cardiomyopathy	I-DIS
TCM	O
also	O
known	O
as	O
broken	O
heart	B-DIS
syndrome	I-DIS
or	O
stress	O
-	B-DIS
induced	O
cardiomyopathy	O
is	O
a	O
rare	O
condition	O
with	O
an	B-EPI
estimated	O
incidence	O
of	O
0.02	B-STAT
%	I-STAT
of	O
all	O
hospitalizations	O
in	O
United	B-LOC
States	I-LOC
and	O
2	B-STAT
%	I-STAT
of	B-DIS
all	I-DIS
acute	I-DIS
coronary	O
syndrome	O
presentations	O
.	O

TCM	B-DIS
predominately	O
presents	O
as	O
a	O
transient	O
wall	O
motion	O
abnormality	O
of	O
the	O
left	O
ventricular	O
apex	O
due	O
to	O
emotional	O
or	O
physical	O
stress	O
.	O

Cardiac	B-DIS
rupture	I-DIS
in	O
the	O
setting	O
of	O
TCM	B-DIS
is	O
an	O
extremely	O
rare	O
phenomenon	O
with	O
limited	O
published	O
case	O
reports	O
.	O

We	O
present	O
a	O
case	O
of	O
a	O
75	O
-	O
year	O
-	O
old	B-DIS
female	I-DIS
who	O
had	O
cardiac	B-DIS
rupture	O
secondary	O
to	O
TCM	O
and	O
performed	O
a	O
literature	O
review	O
using	O
Ovid	O
MEDLINE	O
for	O
published	O
cases	O
showing	O
this	O
association	O
.	O

After	O
the	O
literature	O
review	O
we	O
found	O
20	O
cases	O
showing	O
this	O
association	O
which	O
are	O
listed	O
in	O
a	O
tabular	O
fashion	O
.	O

Background	O
Entamoeba	O
species	O
harbored	O
by	O
humans	O
have	O
different	O
degrees	O
of	O
pathogenicity	O
.	O

The	O
present	O
study	O
explores	O
the	O
intra-	O
and	O
interspecific	O
diversity	O
phylogenetic	O
relationships	O
prevalence	B-EPI
and	O
distribution	O
of	O
tetra-	O
and	O
octonucleated	O
cyst	O
-	O
producing	O
Entamoeba	O
in	O
different	O
Brazilian	O
regions	O
.	O

Methods	O
Cross	O
-	O
sectional	O
studies	O
were	O
performed	O
to	O
collect	O
fecal	O
samples	O
n	O
=	O
1728	O
and	O
sociodemographic	O
data	O
in	O
communities	O
located	O
in	O
four	O
Brazilian	O
biomes	O
Atlantic	O
Forest	O
Caatinga	O
Cerrado	O
and	O
Amazon	O
.	O

Fecal	O
samples	O
were	O
subjected	O
to	O
molecular	O
analysis	O
by	O
partial	O
small	O
subunit	O
ribosomal	O
DNA	O
sequencing	O
SSU	O
rDNA	O
and	O
phylogenetic	O
analysis	O
.	O

Results	O
Light	O
microscopy	O
analysis	O
revealed	O
that	O
tetranucleated	B-DIS
cysts	I-DIS
were	O
found	O
in	O
all	O
the	O
studied	O
biomes	O
.	O

The	O
highest	O
positivity	O
rates	O
were	O
observed	O
in	O
the	O
age	O
group	O
6	O
-	O
10	O
years	O
23.21	B-STAT
%	I-STAT
.	O

For	O
octonucleated	O
cysts	O
positivity	O
rates	O
ranged	O
from	O
1	O
to	O
55.1	B-STAT
%	I-STAT
.	O

Sixty	O
SSU	O
rDNA	O
Entamoeba	O
sequences	O
were	O
obtained	O
and	O
four	O
different	O
species	O
were	O
identified	O
the	O
octonucleated	O
E.	O
coli	O
and	O
the	O
tetranucleated	O
E.	O
histolytica	B-DIS
E.	I-DIS
dispar	I-DIS
and	O
E.	B-DIS
hartmanni	I-DIS
.	O

Novel	O
haplotypes	O
n	O
=	O
32	O
were	O
characterized	O
;	O
however	O
new	O
ribosomal	O
lineages	O
were	O
not	O
identified	O
.	O

The	O
Entamoeba	O
coli	O
ST1	O
subtype	O
predominated	O
in	O
Atlantic	B-LOC
Forest	I-LOC
and	O
Caatinga	B-LOC
and	O
the	O
ST2	O
subtype	O
was	O
predominant	O
in	O
the	O
Amazon	O
biome	O
.	O

E.	O
histolytica	O
was	O
detected	O
only	O
in	O
the	O
Amazon	O
biome	O
.	O

In	O
phylogenetic	O
trees	O
sequences	O
were	O
grouped	O
in	O
two	O
groups	O
the	O
first	O
containing	O
uni-	O
and	O
tetranucleated	O
and	O
the	O
second	O
containing	O
uni-	O
and	O
octonucleated	O
cyst	O
-	O
producing	O
Entamoeba	O
species	O
.	O

Molecular	O
diversity	O
indexes	O
revealed	O
a	O
high	O
interspecific	O
diversity	O
for	O
tetra-	O
and	O
octonucleated	O
Entamoeba	O
spp	O
.	O

H	O
Â±	O
SD	O
=	O
0.9625	O
Â±	O
0.0126	O
.	O

The	O
intraspecific	O
diversity	O
varied	O
according	O
to	O
species	O
or	O
subtype	O
E.	O
dispar	O
and	O
E.	O
histolytica	O
showed	O
lower	O
diversity	O
than	O
E.	O
coli	O
subtypes	O
ST1	O
and	O
ST2	O
and	O
E.	B-DIS
hartmanni	I-DIS
.	O

Conclusions	O
Tetra-	O
and	O
octonucleated	O
cyst	O
-	O
producing	O
Entamoeba	O
are	O
endemic	O
in	O
the	O
studied	O
communities	O
;	O
E.	O
histolytica	O
was	O
found	O
in	O
a	O
low	O
proportion	O
and	O
only	O
in	O
the	O
Amazon	O
biome	O
.	O

With	O
regard	O
to	O
E.	O
coli	O
subtype	O
ST2	O
was	O
predominant	O
in	O
the	O
Amazon	O
biome	O
.	O

The	O
molecular	O
epidemiology	O
of	O
Entamoeba	O
spp	O
.	O

is	O
a	O
field	O
to	O
be	O
further	O
explored	O
and	O
provides	O
information	O
with	O
important	O
implications	O
for	O
public	O
health	O
.	O

Thyroid	B-DIS
cancer	I-DIS
TC	O
represents	O
a	O
worldwide	O
problem	O
the	O
consistent	O
growth	O
of	O
the	O
incidence	B-EPI
increment	O
issues	O
about	O
management	O
of	O
risk	O
factors	O
and	O
curative	O
treatment	O
.	O

Updated	O
statistical	O
data	O
are	O
not	O
complete	O
in	O
the	O
North	B-LOC
East	I-LOC
region	O
of	O
Romania	B-LOC
and	O
need	O
to	O
be	O
improved	O
.	O

Therefore	O
through	O
this	O
study	O
we	O
aim	O
to	O
renew	O
the	O
existing	O
data	O
on	O
thyroid	B-DIS
cancer	I-DIS
.	O

We	O
conducted	O
a	O
retrospective	O
study	O
covering	O
a	O
period	O
of	O
10	O
years	O
.	O

Data	O
were	O
collected	O
from	O
a	O
hospital	O
information	O
system	O
InfoWorld	O
between	O
2009	O
and	O
2019	O
.	O

Patients	O
'	O
age	O
groups	O
were	O
stratified	O
in	O
relation	O
with	O
the	O
age	O
at	O
the	O
moment	O
of	O
the	O
Chernobyl	B-LOC
event	O
.	O

A	O
database	O
was	O
obtained	O
Microsoft	O
Excel	O
and	O
statistical	O
correlations	O
were	O
applied	O
.	O

In	O
the	O
studied	O
period	O
1159	O
patients	O
were	O
diagnosed	O
968	O
females	O
and	O
191	O
males	O
distributed	O
by	O
region	O
with	O
the	O
highest	O
addressability	O
in	O
Iasi	O
529	O
followed	O
by	O
neighboring	O
counties	O
.	O

Age	O
distribution	O
displayed	O
that	O
most	O
of	O
the	O
thyroid	B-DIS
cancers	I-DIS
were	O
in	O
the	O
range	O
4060	O
years	O
old	O
50.94	B-STAT
%	I-STAT
followed	O
by	O
60	O
-	O
80	O
years	O
old	O
32.41	B-STAT
%	I-STAT
.	O

Most	O
patients	O
were	O
diagnosed	O
with	O
papillary	B-DIS
carcinoma	I-DIS
63.10	B-STAT
%	I-STAT
then	O
follicular	O
14.7	B-STAT
%	I-STAT
medullary	O
6.74	B-STAT
%	I-STAT
and	O
undifferentiated	O
1.02	B-STAT
%	I-STAT
.	O

Romania	B-LOC
was	O
in	O
the	O
vicinity	O
of	O
the	O
radioactive	O
cloud	O
at	O
Chernobyl	B-LOC
fallout	O
so	O
we	O
must	O
deliberate	O
whether	O
the	O
increased	O
incidence	B-EPI
of	O
thyroid	B-DIS
cancer	I-DIS
in	O
the	O
age	O
group	O
40	O
-	O
60	O
years	O
is	O
associated	O
with	O
radiogenicity	O
iodine	O
131	O
given	O
the	O
fact	O
that	O
over	O
has	O
35	O
years	O
and	O
the	O
half	O
-	O
life	O
of	O
other	O
radioisotopes	O
like	O
Caesium-137	O
and	O
Strontium	O
-90	O
is	O
completed	O
.	O

Introduction	O
21	B-DIS
-	I-DIS
hydroxylase	I-DIS
deficiency	O
21	O
-	O
OHD	O
is	O
the	O
most	B-DIS
common	I-DIS
form	I-DIS
of	I-DIS
congenital	O
adrenal	O
hyperplasia	O
CAH	O
.	O

In	O
adulthood	O
most	O
studies	O
are	O
reported	O
in	O
females	O
.	O

By	O
contrast	O
data	O
on	O
adult	O
males	O
are	O
scarce	O
.	O

Objective	O
To	O
describe	O
a	O
series	O
of	O
adult	O
males	O
with	O
classic	O
21	B-DIS
-	O
OHD	O
and	O
to	O
assess	O
the	O
presence	O
of	O
adrenal	O
masses	O
and	O
testicular	O
adrenal	B-DIS
rest	I-DIS
tumors	O
TARTs	O
.	O

Material	O
and	O
methods	O
Eight	O
males	O
21	O
-	O
42	O
years	O
were	O
included	O
.	O

We	O
evaluated	O
clinical	O
presentation	O
17	O
-	O
Hydroxyprogesterone	O
17	O
-	O
OHP	O
Testosterone	O
T	O
Î”4Androstenedione	O
Î”4A	O
ACTH	O
LH	O
FSH	O
and	O
plasma	O
renin	O
activitiy	O
PRA	O
levels	O
at	O
consultation	O
.	O

Molecular	O
studies	O
of	O
the	O
CYP21A2	O
gene	O
testicular	O
ultrasound	O
US	B-LOC
semen	O
analysis	O
and	O
adrenal	O
computed	O
tomography	O
CT	O
scan	O
were	O
performed	O
.	O

Treatment	O
and	O
compliance	O
were	O
assessed	O
.	O

Results	O
Basal	O
17	O
-	O
OHP	O
levels	B-STAT
wer	O
20ng	O
/	O
ml	O
in	O
all	O
patients	O
.	O

At	O
consultation	O
median	O
17OH	O
-	O
P	O
was	O
11.5	O
2.3	O
-	O
81	O
ng	O
/	O
ml	O
FSH	O
30.3	O
-	O
4	O
mUI	O
/	O
ml	O
LH	O
1.1	O
0.1	O
-	O
6	O
mUI	O
/	O
ml	O
T	O
4.3	O
1.7	O
-	O
8	O
ng	O
/	O
ml	O
Î”4A	O
5.7	O
1.4	O
-	O
16	O
ng	O
/	O
ml	O
ACTH	O
86.4	O
76	O
-	O
334	O
pg	O
/	O
ml	O
PRA	O
9.5	O
1.3	O
-	O
23.6	O
ng	O
/	O
ml	O
/	O
h	O
.	O

Semen	O
analysis	O
was	O
performed	O
in	O
5/8	B-STAT
patients	O
showing	O
azoospermia	B-DIS
in	O
two	O
.	O

Molecular	O
genetic	O
analysis	O
was	O
performed	O
in	O
4/8	B-STAT
patients	O
.	O

TARTs	B-DIS
were	O
found	O
in	O
5/6	B-STAT
being	O
bilateral	O
in	O
four	O
.	O

Adrenal	O
masses	O
were	O
found	O
in	O
4/6	B-STAT
.	O

In	O
the	O
7	O
patients	O
diagnosed	O
in	O
childhood	O
their	O
follow	O
-	O
up	O
was	O
referred	O
to	O
as	O
irregular	O
both	O
in	O
their	O
attendance	O
at	O
consultations	O
and	O
in	O
compliance	O
with	O
the	O
indicated	O
treatment	O
.	O

Conclusions	O
To	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
series	O
on	O
adult	O
males	O
with	O
classic	O
21	B-DIS
-	O
OHD	O
which	O
concomitantly	O
assesses	O
clinical	O
presentation	O
molecular	O
biology	O
adrenal	O
and	O
testicular	O
imaging	O
studies	O
semen	O
analysis	O
and	O
compliance	O
to	O
treatment	O
.	O

A	O
high	O
prevalence	B-EPI
of	O
adrenal	O
masses	O
and	O
TARTs	B-DIS
was	O
observed	O
possibly	O
associated	O
with	O
poor	O
treatment	O
compliance	O
leading	O
to	O
elevated	O
ACTH	O
and	O
increased	O
proliferation	O
.	O

Our	O
findings	O
on	O
TARTs	B-DIS
agree	O
with	O
reports	O
in	O
international	O
publications	O
of	O
CAH	B-DIS
in	O
males	O
with	O
adrenal	O
imaging	O
being	O
added	O
in	O
our	O
group	O
.	O

Although	O
we	O
are	O
aware	O
that	O
further	O
studies	O
with	O
a	O
larger	O
sample	O
size	O
and	O
more	O
data	O
are	O
needed	O
we	O
consider	O
that	O
our	O
findings	O
contribute	O
to	O
the	O
clinical	O
management	O
of	O
classical	O
21	B-DIS
-	O
OHD	O
in	O
the	O
male	O
population	O
.	O

Aims	O
Takotsubo	B-DIS
syndrome	I-DIS
TTS	O
is	O
a	O
form	O
of	O
acute	B-DIS
myocardial	I-DIS
inflammation	I-DIS
often	O
triggered	O
by	O
catecholamine	O
release	O
surges	O
which	O
accounts	O
for	O
approximately	B-STAT
10	I-STAT
%	I-STAT
of	O
'	O
myocardial	B-DIS
infarctions	I-DIS
'	O
in	O
female	O
patients	O
above	O
the	O
age	O
of	O
50	O
.	O

Its	O
associated	O
substantial	O
risk	O
of	O
in	O
-	O
hospital	O
mortality	O
is	O
mainly	O
driven	O
by	O
the	O
development	B-DIS
of	O
hypotension	B-DIS
and	O
shock	O
.	O

While	O
hypotension	B-DIS
is	O
induced	O
largely	O
by	O
factors	O
other	O
than	O
low	O
cardiac	O
output	O
its	O
precise	O
cause	O
is	O
unknown	O
and	O
clinical	O
parameters	O
associated	O
with	O
hypotension	B-DIS
have	O
not	O
been	O
identified	O
previously	O
.	O

We	O
therefore	O
sought	O
to	O
identify	O
the	O
incidence	B-EPI
and	O
clinical	O
/	O
laboratory	O
correlates	O
of	B-DIS
early	O
hypotension	O
in	O
TTS	O
.	O

Methods	O
and	O
results	O
We	O
analysed	O
the	O
in	O
-	O
hospital	O
data	O
of	O
patients	O
recruited	O
to	O
the	B-LOC
South	I-LOC
Australian	I-LOC
TTS	I-LOC
Registry	I-LOC
.	O

Associations	O
between	O
the	O
development	O
of	O
hypotension	B-DIS
patient	O
demographics	O
severity	O
of	O
the	O
acute	O
TTS	O
attack	O
and	O
key	O
biochemical	O
markers	O
were	O
sought	O
.	O

One	O
hundred	O
thirteen	O
out	O
of	O
319	O
patients	O
35	B-STAT
%	I-STAT
were	O
hypotensive	B-DIS
median	O
systolic	O
blood	O
pressure	O
80	O
mmHg	O
during	O
their	O
index	O
hospitalization	O
.	O

Development	O
of	O
hypotension	B-DIS
preceded	O
all	O
in	O
-	B-DIS
hospital	O
deaths	O
n	O
=	O
8	O
.	O

On	O
univariate	O
analyses	O
patients	O
who	O
developed	O
hypotension	B-DIS
had	O
lower	O
left	O
ventricular	O
ejection	O
fraction	O
P	O
=	O
0.009	O
and	O
higher	O
plasma	O
N	O
-	O
terminal	O
pro	O
brain	O
natriuretic	O
peptide	O
and	O
troponin	O
-	O
T	O
concentrations	O
P	O
=	O
0.046	O
and	O
0.008	O
respectively	O
all	O
markers	O
of	O
severity	O
of	O
the	B-DIS
TTS	O
attack	O
;	O
hypotension	O
also	O
occurred	O
less	O
commonly	O
in	O
male	O
than	O
in	O
female	O
patients	O
P	O
=	O
0.014	O
.	O

On	O
multivariate	O
linear	O
regression	O
analysis	O
female	O
sex	O
and	O
lower	O
left	O
ventricular	O
ejection	O
fraction	O
were	O
independent	O
correlates	O
of	O
the	O
development	O
of	O
hypotension	B-DIS
P	O
=	O
0.009	O
and	O
0.010	O
respectively	O
.	O

Conclusions	O
Early	O
development	O
of	O
hypotension	B-DIS
is	O
very	O
common	O
in	O
TTS	O
and	O
its	O
presence	O
is	O
associated	O
with	O
a	O
substantial	O
risk	O
of	O
in	O
-	O
hospital	O
mortality	O
.	O

Hypotension	B-DIS
is	O
a	O
marker	O
of	O
severe	O
TTS	O
attacks	O
and	O
occurs	O
more	O
commonly	O
in	O
female	O
TTS	O
patients	O
.	O

Factor	O
X	O
deficiency	O
is	O
a	O
severe	O
inherited	O
coagulation	B-DIS
disorder	I-DIS
which	O
is	O
characterized	O
by	O
severe	O
systemic	B-DIS
bleeding	I-DIS
manifestations	O
in	O
affected	O
individuals	O
.	O

It	O
is	O
a	O
rare	O
disorder	O
with	O
a	O
frequency	O
of	O
around	O
11000000	O
in	O
the	O
general	O
population	O
.	O

We	O
present	O
the	O
case	O
of	O
an	O
infant	O
with	O
factor	O
X	O
deficiency	O
who	O
presented	O
with	O
complex	O
febrile	B-DIS
seizure	I-DIS
.	O

Although	O
febrile	B-DIS
seizures	I-DIS
are	O
very	O
common	O
in	O
children	O
a	O
closer	O
scrutiny	O
leads	O
to	O
neuroimaging	O
and	O
finding	O
of	O
intracranial	B-DIS
bleed	I-DIS
.	O

Hematologic	O
and	O
genetic	O
investigations	O
confirmed	O
the	O
diagnosis	O
.	O

A	O
high	O
index	O
of	O
suspicion	O
should	O
be	O
maintained	O
to	O
diagnose	O
uncommon	O
bleeding	B-DIS
disorders	I-DIS
in	O
children	O
.	O

Introduction	O
Primitive	O
neuroectodermal	B-DIS
tumors	I-DIS
PNET	I-DIS
form	O
a	O
group	O
of	O
tumors	B-DIS
defined	O
by	O
their	O
appearance	O
that	O
are	O
thought	O
to	O
develop	O
from	O
primitive	O
undifferentiated	O
nerve	O
cells	O
in	O
the	O
brain	O
.	O

They	O
are	O
rare	O
tumors	B-DIS
and	O
their	O
incidence	B-EPI
is	O
not	O
well	O
defined	O
.	O

Case	O
presentation	O
An	O
18	O
-	O
month	O
-	O
old	O
male	O
presenting	O
with	O
typical	O
Cushingoid	O
appearance	O
moon	B-DIS
face	O
central	O
obesity	O
hirsutism	O
and	O
growth	O
arrest	O
was	O
admitted	O
for	O
evaluation	O
of	O
endocrine	O
problems	O
.	O

Subsequent	O
laboratory	O
studies	O
revealed	O
markedly	O
elevated	O
adrenocorticotropic	O
ACTH	O
and	O
cortisol	O
levels	O
as	O
well	O
as	O
a	O
hypokalemic	O
metabolic	O
alkalosis	O
these	O
data	O
are	O
consistent	O
with	O
the	O
diagnosis	O
of	O
Cushing	B-DIS
's	I-DIS
disease	I-DIS
.	O

He	O
was	O
treated	O
with	O
metyrapone	O
to	O
control	O
hypercortisolemia	B-DIS
.	O

One	O
month	O
and	O
a	O
half	O
later	O
a	O
mass	O
was	O
detected	O
in	O
the	O
abdomen	O
by	O
ultrasonography	O
.	O

An	O
abdominal	O
Computed	O
tomography	O
confirmed	O
a	O
large	O
heterogeneous	O
retroperitoneal	B-DIS
mass	I-DIS
with	O
a	O
significant	O
amount	O
of	O
extension	O
into	O
surrounding	O
structures	O
which	O
was	O
removed	O
by	O
laparoscopic	O
abdominal	O
surgery	O
.	O

The	O
patient	O
's	O
symptoms	O
completely	O
resolved	O
and	O
the	O
ACTH	O
and	O
cortisol	O
levels	O
were	O
also	O
greatly	O
reduced	O
.	O

Histologically	O
the	O
tumor	B-DIS
tissue	O
consistent	O
with	O
the	O
diagnosis	O
of	O
the	O
retroperitoneal	O
primitive	O
neuroectodermal	B-DIS
tumor	I-DIS
which	O
was	O
confirmed	O
immunohistochemically	O
.	O

This	O
case	O
demonstrates	O
the	O
successful	O
diagnosis	O
and	O
treatment	O
of	O
a	O
rare	O
neoplasm	B-DIS
.	O

Conclusion	O
This	O
is	O
the	O
first	O
rare	O
case	O
with	O
ectopic	B-DIS
ACTH	I-DIS
syndrome	I-DIS
caused	O
by	O
the	O
peripheral	O
primitive	O
neuroectodermal	B-DIS
tumor	I-DIS
.	O

BACKGROUNDThe	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
incidence	B-EPI
of	O
fractures	B-DIS
in	O
infancy	O
overall	O
and	O
by	O
type	O
of	O
fracture	B-DIS
its	O
association	O
with	O
accidents	B-DIS
metabolic	O
bone	B-DIS
disease	I-DIS
risk	O
factors	O
and	O
abuse	O
diagnosis	O
.	O

METHODSThe	O
design	O
was	O
a	O
population	O
-	O
based	O
register	O
study	O
in	O
Sweden	B-LOC
.	O

Participants	O
Children	O
born	O
1997	O
-	O
2014	O
0	O
-	O
1	O
years	O
of	O
age	O
diagnosed	O
with	O
fracture	O
-	O
diagnosis	O
according	O
to	O
International	O
Classification	B-DIS
of	I-DIS
Diseases	O
ICD10	O
were	O
retrieved	O
from	O
the	O
National	O
Patient	O
Register	O
and	O
linked	O
to	O
the	O
Swedish	O
Medical	O
Birth	O
Register	O
and	B-DIS
the	O
Death	O
Cause	O
Register	O
.	O

Main	O
outcome	O
measures	O
were	O
fractures	B-DIS
of	O
the	O
skull	O
long	O
bone	O
clavicle	O
and	O
ribs	O
categorized	O
by	O
age	O
younger	O
or	O
older	O
than	O
6	O
months	O
and	O
accident	O
or	O
not	O
.	O

FINDINGSThe	O
incidence	B-EPI
of	O
fractures	B-DIS
during	O
infancy	O
was	O
251	O
per	O
100000	O
infants	O
n	O
=	O
4663	O
.	O

Major	O
fracture	B-DIS
localisations	O
were	O
long	O
bone	O
44Â·9	B-STAT
%	I-STAT
skull	O
31Â·7	B-STAT
%	I-STAT
and	O
clavicle	O
18Â·6	B-STAT
%	I-STAT
while	O
rib	O
fractures	B-DIS
were	O
few	B-STAT
1Â·4	I-STAT
%	I-STAT
.	O

Fall	B-DIS
accidents	I-DIS
were	O
reported	O
among	O
71Â·4	B-STAT
%	I-STAT
.	O

One	O
-	O
third	O
occurred	O
during	O
the	O
first	O
6	O
months	O
.	O

Metabolic	O
bone	B-DIS
disease	I-DIS
risk	O
factors	O
such	O
as	O
maternal	O
obesity	B-DIS
preterm	O
birth	B-DIS
vitamin	I-DIS
D	I-DIS
deficiency	I-DIS
rickets	I-DIS
and	O
calcium	O
metabolic	O
disturbances	O
had	O
increased	O
odds	O
of	O
fractures	B-DIS
of	O
long	O
bones	O
and	O
ribs	O
in	O
early	O
infancy	O
0	O
-	O
6	O
months	O
birth	O
32	O
-	O
36	O
weeks	O
and	O
long	O
bone	O
fracture	O
[	O
AOR	O
2Â·1395	B-STAT
%	I-STAT
CI	O
1Â·67	O
-	O
2Â·93	O
]	O
and	O
rib	O
fracture	O
[	O
AOR	O
4Â·2495	B-STAT
%	I-STAT
CI	O
1Â·40	O
-	O
12Â·8	O
]	O
.	O

Diagnosis	O
of	O
vitamin	O
D	O
deficiency	O
/	O
rickets	O
/	O
disorders	O
of	O
calcium	O
metabolism	O
had	O
increased	O
odds	O
of	O
long	O
bone	O
fracture	O
[	O
AOR	O
49Â·595	O
%	O
CI	O
18Â·3	O
-	O
134	O
]	O
and	O
rib	O
fracture	O
[	O
AOR	O
61795	B-STAT
%	I-STAT
CI	O
162	O
-	O
2506	O
]	O
.	O

Fractures	B-DIS
without	O
a	O
reported	O
accident	O
had	O
higher	O
odds	O
of	O
metabolic	O
risk	O
factors	O
than	O
those	O
with	O
reported	O
accidents	B-DIS
.	O

Abuse	O
diagnosis	O
was	O
registered	O
in	O
105	O
infants	O
with	O
overrepresentation	O
of	O
preterm	O
births	O
multiple	O
births	O
and	O
small	O
-	O
for	O
-	O
gestational	O
age	O
.	O

INTERPRETATIONMetabolic	O
bone	O
disease	O
risk	O
factors	O
are	O
strongly	O
associated	O
with	O
fractures	B-DIS
of	O
long	O
bone	O
and	O
ribs	O
in	O
early	O
infancy	O
.	O

Fracture	B-DIS
cases	O
with	O
abuse	O
diagnosis	O
had	O
a	O
metabolic	O
bone	O
risk	O
factor	O
profile	O
.	O

The	O
Dandy	B-DIS
-	O
Walker	O
Malformation	O
was	O
first	O
described	O
in	O
1914	O
by	O
Dandy	B-DIS
and	O
Blackfan	O
and	O
is	O
characterized	B-DIS
by	I-DIS
hypoplasia	I-DIS
of	I-DIS
the	I-DIS
vermis	I-DIS
pseudocystic	I-DIS
fourth	I-DIS
ventricle	I-DIS
upward	I-DIS
displacement	I-DIS
of	I-DIS
the	I-DIS
tentorium	I-DIS
torcular	I-DIS
and	I-DIS
lateral	I-DIS
sinuses	I-DIS
and	I-DIS
anteroposterior	I-DIS
enlargement	I-DIS
of	I-DIS
the	O
posterior	O
fossa	O
.	O

This	O
syndrome	O
commonly	O
manifests	O
as	O
hydrocephalus	B-DIS
in	O
children	O
though	O
rare	O
adult	O
cases	O
have	O
been	O
reported	O
.	O

The	O
literature	O
reveals	O
adult	O
symptomatology	O
including	O
brainstem	B-DIS
infarction	I-DIS
psychosis	I-DIS
and	O
neuromuscular	B-DIS
disease	I-DIS
.	O

Stroke	B-DIS
is	O
an	O
exceptionally	O
rare	O
presentation	O
of	O
this	O
malformation	O
with	O
only	O
one	O
ischemic	O
event	O
reported	O
in	O
the	O
literature	O
.	O

This	O
case	O
offers	O
a	O
rare	O
opportunity	O
for	O
diagnosis	O
in	O
an	O
adult	O
presenting	O
with	O
a	O
hemorrhagic	B-DIS
stroke	I-DIS
of	O
the	O
basal	O
ganglia	O
in	O
an	O
otherwise	O
asymptomatic	O
young	O
adult	O
male	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
a	O
hemorrhagic	B-DIS
stroke	I-DIS
in	O
an	O
adult	O
patient	O
with	O
Dandy	B-DIS
-	I-DIS
Walker	O
Malformation	O
.	O

The	O
Bernard	B-DIS
-	I-DIS
Soulier	O
syndrome	O
BSS	O
is	O
a	O
rare	O
disease	O
with	B-EPI
a	O
prevalence	B-STAT
of	O
1/1000000	O
;	O
it	O
is	O
characterized	B-DIS
by	O
macrothrombocytopenia	O
.	O

BSS	O
develops	O
as	O
a	O
result	O
of	O
a	O
defect	O
in	O
the	O
glycoprotein	O
GPIb	O
-	O
IX	O
-	O
V	O
complex	O
on	O
the	O
platelet	O
surface	O
.	O

In	O
this	O
article	O
we	O
present	O
a	O
pediatric	O
patient	O
with	O
the	O
novel	O
mutation	O
that	O
has	O
been	O
identified	O
for	O
the	O
first	O
time	O
in	O
BSS	O
.	O

A	O
13	O
-	O
month	O
-	O
old	O
male	O
patient	O
was	B-DIS
admitted	O
with	O
severe	O
thrombocytopenia	O
unresponsive	O
to	O
intravenous	O
immunoglobulin	O
in	O
the	O
neonatal	B-DIS
period	I-DIS
and	O
recurrent	O
mucocutaneous	O
bleeding	O
which	O
initiated	O
at	O
5	O
months	O
of	O
age	O
.	O

glycoprotein	O
GP	O
IX	O
CD42a	O
expression	O
was	O
normal	O
as	O
per	O
flow	O
cytometry	O
results	O
.	O

Genetic	O
analysis	O
revealed	O
a	O
homozygous	O
c.24	B-DIS
A	I-DIS
p.	O
Cys81	O
p.	O
C81	O
mutation	O
.	O

This	O
novel	O
mutation	O
identified	O
by	O
us	O
presents	O
with	O
severe	O
thrombocytopenia	B-DIS
and	O
normal	O
GPIX	O
CD42a	O
expression	O
and	O
is	O
mistaken	O
for	O
immune	O
thrombocytopenia	B-DIS
in	O
the	O
neonatal	O
period	O
.	O

This	O
mutation	O
creates	O
an	O
early	O
stop	O
codon	O
and	O
possibly	O
leads	O
to	O
loss	O
of	O
function	O
of	O
the	O
receptor	O
.	O

Objective	O
Non	O
-	O
operative	O
management	B-DIS
of	I-DIS
blunt	I-DIS
splenic	O
injury	O
in	O
adults	O
has	O
been	O
applied	O
increasingly	O
at	O
the	O
end	O
of	O
the	O
last	O
century	O
.	O

Therefore	O
the	O
lifelong	O
risk	O
of	O
overwhelming	O
post	O
-	O
splenectomy	O
infection	O
has	O
been	O
the	O
major	O
impetus	O
for	O
preservation	O
of	O
the	O
spleen	O
.	O

However	O
the	O
prevalence	B-EPI
of	O
posttraumatic	B-DIS
infection	I-DIS
after	O
splenectomy	O
in	O
contrast	O
to	O
a	O
conservative	O
management	O
is	O
still	O
unknown	O
.	O

Objective	O
was	O
to	O
determine	O
if	O
splenectomy	O
is	O
an	O
independent	O
risk	O
factor	O
for	O
the	O
development	O
of	O
posttraumatic	B-DIS
sepsis	I-DIS
and	O
multi	B-DIS
-	I-DIS
organ	O
failure	O
.	O

Methods	O
13433	O
patients	O
from	O
113	O
hospitals	O
were	O
prospective	O
collected	O
from	O
1993	O
to	O
2005	O
.	O

Patients	O
with	O
an	O
injury	O
severity	O
scor	O
16	O
no	O
isolated	O
head	B-DIS
injury	I-DIS
primary	O
admission	O
to	O
a	O
trauma	B-DIS
center	O
and	O
splenic	B-DIS
injury	I-DIS
were	O
included	O
.	O

Data	O
were	O
allocated	O
according	O
to	O
the	O
operative	O
management	O
into	O
2	O
groups	O
splenectomy	O
I	O
and	O
conservative	O
managed	O
patients	O
II	O
.	O

Results	O
From	O
1630	O
patients	O
with	O
splenic	B-DIS
injury	I-DIS
758	O
patients	O
undergoing	O
splenectomy	O
compared	O
with	O
872	O
non	O
-	O
splenectomized	O
patients	O
.	O

9618.3	B-STAT
%	I-STAT
of	O
the	O
patients	O
with	O
splenectomy	O
and	O
10218.5	B-STAT
%	I-STAT
without	O
splenectomy	O
had	O
apparent	O
infection	B-DIS
after	O
operation	O
.	O

Additionally	O
there	O
was	O
no	O
difference	O
in	O
mortality	O
24.8	B-STAT
%	I-STAT
versus	O
22.2	B-STAT
%	I-STAT
in	O
both	O
groups	O
.	O

After	O
massive	O
transfusion	O
of	O
red	O
blood	O
cells	O
10	O
non	O
-	O
splenectomy	O
patients	O
showed	O
a	O
significant	O
increase	B-DIS
of	I-DIS
multi	O
-	O
organ	O
failure	O
46	B-STAT
%	I-STAT
vs.	B-DIS
40	B-STAT
%	I-STAT
and	O
sepsis	O
38	B-STAT
%	I-STAT
vs.	O
25	B-STAT
%	I-STAT
.	O

Conclusions	O
Non	O
-	O
operative	O
management	O
leads	O
to	B-DIS
lower	I-DIS
systemic	O
infection	O
rates	O
and	O
mortality	O
in	O
adult	O
patients	O
with	B-DIS
moderate	I-DIS
blunt	I-DIS
splenic	I-DIS
injury	I-DIS
grade	I-DIS
1	I-DIS
-	O
3	O
and	O
should	O
therefore	O
be	O
advocated	O
.	O

Patients	O
with	O
grade	O
4	O
and	O
5	O
injury	O
patients	O
with	O
massive	O
transfusion	O
of	O
red	O
blood	O
cells	O
and	O
unstable	O
patients	O
should	O
be	O
managed	O
operatively	O
.	O

This	O
study	O
aims	O
to	O
assess	O
the	O
prevalence	B-EPI
distribution	O
and	O
etiological	O
profile	O
of	O
intestinal	O
parasitism	O
in	O
children	O
living	O
in	O
periurban	O
areas	O
in	O
Cachoeiras	O
de	O
Macacu	O
Rio	O
de	O
Janeiro	O
Brazil	B-LOC
.	O

A	O
community	O
-	O
based	O
cross	O
-	O
sectional	O
survey	O
n	O
=	O
479	O
was	O
carried	O
out	O
.	O

Prevalence	B-EPI
of	O
infection	B-DIS
with	O
G.	O
duodenalis	O
and	O
E.	O
histolytica	O
/	O
E.	O
dispar	O
was	O
8.6	B-STAT
%	I-STAT
n	O
=	O
41	O
and	O
13.4	B-STAT
%	I-STAT
n	O
=	O
64	O
respectively	O
.	O

Infection	B-DIS
with	O
G.	O
duodenalis	O
was	O
significantly	O
more	O
frequent	O
among	O
children	O
living	O
in	O
poor	O
families	O
24/187	B-STAT
12.8	I-STAT
%	I-STAT
vs.	O
16/272	B-STAT
5.9	I-STAT
%	I-STAT
;	O
prevalence	B-EPI
ratio	O
PR	O
=	O
2.18	O
;	O
95	B-STAT
%	I-STAT
confidence	O
interval	O
CI	O
=	O
1.19	O
-	O
3.99	O
;	O
p	O
=	O
0.011	O
.	O

This	O
difference	O
was	O
also	O
significant	O
for	O
infection	B-DIS
with	O
any	O
pathogenic	O
parasite	O
43/18723	B-STAT
%	I-STAT
vs.	O
40/272	B-STAT
14/7	B-STAT
%	I-STAT
;	O
PR	O
=	O
1.56	O
;	O
95	B-STAT
%	I-STAT
CI	O
=	O
1.06	O
-	O
2.30	O
;	O
p	O
=	O
0.026	O
.	O

In	O
addition	O
people	O
residing	O
in	O
houses	O
with	O
more	O
than	O
four	O
inhabitants	O
showed	O
significantly	O
higher	O
positivity	O
for	O
infections	B-DIS
with	O
G.	O
duodenalis	O
and	O
with	O
E.	B-DIS
histolytica	I-DIS
/	I-DIS
E.	I-DIS
dispar	I-DIS
22/138	B-STAT
15.9	B-STAT
%	I-STAT
vs.	O
16/311	B-STAT
5.1	I-STAT
%	I-STAT
;	O
PR	O
=	O
3.09	O
;	O
95	B-STAT
%	I-STAT
CI	O
=	O
1.68	O
-	O
5.71	O
;	O
p	O
<	O
0.001	O
for	O
G.	O
duodenalis	O
and	O
32/138	B-STAT
23.2	I-STAT
%	I-STAT
vs.	O
30/311	B-STAT
9.6	I-STAT
%	I-STAT
;	O
PR	O
=	O
2.40	O
;	O
95	B-STAT
%	I-STAT
CI	O
=	O
1.52	O
-	O
3.79	O
;	O
p	O
<	O
0.001	O
for	O
E.	O
histolytica	O
/	O
E.	O
dispar	O
.	O

Laboratory	O
diagnosis	O
of	O
protozoan	O
enteric	O
infections	B-DIS
and	O
effective	O
drugs	O
for	O
their	O
treatment	O
are	O
unmet	O
goals	O
in	O
the	O
primary	O
health	O
care	O
system	O
.	O

Therefore	O
giardiasis	B-DIS
and	O
amebiasis	B-DIS
are	O
neglected	O
conditions	O
.	O

Objective	O
/	O
background	O
Knowledge	B-DIS
of	I-DIS
idiopathic	O
hypersomnia	O
symptomatology	O
derives	O
from	O
clinical	O
case	O
series	O
.	O

Web	O
-	O
based	O
registries	O
provide	O
complementary	O
information	O
by	O
allowing	O
larger	O
sample	O
sizes	O
with	O
greater	O
geographic	O
and	O
social	O
diversity	O
.	O

Patients	O
/	O
methods	O
Data	O
were	O
obtained	O
from	B-DIS
the	O
Hypersomnia	O
Foundation	O
's	O
online	O
registry	O
.	O

Common	O
clinical	O
features	O
of	O
idiopathic	B-DIS
hypersomnia	I-DIS
and	O
other	O
central	O
disorders	O
of	O
hypersomnolence	B-DIS
were	O
queried	O
for	O
the	O
last	O
thirty	O
days	O
and	O
when	O
symptoms	O
were	O
most	O
severe	O
.	O

Symptoms	O
were	O
compared	O
between	O
idiopathic	B-DIS
hypersomnia	I-DIS
participants	O
with	O
and	O
without	O
long	O
sleep	O
durations	O
and	O
between	O
participants	O
with	O
idiopathic	B-DIS
hypersomnia	I-DIS
and	O
those	O
with	O
either	O
form	O
of	O
narcolepsy	B-DIS
.	O

Frequency	O
of	O
medication	O
use	O
and	O
residual	O
symptoms	O
on	O
medication	O
were	O
evaluated	O
.	O

Results	O
Five	O
-	O
hundred	O
sixty	O
-	O
three	O
registry	O
respondents	B-DIS
were	I-DIS
included	O
with	O
idiopathic	O
hypersomnia	O
n	O
=	O
468	O
narcolepsy	O
type	O
2	O
n	B-DIS
=	O
44	B-STAT
and	I-STAT
narcolepsy	I-STAT
type	I-STAT
1	O
n	O
=	O
51	O
.	O

`	O
`	O
Brain	O
fog	O
`	O
`	O
poor	O
memory	O
and	O
sleep	O
drunkenness	O
were	O
all	O
present	O
in	O
most	O
idiopathic	B-DIS
hypersomnia	I-DIS
respondents	O
with	O
brain	O
fog	O
and	O
sleep	O
drunkenness	O
more	O
commonly	O
endorsed	O
by	O
those	O
with	O
long	O
sleep	O
durations	O
.	O

Eighty	B-STAT
-	I-STAT
two	I-STAT
percent	I-STAT
of	O
participants	B-DIS
with	I-DIS
idiopathic	O
hypersomnia	O
were	O
currently	O
treated	O
with	O
medication	O
most	O
commonly	O
traditional	O
psychostimulants	O
such	O
as	O
amphetamine	O
salts	O
.	O

Among	O
treated	O
patients	O
symptoms	O
improved	O
while	O
on	O
medication	O
but	O
substantial	O
residual	O
hypersomnia	B-DIS
symptoms	O
remained	O
.	O

Participants	O
with	O
narcolepsy	B-DIS
type	O
1	O
were	O
more	O
likely	O
than	O
those	O
with	O
idiopathic	B-DIS
hypersomnia	I-DIS
to	O
endorse	O
intentional	B-DIS
and	I-DIS
unintentional	I-DIS
daytime	I-DIS
naps	I-DIS
and	O
automatic	O
behaviors	O
.	O

Conclusions	O
Symptoms	O
of	O
idiopathic	B-DIS
hypersomnia	I-DIS
extend	O
well	O
beyond	O
excessive	O
daytime	B-DIS
sleepiness	I-DIS
and	O
these	O
symptoms	O
frequently	O
persist	O
despite	O
treatment	O
.	O

These	O
findings	O
highlight	O
the	O
importance	O
of	O
online	O
registries	O
in	O
identifying	O
gaps	O
in	O
the	O
use	O
and	O
effectiveness	O
of	O
current	O
treatments	O
.	O

Background	O
Many	O
public	O
health	O
surveillance	O
programs	O
utilize	O
hospital	O
discharge	O
data	O
in	O
their	O
estimation	O
of	O
disease	O
prevalence	B-EPI
.	O

These	O
databases	O
commonly	O
use	O
the	O
International	O
Classification	O
of	O
Diseases	O
ICD	O
coding	O
scheme	O
which	O
transitioned	O
from	O
the	O
ICD-9	O
clinical	O
modification	O
ICD-9	B-LOC
-	I-LOC
CM	I-LOC
to	O
ICD-10	O
-	O
CM	O
on	O
October	O
12015	O
.	O

This	O
study	O
examined	O
this	O
transition	O
's	O
impact	O
on	O
the	O
prevalence	B-EPI
of	O
major	O
birth	B-DIS
defects	I-DIS
among	O
infant	O
hospitalizations	O
.	O

Methods	O
Using	O
data	O
from	O
the	O
Agency	O
for	O
Health	O
Care	O
Research	O
and	O
Quality	O
-	O
sponsored	O
National	O
Inpatient	O
Sample	O
hospitalizations	O
during	O
the	O
first	O
year	O
of	O
life	O
with	O
a	O
discharge	O
date	O
between	O
January	O
12012	O
and	O
December	O
312016	O
were	O
used	O
to	O
estimate	O
the	O
monthly	O
national	B-EPI
hospital	O
prevalence	O
of	B-DIS
46	I-DIS
birth	O
defects	O
for	O
the	O
ICD-9	O
-	O
CM	O
and	O
ICD-10	O
-	O
CM	O
timeframes	O
separately	O
.	O

Survey	O
-	O
weighted	O
Poisson	O
regression	O
was	O
used	O
to	O
estimate	O
95	B-STAT
%	I-STAT
confidence	O
intervals	O
for	O
each	B-EPI
hospital	O
prevalence	O
.	O

Interrupted	O
time	O
series	O
framework	O
and	O
corresponding	O
segmented	O
regression	O
was	O
used	O
to	O
estimate	O
the	O
immediate	O
change	O
in	O
monthly	O
hospital	O
prevalence	B-EPI
following	O
the	O
ICD-9	O
-	O
CM	O
to	O
ICD-10	O
-	O
CM	O
transition	O
.	O

Results	O
Between	O
2012	O
and	O
2016	O
over	O
21	O
million	O
inpatient	O
hospitalizations	O
occurred	O
during	O
the	O
first	O
year	O
of	O
life	O
.	O

Among	O
the	O
46	O
defects	O
studied	O
statistically	O
significant	O
decreases	O
in	O
the	O
immediate	O
hospital	O
prevalence	B-EPI
of	O
five	O
defects	O
and	O
significant	O
increases	O
in	O
the	O
immediate	O
hospital	O
prevalence	B-EPI
of	O
eight	O
defects	O
were	O
observed	O
after	O
the	O
ICD-10	O
-	O
CM	O
transition	O
.	O

Conclusions	O
Changes	O
in	O
prevalence	B-EPI
were	O
expected	O
based	O
on	O
changes	O
to	O
ICD-10	O
-	O
CM	O
.	O

Observed	O
changes	O
for	O
some	O
conditions	O
may	O
result	O
from	O
variation	O
in	O
monthly	O
hospital	O
prevalence	B-EPI
or	O
initial	O
unfamiliarity	O
of	O
coders	O
with	O
ICD-10	O
-	O
CM	O
.	O

These	O
findings	O
may	O
help	O
birth	B-DIS
defects	I-DIS
surveillance	O
programs	O
evaluate	O
and	O
interpret	O
changes	O
in	O
their	O
data	O
related	O
to	O
the	O
ICD-10	O
-	O
CM	O
transition	O
.	O

Background	O
May	B-DIS
-	I-DIS
Hegglin	O
anomaly	O
is	O
an	O
autosomal	O
dominant	O
inherited	O
condition	O
characterized	B-DIS
by	O
thrombocytopenia	O
giant	O
platelets	O
and	O
Dohle	O
-	O
like	O
bodies	O
.	O

Incidence	B-EPI
is	O
unknown	O
and	O
affected	O
individuals	O
can	O
show	O
from	O
mild	O
to	O
moderate	O
-	O
severe	O
haemorrhagic	O
symptoms	O
.	O

The	O
cyst	O
of	O
cavum	O
veli	O
interpositi	O
a	O
virtual	O
space	O
filled	O
with	O
fluid	O
within	O
the	O
third	O
ventricle	O
is	O
rarely	O
reported	O
in	O
the	O
foetal	O
period	O
.	O

Furthermore	O
it	O
is	O
unclear	O
whether	O
isolated	O
cavum	O
veli	B-DIS
interpositi	I-DIS
cysts	I-DIS
are	O
a	O
normal	O
variant	O
or	O
developmental	O
malformations	O
.	O

The	O
simultaneous	O
presence	O
of	O
these	O
two	O
anomalies	B-DIS
was	O
never	O
described	O
.	O

Case	O
presentation	O
We	O
describe	O
a	O
very	O
rare	O
case	O
of	O
a	O
twin	O
monochorionic	O
pregnancy	O
in	O
a	O
woman	O
with	O
the	O
May	B-DIS
-	I-DIS
Hegglin	O
anomaly	O
whose	O
foetuses	O
carried	B-DIS
cavum	I-DIS
veli	I-DIS
interpositi	O
cysts	O
.	O

Since	O
childhood	O
our	O
patient	O
had	O
shown	O
macro	B-DIS
-	I-DIS
thrombocytopenia	O
deafness	B-DIS
and	I-DIS
bleeding	O
epistaxis	B-DIS
and	O
menorrhagia	O
but	O
she	O
was	O
misdiagnosed	O
until	O
the	O
age	O
of	O
30	O
years	O
when	O
our	O
Centre	O
identified	O
a	O
de	O
novo	O
allelic	O
variant	O
in	O
the	O
gene	O
MYH9	O
coding	O
for	O
the	O
non	O
-	O
muscle	O
myosin	O
heavy	O
chain	O
IIa	O
.	O

Our	O
patient	O
bled	O
neither	O
during	O
the	O
pregnancy	O
nor	O
in	O
the	O
peripartum	O
period	O
.	O

Children	O
are	O
now	O
eight	O
-	O
months	O
-	O
old	O
and	O
have	O
never	O
bled	O
although	O
both	O
inherited	O
the	O
MYH9	B-DIS
variant	O
and	O
have	O
thrombocytopenia	O
with	O
giant	O
platelets	O
.	O

Furthermore	O
none	O
of	O
them	O
developed	O
psychomotor	B-DIS
disorders	I-DIS
.	O

Conclusions	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
this	O
is	O
the	O
sixth	O
case	O
of	O
twin	O
pregnancy	O
in	O
a	O
woman	O
carrying	O
May	B-DIS
-	I-DIS
Hegglin	O
anomaly	O
and	O
the	O
first	O
one	B-DIS
with	I-DIS
cavum	I-DIS
veli	I-DIS
interpositi	O
cysts	O
in	O
the	O
neonates	O
.	O

We	O
speculate	O
that	O
MYH9	O
could	O
have	O
at	O
least	O
in	O
part	O
played	O
a	O
role	O
in	O
the	O
development	O
of	O
both	O
conditions	O
as	O
this	O
gene	O
has	O
a	O
pleiotropic	O
effect	O
.	O

Pyridoxine	B-DIS
-	I-DIS
dependent	O
epilepsy	O
PDE	O
is	O
a	O
recessive	O
genetic	O
disease	O
characterized	B-DIS
by	I-DIS
epileptic	O
encephalopathy	O
with	O
therapeutic	O
response	O
to	O
pharmacological	O
doses	O
of	O
pyridoxine	O
and	O
resistance	O
to	O
anti	O
-	O
epileptic	O
treatments	O
.	O

The	O
recent	O
discovery	O
in	O
2006	O
of	O
the	O
genetic	O
defect	O
antiquitin	O
ALDH7A1	B-DIS
OMIM	I-DIS
#	O
266100	O
has	O
helped	O
to	O
understand	O
the	O
underlying	O
mechanism	O
which	O
is	O
the	O
accumulation	O
of	O
neurotoxic	B-DIS
intermediates	O
in	O
the	O
lysine	O
catabolic	O
pathway	O
.	O

The	O
goal	O
of	O
the	O
new	O
therapeutic	O
approach	O
termed	O
triple	O
therapy	O
TT	O
pyridoxine	O
lysine	O
-	O
restricted	O
diet	O
and	O
arginine	O
supplementation	O
is	O
to	B-DIS
improve	O
epilepsy	O
control	O
and	O
neurocognitive	O
development	O
in	O
patients	O
with	O
PDE	O
.	O

We	O
present	O
the	O
3	O
-	O
year	O
treatment	O
outcome	O
for	O
a	O
child	O
with	O
PDE	O
on	O
pyridoxine	O
treatment	O
started	O
at	O
age	O
5	O
months	O
lysine	O
-	O
restricted	O
diet	O
started	O
at	O
age	O
17	O
months	O
and	O
arginine	O
supplementation	O
therapy	O
started	O
at	O
age	O
19	O
months	O
.	O

The	O
TT	O
was	O
well	O
-	O
tolerated	O
with	O
good	O
compliance	O
.	O

No	O
adverse	O
events	O
were	O
reported	O
.	O

We	O
observed	O
a	O
neurodevelopmental	O
improvement	O
significantly	O
fewer	O
seizures	B-DIS
and	O
a	O
reduction	O
of	O
pipecolic	O
acid	O
PA	O
as	O
a	O
biomarker	O
of	O
the	O
illness	O
.	O

Our	O
results	O
show	O
an	O
improving	O
clinical	O
evolution	O
supporting	O
and	O
extending	O
previous	O
studies	O
reporting	O
efficacy	O
of	O
TT	O
.	O

Objective	O
The	O
Global	O
FKRP	O
Registry	O
is	O
a	O
database	O
for	O
individuals	O
with	O
conditions	O
caused	O
by	O
mutations	O
in	O
the	O
Fukutin	O
-	O
Related	O
Protein	O
FKRP	O
gene	B-DIS
limb	I-DIS
girdle	I-DIS
muscular	O
dystrophy	O
R9	O
LGMDR9	B-DIS
formerly	O
LGMD2I	B-DIS
and	I-DIS
congenital	I-DIS
muscular	I-DIS
dystrophies	I-DIS
MDC1C	I-DIS
Muscle	O
-	B-DIS
Eye	I-DIS
-	O
Brain	O
Disease	O
and	O
Walker	O
-	O
Warburg	O
Syndrome	O
.	O

The	O
registry	O
seeks	O
to	O
further	O
understand	O
the	O
natural	O
history	O
and	O
prevalence	B-EPI
of	O
FKRP	B-DIS
-	O
related	O
conditions	O
;	O
aid	O
the	O
rapid	O
identification	O
of	O
eligible	O
patients	O
for	O
clinical	O
studies	O
;	O
and	O
provide	O
a	O
source	O
of	O
information	O
to	O
clinical	O
and	O
academic	O
communities	O
.	O

Methods	O
Registration	O
is	O
patient	O
-	O
initiated	O
through	O
a	O
secure	O
online	O
portal	O
.	O

Data	O
reported	O
by	O
both	O
patients	O
and	O
their	O
clinicians	O
include	O
age	O
of	O
onset	O
presenting	O
symptoms	O
family	O
history	O
motor	O
function	O
and	O
muscle	O
strength	O
respiratory	O
and	O
cardiac	O
function	O
medication	O
quality	O
of	O
life	O
and	O
pain	B-DIS
.	O

Results	O
Of	O
663	O
registered	O
participants	O
305	O
were	O
genetically	O
confirmed	O
LGMDR9	O
patients	O
from	O
23	O
countries	O
.	O

A	O
majority	O
of	O
LGMDR9	O
patients	O
carried	O
the	O
common	O
mutation	O
c.826	O
A	O
on	O
one	O
or	O
both	O
alleles	O
;	O
67.9	B-STAT
%	I-STAT
were	O
homozygous	O
and	O
28.5	B-STAT
%	I-STAT
were	O
compound	O
heterozygous	O
for	O
this	O
mutation	O
.	O

The	O
mean	O
ages	O
of	O
symptom	O
onset	O
and	O
disease	O
diagnosis	O
were	O
higher	O
in	O
individuals	O
homozygous	O
for	O
c.826	O
A	O
compared	O
with	O
individuals	O
heterozygous	O
for	O
c.826	O
A	O
.	O

This	O
divergence	O
was	O
replicated	O
in	O
ages	O
of	O
loss	O
of	O
running	O
ability	O
wheelchair	O
-	O
dependence	O
and	O
ventilation	O
assistance	O
;	O
consistent	O
with	O
the	O
milder	O
phenotype	O
associated	O
with	O
individuals	O
homozygous	O
for	O
c.826	O
A	O
.	O

In	O
LGMDR9	O
patients	O
75.1	B-STAT
%	I-STAT
were	O
currently	O
ambulant	O
and	O
24.6	B-STAT
%	I-STAT
nonambulant	B-DIS
unreported	O
in	O
0.3	B-STAT
%	I-STAT
.	O

Cardiac	B-DIS
impairment	I-DIS
was	O
reported	O
in	O
23.2	B-STAT
%	I-STAT
30/129	B-STAT
.	O

Interpretation	O
The	O
Global	O
FKRP	O
Registry	O
enables	O
the	O
collection	O
of	O
patient	O
natural	O
history	O
data	O
which	O
informs	O
academics	O
healthcare	O
professionals	O
and	O
industry	O
.	O

It	O
represents	O
a	O
trial	O
-	O
ready	O
cohort	O
of	O
individuals	O
and	O
is	O
centrally	O
placed	O
to	O
facilitate	O
recruitment	O
to	O
clinical	O
studies	O
.	O

Herpes	B-DIS
zoster	I-DIS
oticus	I-DIS
also	O
known	O
as	O
Ramsay	O
Hunt	O
syndrome	O
is	O
a	O
rare	O
complication	O
of	O
herpes	B-DIS
zoster	I-DIS
in	O
which	O
reactivation	O
of	O
latent	O
varicella	O
zoster	B-DIS
virus	I-DIS
infection	I-DIS
in	O
the	O
geniculate	O
ganglion	O
causes	O
otalgia	B-DIS
auricular	O
vesicles	O
and	O
peripheral	B-DIS
facial	I-DIS
paralysis	I-DIS
.	O

Ramsay	O
Hunt	O
syndrome	O
is	O
rare	O
in	O
children	O
and	O
affects	O
both	O
sexes	O
equally	O
.	O

Incidence	B-EPI
and	O
clinical	O
severity	O
increases	O
when	O
host	O
immunity	O
is	O
compromised	O
.	O

Because	O
these	O
symptoms	O
do	O
not	O
always	O
present	O
at	O
the	O
onset	O
this	O
syndrome	O
can	O
be	O
misdiagnosed	O
.	O

Although	O
secondary	O
to	O
Bell	O
's	O
palsy	B-DIS
in	O
terms	O
of	O
the	O
cause	O
of	O
acute	O
atraumatic	O
peripheral	B-DIS
facial	I-DIS
paralysis	I-DIS
Ramsay	O
Hunt	O
syndrome	O
with	O
incidence	B-EPI
ranged	O
from	O
0.3	B-STAT
to	I-STAT
18	I-STAT
%	I-STAT
has	O
a	O
worse	O
prognosis	O
.	O

Herpes	B-DIS
zoster	I-DIS
oticus	I-DIS
accounts	O
for	O
about	B-STAT
12	I-STAT
%	I-STAT
cases	O
of	O
facial	O
palsy	B-DIS
which	O
is	O
usually	O
unilateral	O
and	O
complete	O
and	O
full	O
recovery	O
occurs	O
in	O
only	B-STAT
about	I-STAT
20	I-STAT
%	I-STAT
of	O
untreated	O
patients	O
.	O

The	O
most	O
advisable	O
method	O
to	O
treat	O
Ramsay	O
Hunt	O
syndrome	O
is	O
the	O
combination	O
therapy	O
with	O
acyclovir	O
and	O
prednisone	O
but	O
still	O
not	O
promising	O
and	O
several	O
prerequisites	O
are	O
required	O
for	O
better	O
results	O
.	O

We	O
present	O
a	O
case	O
of	O
32	O
-	O
year	O
-	O
old	O
man	O
suffering	O
from	O
Ramsay	O
Hunt	O
syndrome	O
with	B-DIS
grade	O
V	O
facial	O
palsy	O
treated	O
effectively	O
with	O
rehabilitation	O
program	O
after	O
the	O
termination	O
of	O
the	O
combination	O
therapy	O
of	O
acyclovir	O
and	O
prednisone	O
.	O

Since	O
1984	O
we	O
have	O
diagnosed	O
at	O
the	O
La	O
Paz	O
University	O
Hospital	O
Madrid	O
Spain	B-LOC
41	O
patients	O
with	O
hypoxanthine	O
phosphoribosyltransferase	O
HPRT	O
activity	O
deficiency	O
.	O

These	O
patients	O
belonged	O
to	O
34	O
families	O
.	O

We	O
have	O
also	O
performed	O
molecular	O
and	O
enzymatic	O
diagnosis	O
in	O
three	O
patients	O
from	O
India	B-LOC
one	O
from	O
Belgium	B-LOC
and	O
three	O
from	O
Colombia	B-LOC
.	O

About	O
1/3	B-STAT
of	O
these	O
patients	O
were	O
followed	O
up	O
at	O
La	O
Paz	O
University	O
Hospital	O
at	O
least	O
every	O
year	O
.	O

This	O
fact	O
has	O
allowed	O
us	O
to	O
examine	O
the	O
complete	O
spectrum	O
of	O
HPRT	O
deficiency	O
as	O
well	O
as	O
to	O
perform	O
a	O
more	O
accurate	O
diagnosis	O
and	O
treatment	O
.	O

In	O
the	O
present	O
review	O
we	O
also	O
summarized	O
our	O
studies	O
on	O
the	O
basis	O
of	O
physiopathology	O
of	O
the	O
neurological	O
manifestation	O
of	O
Lesch	O
Nyhan	B-DIS
disease	I-DIS
LND	O
.	O

Introduction	O
'	O
Chronic	O
inflammatory	B-DIS
immune	I-DIS
-	I-DIS
related	I-DIS
skin	O
disease	O
'	O
ISDs	O
is	O
an	O
umbrella	O
term	O
grouping	O
together	O
heterogeneous	O
entities	O
characterized	B-DIS
by	I-DIS
chronic	O
inflammation	O
potentially	O
involving	O
the	O
whole	O
skin	O
.	O

We	O
are	O
not	O
covering	O
all	O
ISDs	O
in	O
this	O
review	O
but	O
take	O
a	O
few	O
as	O
the	O
most	O
representative	O
including	O
nonbullous	B-DIS
and	O
bullous	B-DIS
diseases	I-DIS
.	O

The	O
question	O
we	O
are	O
aiming	O
to	O
address	O
can	O
be	O
summarized	O
as	O
follows	O
'	O
despite	O
the	O
differences	O
is	O
it	O
possible	O
to	O
define	O
some	O
unifying	O
epidemiologic	O
characteristics	O
and	O
shared	O
progression	O
pathways	O
which	O
can	O
guide	O
the	O
organization	O
of	O
healthcare	O
?	O
'	O

Areas	O
covered	O
This	O
review	O
covers	O
incidence	B-EPI
prevalence	B-EPI
risk	O
factors	O
and	O
prognosis	O
of	O
psoriasis	B-DIS
atopic	O
dermatitis	B-DIS
AD	I-DIS
pemphigus	I-DIS
and	O
pemphigoid	B-DIS
.	O

Medline	O
Embase	O
and	O
the	O
Cochrane	O
Library	O
were	O
searched	O
for	O
papers	O
published	O
between	O
January	O
2005	O
and	O
December	O
2019	O
.	O

Expert	O
opinion	O
ISDs	O
epidemiology	O
varies	O
according	O
to	O
the	O
ISD	O
type	O
age	O
sex	O
climate	O
and	O
sociodemographic	O
variables	O
.	O

AD	O
and	O
psoriasis	B-DIS
pose	O
a	O
considerable	O
public	O
health	O
burden	O
owing	O
to	O
their	O
high	O
prevalence	B-EPI
worldwide	O
and	O
morbidity	O
.	O

Their	O
secular	O
trend	O
of	O
increasing	O
incidence	B-EPI
points	O
to	O
a	O
role	O
for	O
environmental	O
factors	O
and	O
gene	O
-	O
environment	O
interactions	O
.	O

Bullous	B-DIS
diseases	I-DIS
are	O
much	O
rarer	O
with	O
limited	O
data	O
available	O
.	O

Worldwide	O
the	O
leading	O
cause	O
of	O
skin	B-DIS
disease	I-DIS
disability	O
-	O
adjusted	O
life	O
-	O
years	O
DALYs	O
is	O
attributable	O
to	O
AD	O
.	O

Future	O
research	O
should	O
focus	O
on	O
risk	O
factors	O
and	O
prevention	O
at	O
the	O
global	O
level	O
.	O

Background	B-DIS
Q	I-DIS
fever	I-DIS
osteoarticular	I-DIS
infections	I-DIS
are	O
a	O
rare	O
complication	O
of	O
the	O
chronic	O
form	O
of	O
Q	B-DIS
fever	I-DIS
.	O

We	O
aimed	O
to	O
characterize	O
chronic	B-DIS
Q	I-DIS
fever	I-DIS
vertebral	I-DIS
osteomyelitis	I-DIS
through	O
our	O
experience	O
and	O
a	O
review	O
of	O
the	O
literature	O
.	O

Methods	O
Four	O
adult	O
patients	O
with	O
Q	B-DIS
fever	I-DIS
vertebral	I-DIS
osteomyelitis	I-DIS
diagnosed	O
in	O
a	O
tertiary	O
hospital	O
in	O
northern	O
Israel	B-LOC
between	O
2016	O
to	O
2020	O
are	O
described	O
.	O

In	O
addition	O
a	O
30	O
years	O
'	O
literature	O
review	O
of	O
Q	B-DIS
fever	I-DIS
vertebral	I-DIS
osteomyelitis	I-DIS
characterizing	O
predisposing	O
factors	O
clinical	O
presentation	O
course	O
of	O
disease	O
treatment	O
and	O
outcomes	O
was	O
performed	O
.	O

Results	O
Thirty	O
-	O
four	O
adult	O
patients	B-DIS
with	I-DIS
Q	I-DIS
fever	I-DIS
vertebral	O
osteomyelitis	O
were	O
identified	O
.	O

The	O
vast	O
majority	O
were	O
male	O
30/3488	B-STAT
%	I-STAT
with	O
a	O
mean	O
age	O
of	O
67.2	O
Â±	O
10	O
years	O
.	O

Involvement	O
of	O
the	O
adjacent	O
aorta	O
likely	O
the	O
origin	O
of	O
the	O
infection	B-DIS
was	O
observed	O
in	O
23/3468	B-STAT
%	I-STAT
of	O
the	O
patients	O
usually	O
among	O
patients	O
with	O
aortic	O
graft	O
or	O
aneurysm	B-DIS
.	O

Clinical	O
presentation	O
was	O
insidious	O
and	O
fever	B-DIS
was	O
frequently	O
absent	O
.	O

Delayed	O
diagnosis	O
for	O
months	O
to	O
years	O
after	O
symptoms	O
onset	O
was	O
frequently	O
reported	O
.	O

Vascular	O
infections	B-DIS
were	O
managed	O
with	O
or	O
without	O
extraction	O
of	O
the	O
infected	O
aneurysm	O
/	O
aorta	O
and	O
graft	O
placement	O
.	O

The	O
outcome	O
was	O
variable	O
with	O
limited	O
follow	O
-	O
up	O
data	O
in	O
most	O
cases	O
.	O

Patients	O
were	O
usually	O
treated	O
with	O
prolonged	O
antimicrobial	O
therapy	O
most	O
commonly	O
doxycycline	O
and	O
hydroxychloroquine	O
combination	O
therapy	O
.	O

Conclusion	B-DIS
Q	I-DIS
fever	I-DIS
should	O
be	O
included	O
in	O
the	O
differential	O
diagnosis	O
of	O
vertebral	B-DIS
osteomyelitis	I-DIS
in	O
endemic	O
settings	O
in	O
particular	O
when	O
concomitant	O
adjacent	O
vascular	O
infection	O
exists	O
.	O

Incidence	B-EPI
of	O
nontuberculous	B-DIS
mycobacterial	O
infections	O
has	O
increased	O
during	O
the	O
past	O
decades	O
.	O

Disseminated	O
infections	B-DIS
are	O
relatively	O
rare	O
and	O
associated	O
with	O
immunocompromised	O
status	O
.	O

We	O
report	O
a	O
case	O
of	O
disseminated	O
Mycobacterium	O
szulgai	B-DIS
infection	I-DIS
of	O
cervical	O
lymphadenitis	B-DIS
and	O
pulmonary	O
involvement	O
with	O
positive	O
anti	O
-	O
interferon	O
-	O
gamma	O
autoantibodies	O
.	O

The	O
patient	O
was	O
successfully	O
treated	O
with	O
rifampin	O
ethambutol	O
and	O
clarithromycin	O
.	O

The	O
case	O
reports	O
and	O
series	O
through	O
search	O
engines	O
of	O
Pubmed	O
and	O
Google	O
with	O
the	O
keyword	O
of	O
disseminated	O
infection	B-DIS
of	O
M.	O
szulgai	O
were	O
reviewed	O
.	O

Fifteen	O
patients	O
of	O
disseminated	O
M.	O
szulgai	B-DIS
infection	I-DIS
were	O
reviewed	O
and	O
included	O
.	O

Disseminated	O
M.	O
szulgai	B-DIS
infection	I-DIS
involves	O
bone	O
skin	O
and	O
lymph	O
node	O
more	O
common	O
instead	O
of	O
pulmonary	O
involvement	O
and	O
most	O
are	O
associated	O
with	O
immunocompromised	O
status	O
with	O
neoplastic	B-DIS
hematologic	I-DIS
disorders	I-DIS
.	O

In	O
patients	O
with	O
disseminated	O
M.	O
szulgai	B-DIS
infection	I-DIS
long	O
term	O
anti	O
-	O
mycobacterial	O
agents	O
are	O
necessary	O
.	O

Most	O
patients	O
will	O
respond	O
to	O
rifampin	O
and	O
ethambutol	O
combination	O
regimens	O
.	O

Ever	O
since	O
SARS	O
-	O
CoV-2	O
began	O
infecting	O
people	O
by	O
the	O
end	O
of	O
2019	O
of	O
whom	O
some	O
developed	B-DIS
severe	O
pneumonia	O
about	B-STAT
5	I-STAT
%	I-STAT
which	O
could	O
be	O
fatal	O
case	O
fatality	O
~3.5	O
%	O
the	O
extent	O
and	O
speed	O
of	O
the	O
COVID-19	O
outbreak	O
has	O
been	O
phenomenal	O
.	O

Within	O
2.5	O
months	O
by	O
March	O
182020	O
over	O
191127	O
COVID-19	O
patients	O
have	O
been	O
identified	O
in	O
161	O
countries	O
.	O

By	O
then	O
over	O
700	O
pediatric	O
patients	O
were	O
confirmed	O
to	O
have	O
COVID-19	O
in	O
China	B-LOC
with	O
only	O
about	O
58	O
diagnosed	O
elsewhere	O
.	O

By	O
now	O
there	O
are	O
thousands	O
of	O
children	O
and	O
adolescents	B-DIS
infected	I-DIS
.	O

Chinese	O
pediatricians	O
would	O
like	O
to	O
share	O
their	O
experience	O
on	O
how	O
these	O
patients	O
were	O
managed	O
in	O
China	B-LOC
and	O
the	O
key	O
recommendations	O
that	O
had	O
guided	O
them	O
in	O
meeting	O
the	O
evolving	O
challenges	O
.	O

A	O
group	O
of	O
experts	O
were	O
summoned	O
by	O
the	O
Chinese	O
Pediatric	O
Society	O
and	O
Editorial	O
Board	O
of	O
Chinese	O
Journal	O
of	O
Pediatrics	O
to	O
extract	O
informative	O
data	O
from	O
a	O
survey	O
on	O
confirmed	O
COVID-19	O
pediatric	O
patients	O
in	O
China	B-LOC
.	O

Consensus	O
on	O
diagnosis	O
management	O
and	O
prevention	O
of	O
pediatric	O
COVID-19	O
were	O
drawn	O
up	O
based	O
on	O
the	O
analysis	O
of	O
such	O
data	O
plus	O
insights	O
gained	O
from	O
the	O
past	O
SARS	B-DIS
and	O
MERS	O
coronavirus	O
outbreaks	O
.	O

Relevant	O
cumulating	O
experiences	O
from	O
physicians	O
managing	O
adult	O
patients	O
expedited	O
reports	O
on	O
clinical	O
and	O
scientific	O
COVID-19	O
and	O
SARS	O
-	O
CoV-2	O
data	O
and	O
the	O
National	O
Health	O
Committee	O
guidelines	O
on	O
COVID-19	O
management	O
were	O
integrated	O
into	O
this	O
proposal	O
.	O

White	O
-	O
tailed	O
deer	O
WTD	O
are	O
abundant	O
mammals	O
widely	O
distributed	O
across	O
the	B-LOC
United	I-LOC
States	I-LOC
.	O

As	O
a	O
result	O
WTD	O
are	O
considered	O
to	O
be	O
excellent	O
sentinels	O
for	O
detecting	O
arboviral	O
activity	O
in	O
certain	O
geographic	O
areas	O
.	O

Evidence	O
of	O
West	B-LOC
Nile	I-LOC
virus	O
WNV	B-DIS
antibody	O
in	O
WTD	O
has	O
been	O
reported	O
previously	O
in	O
several	O
states	O
.	O

However	O
WNV	B-DIS
infection	I-DIS
in	O
WTD	O
has	O
not	O
been	O
reported	O
from	O
Texas	B-LOC
where	O
the	O
incidence	B-EPI
of	O
human	O
West	B-LOC
Nile	I-LOC
WN	I-LOC
cases	O
is	O
among	O
the	O
highest	O
in	O
the	B-LOC
United	I-LOC
States	I-LOC
.	O

Therefore	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
prevalence	B-EPI
of	O
WNV	B-DIS
antibody	O
in	O
WTD	O
in	O
central	O
Texas	B-LOC
.	O

Sera	O
samples	O
n	O
=	O
644	O
were	O
collected	O
from	O
deer	O
during	O
the	O
fall	O
and	O
winter	O
in	O
western	O
Travis	B-LOC
County	I-LOC
Texas	B-LOC
from	O
2014	O
to	O
2018	O
and	O
tested	O
for	O
WNV	B-DIS
immunoglobulin	O
G	O
IgG	O
antibody	O
by	O
an	O
indirect	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
ELISA	O
.	O

ELISA	O
antibody	O
-	O
positive	O
samples	O
were	O
further	O
tested	B-DIS
for	O
WNV	O
and	O
St.	B-DIS
Louis	I-LOC
encephalitis	B-DIS
virus	O
SLEV	O
antibodies	O
by	O
an	O
80	B-STAT
%	I-STAT
plaque	O
-	O
reduction	O
neutralization	O
tests	O
PRNT	O
80	O
<	O
/s	O
.	O

Overall	O
9	B-STAT
%	I-STAT
n	O
=	O
58	O
and	O
0.31	B-STAT
%	I-STAT
n	O
=	O
2	O
of	O
the	O
deer	O
samples	O
had	O
serological	O
evidence	O
of	O
WNV	B-DIS
and	O
SLEV	B-DIS
infections	I-DIS
respectively	O
.	O

WNV	B-DIS
seroprevalence	O
differed	O
significantly	O
by	O
age	O
p	O
<	O
0.05	O
but	O
there	O
was	O
no	O
significant	O
difference	O
between	O
sex	O
.	O

Interestingly	O
3.1	B-STAT
%	I-STAT
n	O
=	O
20	O
of	O
the	O
samples	O
were	O
positive	O
for	O
Flavivirus	O
IgG	O
antibody	O
by	O
ELISA	O
but	O
negative	O
for	O
SLEV	B-DIS
and	O
WNV	B-DIS
antibodies	O
suggesting	O
that	O
other	O
Flaviviruses	O
may	O
be	O
circulating	O
among	O
WTD	O
in	O
Texas	B-LOC
.	O

Finally	O
these	O
results	O
supported	O
WNV	B-DIS
infection	I-DIS
among	O
WTD	O
and	O
highlight	O
their	O
potential	O
role	O
as	O
sentinels	O
for	O
the	O
detection	O
of	O
WNV	B-DIS
in	O
Texas	B-LOC
and	O
warrant	O
further	O
studies	O
to	O
determine	O
the	O
role	O
WTD	O
play	O
in	O
the	O
maintenance	O
and	O
transmission	O
of	O
WNV	B-DIS
.	O

Pallister	B-DIS
-	I-DIS
Hall	O
syndrome	O
PHS	O
is	O
an	O
extremely	O
rare	O
syndrome	O
of	B-EPI
unknown	O
prevalence	B-DIS
with	O
autosomal	O
dominant	O
inheritance	O
due	O
to	O
GLI3	O
gene	O
mutations	O
classically	O
characterized	O
by	O
the	O
presence	O
of	B-DIS
a	I-DIS
hypothalamic	O
hamartoma	B-DIS
and	O
polydactyly	O
.	O

Additional	O
diagnostic	O
criteria	O
include	O
bifid	B-DIS
epiglottis	I-DIS
imperforate	I-DIS
anus	I-DIS
small	I-DIS
nails	I-DIS
hypopituitarism	I-DIS
growth	I-DIS
hormone	I-DIS
deficiency	I-DIS
and	O
genital	B-DIS
hypoplasia	I-DIS
.	O

It	O
is	O
typically	O
diagnosed	O
in	O
infancy	O
and	O
early	O
childhood	O
presenting	O
with	O
seizures	B-DIS
and/or	O
precocious	O
puberty	O
due	O
to	O
the	O
hypothalamic	B-DIS
hamartoma	I-DIS
and	O
with	O
limb	O
anomalies	B-DIS
due	O
to	O
central	O
polydactyly	O
.	O

Our	O
patient	O
had	O
presented	O
with	O
polysyndactyly	B-DIS
at	O
birth	O
.	O

However	O
as	O
this	O
is	O
not	O
uncommon	O
in	O
infants	O
and	O
is	O
usually	O
as	O
part	O
of	O
the	O
sporadic	O
isolated	O
form	O
of	O
polydactyly	B-DIS
no	O
further	O
work	O
up	O
was	O
done	O
.	O

He	O
then	O
presented	O
at	O
age	O
16	O
years	O
with	O
a	O
headache	B-DIS
and	O
subjective	O
visual	O
changes	O
with	O
brain	O
imaging	O
revealing	O
a	O
hypothalamic	B-DIS
hamartoma	I-DIS
.	O

He	O
did	O
not	O
have	O
a	O
history	O
of	O
seizures	B-DIS
or	O
central	O
precocious	O
puberty	O
.	O

Genotyping	O
revealed	O
a	O
pathogenic	O
variant	O
affecting	O
the	O
GLI3	O
gene	O
.	O

We	O
encourage	O
all	O
clinicians	O
to	O
consider	O
PHS	O
or	O
an	O
associated	O
syndrome	O
with	O
a	O
clinical	O
finding	O
of	O
polydactyly	B-DIS
.	O

Further	O
as	O
the	O
natural	O
history	O
continues	O
to	O
reveal	O
itself	O
this	O
patient	O
's	O
presentation	O
provides	O
important	O
new	O
data	O
to	O
the	O
broad	O
phenotypic	O
spectrum	O
of	O
PHS	O
.	O

Background	O
Pseudohypoparathyroidism	B-DIS
PHP	I-DIS
OMIM	I-DIS
#	I-DIS
103580	I-DIS
is	O
a	O
very	O
rare	O
disease	O
incidence	B-EPI
0.3	O
-	O
1/100000	B-STAT
.	O

Heterozygous	O
inactivating	O
mutations	O
involving	O
the	O
maternal	O
GNAS	O
exons	O
1	B-STAT
-	I-STAT
13	I-STAT
that	O
encodes	O
the	O
alpha	O
subunit	O
of	O
the	O
stimulatory	O
G	O
protein	O
GsÎ±	O
cause	O
inactivating	O
parathyroid	O
hormone	O
PTH	O
/PTHrP	O
signalling	O
disorder	B-DIS
type	I-DIS
2	I-DIS
iPPSD2	I-DIS
or	O
PHP	O
type	O
1A	O
which	O
is	O
characterized	O
by	O
Albright	B-DIS
hereditary	I-DIS
osteodystrophy	I-DIS
and	O
resistance	O
to	O
multiple	O
hormones	O
that	O
act	O
through	O
the	O
GsÎ±	O
signalling	O
pathway	O
including	O
PTH	O
thyroid	O
-	O
stimulating	O
hormone	O
and	O
Î±	O
-	O
melanocyte	O
-	O
stimulating	O
hormone	O
.	O

To	O
date	O
little	O
information	O
is	O
available	O
on	O
craniofacial	O
features	O
in	O
patients	O
with	O
PHP	B-DIS
.	O

The	O
small	O
number	O
of	O
patients	O
studied	O
in	O
previous	O
reports	O
as	O
well	O
as	O
the	O
lack	O
of	O
molecular	O
characterization	O
of	O
the	O
patients	O
may	O
have	O
precluded	O
the	O
detection	O
of	O
specific	O
orofacial	O
manifestations	O
in	O
the	O
different	O
PHP	O
subtypes	O
.	O

Materials	O
/	O
methods	O
We	O
conducted	O
a	O
systematic	O
analysis	O
of	O
dental	O
and	O
craniofacial	O
features	O
in	O
19	O
patients	O
with	O
iPPSD2	O
and	B-DIS
maternal	O
GNAS	O
inactivating	O
mutations	O
to	O
assess	O
the	O
frequency	O
and	O
specificity	O
of	B-DIS
the	O
anomalies	O
.	O

Results	O
Facial	O
examinations	O
showed	O
reduced	O
vertical	O
sagittal	O
and	O
transverse	O
development	O
of	O
the	O
mid	O
-	O
facial	O
structures	O
.	O

Intraoral	O
and	O
radiographic	O
examinations	O
revealed	O
that	O
89	O
per	O
cent	O
of	O
the	O
patients	O
had	O
at	O
least	O
one	O
dental	O
anomaly	B-DIS
including	O
tooth	O
submergence	O
leading	O
to	O
severe	O
infraocclusion	O
in	O
83	O
per	O
cent	O
of	O
cases	O
.	O

Craniofacial	O
analysis	O
of	O
lateral	O
cephalometric	O
radiographs	O
also	O
showed	O
a	O
significant	O
alteration	O
in	O
the	O
development	O
of	O
the	O
cranial	O
base	O
and	O
maxillary	O
and	O
mandibular	O
structures	O
in	O
these	O
patients	O
.	O

Conclusions	O
Patients	O
with	O
iPPSD2	O
and	O
maternal	O
GNAS	B-DIS
mutations	O
had	O
specific	O
craniofacial	B-DIS
alterations	I-DIS
and	O
dental	O
abnormalities	O
.	O

These	O
specific	O
defects	O
should	O
be	O
assessed	O
in	O
order	O
to	O
provide	O
appropriate	O
dental	O
and	O
orthodontic	O
care	O
to	O
these	O
patients	O
.	O

clinical	O
trial	O
registration	O
1920371	O
v	O
0	O
French	O
Nationale	O
Data	O
Processing	O
and	O
Liberties	O
Commission	O
-	O
CNIL	O
.	O

Introduction	O
/	B-DIS
background	I-DIS
Bladder	O
exstrophy	O
patients	O
have	O
a	B-EPI
high	O
prevalence	B-DIS
of	I-DIS
inguinal	O
hernia	O
that	O
often	O
become	O
clinically	O
evident	O
following	O
bladder	O
closure	O
.	O

Understanding	O
when	O
the	O
bladder	B-DIS
exstrophy	I-DIS
patient	O
is	O
under	O
greatest	O
risk	O
of	O
developing	O
an	O
inguinal	B-DIS
hernia	I-DIS
following	O
bladder	O
closure	O
is	O
important	O
since	O
incarceration	O
resulting	O
in	O
strangulation	O
of	O
intra	B-DIS
-	O
abdominal	O
contents	O
can	O
lead	O
to	O
significant	O
morbidity	O
if	O
not	O
addressed	O
in	O
a	O
timely	O
fashion	O
.	O

Although	O
the	O
incidence	B-EPI
and	O
risk	O
factors	O
of	O
inguinal	B-DIS
hernia	I-DIS
have	O
been	O
reported	O
the	O
timing	O
of	O
occurrence	O
is	O
not	O
well	O
understood	O
.	O

Objective	O
The	O
primary	O
objective	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
timing	O
of	O
inguinal	B-DIS
hernia	I-DIS
following	O
complete	O
primary	O
repair	O
of	O
bladder	B-DIS
exstrophy	I-DIS
CPRE	O
.	O

In	O
addition	O
we	O
aimed	O
to	O
evaluate	O
possible	O
risk	O
factors	O
associated	O
with	O
inguinal	B-DIS
hernia	I-DIS
including	O
sex	O
age	O
at	O
bladder	O
closure	O
and	O
iliac	O
osteotomy	O
status	O
.	O

Study	O
design	O
A	O
multi	O
-	O
institutional	O
retrospective	O
review	O
identified	O
patients	B-DIS
with	I-DIS
bladder	O
exstrophy	O
repaired	O
by	O
CPRE	O
under	O
6	O
months	O
of	O
age	O
while	O
excluding	O
those	O
who	B-DIS
underwent	I-DIS
inguinal	O
hernia	O
repair	O
before	O
or	O
during	O
bladder	O
closure	O
.	O

Timing	O
of	O
inguinal	B-DIS
hernia	I-DIS
following	O
bladder	O
closure	O
was	O
evaluated	O
using	O
Kaplan	O
-	O
Meier	O
methods	O
.	O

Cox	O
proportional	O
hazards	O
model	O
was	O
used	O
to	O
investigate	O
association	O
of	O
sex	O
age	O
at	O
bladder	O
closure	O
and	O
osteotomy	O
on	O
the	O
risk	O
of	O
developing	O
of	O
inguinal	B-DIS
hernia	I-DIS
while	O
clustering	O
for	O
institution	O
.	O

Results	O
91	O
subjects	O
were	O
included	O
in	O
our	O
analysis	O
with	O
median	O
follow	O
-	O
up	O
time	O
of	O
6.5	O
years	O
.	O

34	O
of	O
53	O
males	O
64.2	B-STAT
%	I-STAT
and	O
2	O
of	O
38	O
females	O
5.3	B-STAT
%	I-STAT
underwent	O
inguinal	B-DIS
hernia	I-DIS
repair	O
.	O

The	O
median	O
time	O
to	O
inguinal	B-DIS
hernia	I-DIS
was	O
4.7	O
months	O
following	O
closure	O
.	O

The	O
greatest	O
hazard	O
of	O
inguinal	B-DIS
hernia	I-DIS
was	O
within	O
the	O
first	O
six	O
months	O
following	O
closure	O
.	O

In	O
multivariate	O
analysis	O
male	O
sex	O
was	O
strongly	O
associated	O
with	O
inguinal	B-DIS
hernia	I-DIS
HR	O
=	O
19.00	O
p	O
=	O
0.0038	O
.	O

Osteotomy	O
and	O
delay	O
in	O
closure	O
were	O
not	O
significantly	O
associated	O
with	O
inguinal	B-DIS
hernia	I-DIS
.	O

7	O
of	O
36	O
patients	O
19.4	B-STAT
%	I-STAT
who	O
underwent	O
inguinal	B-DIS
hernia	I-DIS
repair	O
presented	O
with	O
recurrence	O
on	O
the	O
ipsilateral	O
side	O
.	O

Discussion	O
Our	O
results	O
suggest	O
that	O
the	O
greatest	O
risk	O
of	O
inguinal	B-DIS
hernia	I-DIS
is	O
within	O
the	O
first	O
six	O
months	O
following	O
bladder	O
closure	O
.	O

The	O
decreased	O
risk	O
of	O
inguinal	B-DIS
hernia	I-DIS
after	O
one	O
year	O
of	O
follow	O
-	O
up	O
may	O
reflect	O
anatomic	O
stability	O
that	O
is	O
reached	O
following	O
major	O
reconstruction	O
of	O
the	O
pelvis	O
.	O

While	O
male	O
bladder	B-DIS
exstrophy	I-DIS
patients	O
are	O
significantly	O
more	O
susceptible	O
to	O
inguinal	B-DIS
hernias	I-DIS
following	O
CPRE	O
osteotomy	O
and	O
delayed	O
bladder	O
closure	O
do	O
not	O
appear	O
to	O
be	O
protective	O
factors	O
for	O
inguinal	B-DIS
hernia	I-DIS
development	O
following	O
initial	O
bladder	O
closure	O
.	O

Conclusions	O
There	O
is	O
a	O
heightened	O
risk	O
of	O
inguinal	B-DIS
hernia	I-DIS
in	O
the	O
first	O
six	O
months	O
following	O
closure	O
.	O

The	O
rate	O
of	O
recurrence	O
following	O
inguinal	B-DIS
hernia	I-DIS
repair	O
is	O
significantly	O
elevated	O
compared	O
to	O
the	O
general	O
pediatric	O
population	O
.	O

Age	O
-	B-DIS
related	I-DIS
bone	O
disorders	O
such	B-DIS
as	O
osteoporosis	B-DIS
or	O
osteoarthritis	O
are	O
a	O
major	O
public	O
health	O
problem	O
due	O
to	B-DIS
the	I-DIS
functional	O
disability	O
for	O
millions	O
of	O
people	O
worldwide	O
.	O

Furthermore	O
fractures	B-DIS
are	O
associated	O
with	O
a	O
higher	O
degree	O
of	O
morbidity	O
and	O
mortality	O
in	O
the	O
long	O
term	O
which	O
generates	O
greater	O
financial	O
and	O
health	O
costs	O
.	O

As	O
the	O
world	O
population	O
becomes	O
older	O
the	O
incidence	B-EPI
of	O
this	O
type	O
of	O
disease	O
increases	O
and	O
this	O
effect	O
seems	O
notably	O
greater	O
in	O
those	O
countries	O
that	O
present	O
a	O
more	O
westernized	O
lifestyle	O
.	O

Thus	O
increased	O
efforts	O
are	O
directed	O
toward	O
reducing	O
risks	O
that	O
need	O
to	O
focus	O
not	O
only	O
on	O
the	O
prevention	O
of	O
bone	B-DIS
diseases	I-DIS
but	O
also	O
on	O
the	O
treatment	O
of	O
persons	O
already	O
afflicted	O
.	O

Evidence	O
is	O
accumulating	O
that	O
dietary	O
lipids	O
play	O
an	O
important	O
role	O
in	O
bone	O
health	O
which	O
results	O
relevant	O
to	O
develop	O
effective	O
interventions	O
for	O
prevent	O
bone	B-DIS
diseases	I-DIS
or	I-DIS
alterations	I-DIS
especially	O
in	O
the	O
elderly	O
segment	O
of	O
the	O
population	O
.	O

This	O
review	O
focuses	O
on	O
evidence	O
about	O
the	O
effects	O
of	O
dietary	O
lipids	O
on	O
bone	O
health	O
and	O
describes	O
possible	O
mechanisms	O
to	O
explain	O
how	O
lipids	O
act	O
on	O
bone	O
metabolism	O
during	O
aging	O
.	O

Little	O
work	O
however	O
has	O
been	O
accomplished	O
in	O
humans	O
so	O
this	O
is	O
a	O
challenge	O
for	O
future	O
research	O
.	O

Introduction	O
Charcot	B-DIS
-	I-DIS
Marie	I-DIS
-	O
Tooth	O
disease	B-DIS
CMT	O
and	O
related	O
neuropathies	O
represent	O
the	B-DIS
most	I-DIS
prevalent	O
inherited	O
neuromuscular	O
disorders	O
.	O

Nonetheless	O
there	O
is	O
still	O
no	O
pharmacological	O
treatment	O
available	O
for	O
any	O
CMT	B-DIS
type	O
.	O

However	O
the	O
landscape	O
is	O
rapidly	O
evolving	O
and	O
several	O
novel	O
approaches	O
are	O
providing	O
encouraging	O
results	O
in	O
preclinical	O
studies	O
and	O
leading	O
to	O
clinical	O
trials	O
.	O

Areas	O
covered	O
The	O
authors	O
review	O
the	O
most	O
promising	O
therapies	O
under	O
study	O
and	O
the	O
ongoing	O
/	O
planned	O
clinical	O
trials	O
.	O

Several	O
approaches	O
to	O
address	O
PMP22	B-DIS
overexpression	O
underlying	O
CMT1A	O
the	O
most	O
frequent	O
subtype	O
are	O
being	O
tested	O
.	O

Gene	O
silencing	O
targeting	O
PMP22	O
and	O
gene	O
therapy	O
to	O
introduce	O
specific	O
genes	O
or	O
to	O
substitute	O
or	O
modulate	O
defective	O
ones	O
are	O
being	O
experimented	O
in	O
animal	O
models	O
.	O

Compounds	O
acting	O
on	O
ER	O
stress	O
unfolded	O
protein	O
response	O
neuregulin	O
pathways	O
phosphoinositides	O
metabolism	O
axonal	O
transport	O
and	O
degeneration	B-DIS
inflammation	I-DIS
polyol	O
pathway	O
deoxysphingolipid	O
metabolism	O
purine	O
nucleotide	O
pool	O
are	O
potential	O
therapeutic	O
candidates	O
for	O
different	O
forms	O
of	O
CMT	B-DIS
and	O
related	O
neuropathies	B-DIS
.	O

Expert	O
opinion	O
We	O
are	O
getting	O
closer	O
to	O
find	O
effective	O
therapies	O
for	O
CMT	B-DIS
but	O
are	O
far	O
behind	O
the	O
exciting	O
examples	O
of	O
other	O
genetic	O
neuromuscular	B-DIS
disorders	I-DIS
.	O

The	O
authors	O
analyze	O
the	O
possible	O
reasons	O
for	O
this	O
gap	O
and	O
the	O
way	O
to	O
fill	O
it	O
.	O

Preclinical	O
and	O
clinical	O
research	O
is	O
ongoing	O
with	O
coordinated	O
efforts	O
and	O
they	O
are	O
confident	O
that	O
in	O
the	O
next	O
few	O
years	O
we	O
will	O
see	O
the	O
first	O
effective	O
treatments	O
.	O

Mitochondria	O
are	O
ubiquitous	O
intracellular	O
organelles	O
found	O
in	O
almost	O
all	O
eukaryotes	O
and	O
involved	O
in	O
various	O
aspects	O
of	O
cellular	O
life	O
with	O
a	O
primary	O
role	O
in	O
energy	O
production	O
.	O

The	O
interest	O
in	O
this	O
organelle	O
has	O
grown	O
stronger	O
with	O
the	O
discovery	O
of	O
their	O
link	O
to	O
various	O
pathologies	O
including	O
cancer	B-DIS
aging	I-DIS
and	O
neurodegenerative	B-DIS
diseases	I-DIS
.	O

Indeed	O
dysfunctional	O
mitochondria	O
can	O
not	O
provide	O
the	O
required	O
energy	O
to	O
tissues	O
with	O
a	O
high	O
-	O
energy	O
demand	O
such	O
as	O
heart	O
brain	O
and	O
muscles	O
leading	O
to	O
a	O
large	O
spectrum	O
of	O
clinical	O
phenotypes	O
.	O

Mitochondrial	O
defects	O
are	O
at	O
the	O
origin	O
of	O
a	O
group	O
of	O
clinically	O
heterogeneous	O
pathologies	O
called	O
mitochondrial	B-DIS
diseases	I-DIS
with	O
an	O
incidence	B-EPI
of	O
1	B-STAT
in	I-STAT
5000	I-STAT
live	O
births	O
.	O

Primary	B-DIS
mitochondrial	I-DIS
diseases	I-DIS
are	O
associated	O
with	O
genetic	O
mutations	O
both	O
in	O
nuclear	O
and	O
mitochondrial	O
DNA	O
mtDNA	O
affecting	O
genes	O
involved	O
in	O
every	O
aspect	O
of	O
the	O
organelle	O
function	O
.	O

As	O
a	O
consequence	O
it	O
is	O
difficult	O
to	O
find	O
a	O
common	O
cause	O
for	O
mitochondrial	B-DIS
diseases	I-DIS
and	O
subsequently	O
to	O
offer	O
a	O
precise	O
clinical	O
definition	O
of	O
the	O
pathology	O
.	O

Moreover	O
the	O
complexity	O
of	O
this	O
condition	O
makes	O
it	O
challenging	O
to	O
identify	O
possible	O
therapies	O
or	O
drug	O
targets	O
.	O

Varicella	B-DIS
-	I-DIS
zoster	I-DIS
virus	O
VZV	O
is	O
a	O
teratogen	O
that	O
can	O
cross	O
the	O
placenta	O
and	O
cause	B-DIS
the	I-DIS
congenital	I-DIS
varicella	O
syndrome	O
CVS	O
which	O
is	O
characterised	B-DIS
by	I-DIS
multi	O
-	O
system	O
anomalies	O
.	O

There	O
have	O
been	O
130	O
reported	O
cases	O
of	O
CVS	O
from	O
1947	O
to	O
2013	O
.	O

The	O
estimated	O
incidence	B-EPI
of	O
CVS	O
was	O
0.59	B-STAT
%	I-STAT
and	O
0.84	B-STAT
%	I-STAT
for	O
women	O
infected	O
with	O
VZV	B-DIS
during	O
the	O
entire	O
pregnancy	O
and	O
for	O
those	O
infected	O
the	O
first	O
20	O
weeks	O
of	O
pregnancy	O
respectively	O
.	O

Nine	O
cases	O
were	O
reported	O
at	O
21	O
-	O
27	O
weeks	O
of	O
gestation	O
and	O
one	O
case	O
was	O
identified	O
at	O
36	O
weeks	O
.	O

Herpes	B-DIS
zoster	I-DIS
caused	O
CVS	O
in	O
two	O
cases	O
.	O

Regarding	O
treatment	O
varicella	O
zoster	B-DIS
immunoglobulin	O
treatment	O
irrespective	O
of	O
gestational	O
age	O
should	O
be	O
considered	O
in	O
addition	O
to	O
antiviral	O
drugs	O
for	O
women	O
who	O
have	O
been	O
exposed	O
to	O
or	O
infected	O
with	O
virus	O
.	O

Purpose	O
We	O
observed	O
four	O
individuals	O
in	O
two	O
unrelated	O
but	O
consanguineous	B-DIS
families	O
from	O
Portugal	B-LOC
and	O
Brazil	B-LOC
affected	O
by	O
early	O
-	B-DIS
onset	I-DIS
retinal	I-DIS
degeneration	I-DIS
sensorineural	I-DIS
hearing	I-DIS
loss	I-DIS
microcephaly	I-DIS
intellectual	O
disability	B-DIS
and	I-DIS
skeletal	O
dysplasia	B-DIS
with	O
scoliosis	O
and	B-DIS
short	O
stature	O
.	O

The	O
phenotype	O
precisely	O
matched	O
that	O
of	O
an	O
individual	O
of	O
Azorean	O
descent	O
published	O
in	O
1986	O
by	O
Liberfarb	B-LOC
and	O
coworkers	O
.	O

Methods	O
Patients	O
underwent	O
specialized	O
clinical	O
examinations	O
including	O
ophthalmological	O
audiological	O
orthopedic	O
radiological	O
and	O
developmental	O
assessment	O
.	O

Exome	O
and	O
targeted	O
sequencing	O
was	O
performed	O
on	O
selected	O
individuals	O
.	O

Minigene	O
constructs	O
were	O
assessed	O
by	O
quantitative	O
polymerase	O
chain	O
reaction	O
qPCR	O
and	O
Sanger	O
sequencing	O
.	O

Results	O
Affected	O
individuals	O
shared	O
a	O
3.36	O
-	O
Mb	O
region	O
of	O
autozygosity	O
on	O
chromosome	O
22q12.2	O
including	O
a	O
10	O
-	O
bp	O
deletion	O
NM_014338.3c.904	O
-	O
12_904	O
-	O
3delCTATCACCAC	O
immediately	O
upstream	O
of	O
the	O
last	O
exon	O
of	O
the	O
PISD	O
phosphatidylserine	O
decarboxylase	O
gene	O
.	O

Sequencing	O
of	O
PISD	O
from	O
paraffin	O
-	O
embedded	O
tissue	O
from	O
the	O
1986	O
case	O
revealed	O
the	O
identical	O
homozygous	O
variant	O
.	O

In	O
HEK293	B-LOC
T	O
cells	O
this	O
variant	O
led	O
to	O
aberrant	O
splicing	O
of	O
PISD	O
transcripts	O
.	O

Conclusion	O
We	O
have	O
identified	O
the	O
genetic	O
etiology	O
of	O
the	O
Liberfarb	B-LOC
syndrome	O
affecting	O
brain	O
eye	O
ear	O
bone	O
and	O
connective	O
tissue	O
.	O

Our	O
work	O
documents	O
the	O
migration	O
of	O
a	O
rare	O
Portuguese	O
founder	O
variant	O
to	O
two	O
continents	O
and	O
highlights	O
the	O
link	O
between	O
phospholipid	O
metabolism	O
and	O
bone	O
formation	O
sensory	O
defects	O
and	O
cerebral	O
development	O
while	O
raising	O
the	O
possibility	O
of	O
therapeutic	O
phospholipid	O
replacement	O
.	O

The	O
review	O
lists	O
the	O
genetic	O
diseases	O
reported	O
in	O
Lebanese	O
individuals	O
surveys	O
genetic	O
programs	O
and	O
services	O
and	O
highlights	O
the	O
absence	O
of	O
basic	O
genetic	O
health	O
services	O
at	O
the	O
individual	O
and	O
community	O
level	O
.	O

The	O
incidence	B-EPI
of	O
individual	O
diseases	O
is	O
not	O
determined	O
yet	O
the	O
variety	O
of	O
genetic	O
diseases	O
reported	O
is	O
tremendous	O
most	O
of	O
which	O
follow	O
autosomal	O
recessive	O
inheritance	O
reflecting	O
the	O
social	O
norms	O
in	O
the	O
population	O
including	O
high	O
rates	O
of	O
consanguinity	B-DIS
which	O
favor	O
the	O
increase	O
in	O
incidence	B-EPI
of	O
these	O
diseases	O
.	O

Genetic	O
services	O
including	O
all	O
activities	O
for	O
the	O
diagnosis	O
care	O
and	O
prevention	O
of	O
genetic	O
diseases	O
at	O
community	O
level	O
are	O
extremely	O
inadequate	O
.	O

Services	O
are	O
limited	O
to	O
some	O
clinical	O
and	O
laboratory	O
diagnostic	O
services	O
with	O
no	O
genetic	O
counseling	O
.	O

These	O
services	O
are	O
localized	O
within	O
the	O
capital	O
thus	O
preventing	O
their	O
accessibility	O
to	O
high	O
-	O
risk	O
communities	O
.	O

Screening	O
programs	O
which	O
are	O
at	O
the	O
core	O
of	O
public	O
health	O
prevention	O
services	O
are	O
minimal	O
and	O
not	O
nationally	O
mandated	O
.	O

The	O
absence	O
of	O
adequate	O
genetic	O
services	O
is	O
attributed	O
to	O
many	O
factors	O
undermining	O
the	O
importance	O
of	O
genetic	O
diseases	O
and	O
their	O
burden	O
on	O
society	O
the	O
most	O
important	O
of	O
which	O
is	O
genetic	O
illiteracy	O
at	O
all	O
levels	O
of	O
the	O
population	O
including	O
high	O
-	O
risk	O
families	O
the	O
general	O
public	O
and	O
most	O
importantly	O
health	O
care	O
providers	O
and	O
public	O
health	O
officials	O
.	O

Thus	O
a	O
country	O
like	O
Lebanon	B-LOC
where	O
genetic	O
diseases	O
are	O
expected	O
to	O
be	O
highly	O
prevalent	O
is	O
in	O
utmost	O
need	O
for	O
community	O
genetics	O
services	O
.	O

Strategies	O
need	O
to	O
be	O
developed	O
to	O
familiarize	O
public	O
health	O
officials	O
and	O
medical	O
professionals	O
with	O
medical	O
genetics	O
leading	O
to	O
a	O
public	O
health	O
infrastructure	O
that	O
delivers	O
community	O
genetics	O
services	O
for	O
the	O
prevention	O
and	O
care	O
of	O
genetic	O
disorders	O
at	O
community	O
level	O
.	O

